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Abstract
Cancer is the leading cause of death in U.S. next to deaths caused by heart diseases. Cancer
causes extreme pain to the patient physical and mental health. Prostate cancer is one of the most
common type of cancer in American men besides skin cancer. Even though extreme efforts are
being placed in the field of science and technology to develop reliable cancer therapeutics, no cure
was found to eradicate or alleviate the pain caused by cancer. Cancer biomarker proteins that are
abnormally expressed and secreted into blood in a diseased state could provide early cancer
diagnosis and provide better healthcare. This helps in addressing better therapeutic options in much
early stages of cancer even before advanced tumors developed where the survival rates are
extremely low. As of now for prostate cancer, serum levels of prostate specific antigen is widely
used as a diagnostic tool. But over expression of PSA could be from many other prostate related
issues leading to false positives. This further results in causing patients stress due to exaggerated
diagnosis and treatment options. Detection of panel of prostate cancer biomarkers from serum

sample simultaneous with high sensitivity and selectivity could provide valuable information for
early cancer diagnostics and better treatment options.
The primary goal of this thesis is to develop ECL based automated diagnostic platforms
that can detect panel of prostate cancer biomarkers with high sensitivity and high throughput. The
assay platforms being low cost, rapid and non-complex they can be easily translated into public
health care much faster and provide conclusive results with no ambiguity for better treatment
options. This thesis explores many new device fabrication, automation strategies and liquid
handing systems for easier completion of sensitive immunoassays with ultralow detection limits.
Nano structured detection platforms and RuBPY dye doped silica nanoparticles have been used as
amplification strategies to detect the serum proteins at low femtogram levels. We successfully
developed immunoassay platforms that can detect small protein panel (3 proteins) to large protein
(8 proteins) panel. We demonstrated 3-D printing as rapid fabrication tool to make microfluidic
immunoarrays that enabled low cost sensors with relatively low sample volume requirements. The
developed ECL arrays holds great promise in accurate detection of early stages of cancer in
physician’s clinic and point of care settings.
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Chapter 1

Introduction

1.1 Purpose of Study and Significance
Cancer is leading cause of death in United States, second only to heart disease. Prostate
cancer is most common type of cancer in American men besides skin cancer. 1 As per American
cancer society new prostate cancer cases are about 161,360 and about 26,730 deaths from prostate
cancer. The average age of prostate cancer diagnosis is about 66 years and usually 6 in 10 men
diagnosed with prostate cancer are above age of 65 years. 1 in 7 men will be diagnosed with
prostate cancer during their lifetime. 2 Currently prostate specific antigen (PSA) detection in serum
samples is being used as early detection tool. While doctors agree that just doing PSA test alone
can’t be prefect to find prostate cancer reliably, doctors rely upon getting biopsies using transrectal
ultrasound lo locate cancerous tissues. Still there is chance of missing as it may not detect certain
areas of the containing cancer. This causes extreme discomfort to the patient mentally and
physically even before knowing the presence of cancer. Besides just identification of presence of
cancer staging the cancer or knowing the extent of cancer also plays crucial role in determining
better treatment options. Imaging tests are currently employes to understand the extent of tumor
but several type of scanning procedures used currently like computed tomography scan (CT) or
magnetic resonance imaging (MRI) can’t detect small areas of cancerous tissues like lymph nodes.
Looking at the magnitude of the cancer prevalence and issues dealing with diagnosing cancer and
staging cancer with less false positives and less false negatives it is of absolute necessity. There is
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need to develop a diagnostic tool that can detect the diseased state with relatively less complexity
and more confidence can increase the chance of survival of cancer individual and provide better
therapeutic choices.
Detecting elevated levels of proteins in blood serum have a great prospective as biomarkers
of a diseased state can be used in early detection of cancer. 3,4 Detecting panel of these biomarkers
from serum samples promise better futuristic personized health care. 5,6,7 detection of these multiple
proteins from serum samples simultaneously could reduce the possibility of false positives and
false negatives enormously as supposed to just single protein detection might have variations in
expression from person to person. 8,9 There is a lesser chance of failed expression of all the
biomarkers in a panel compared to a single marker. This increases the confidence in diagnosis of
cancer and help in better judgment of cancer treatment options.

Diagnostic platforms

which can detect such panels of biomarkers needs universal acceptance to maximize their use for
better patient health care. The protein measurements of such panels at clinical point of care requires
to be rapid (short assay times), simple (no complex operations so that they can be adapted easily
without need for new training procedures and can be adapted to current health care settings),
sensitive (should be able to detect the selective markers in complex serum samples with precision
and low detections), automated (for better and cohesive work flow reducing errors from human
operations) finally need to be inexpensive so that it can replace current methodologies with benefit
of cost reduction.4,5
Diagnostic platforms based on microfluidics promises all the above mentioned advantages
while having a lot of complex operations integrated into a simple, portable, inexpensive, compact
devices also having greater fluidic control of reagents required for the assay. 10,4 Current
methodologies that are commercially used and considered as gold standard to detect proteins are
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single protein enzyme linked immunosorbent assay (ELISA) and western blot assays. 11 While
these assays are considered to most reliable and being widely used some critical issues like assay
time, cost, complexity and labor intensive protocols hinder them to be acting a point of care
diagnostic tools for better health care. 12 Besides the complexity issues use of higher sample volume
of precious biological samples is also an important issue to address. Some new age commercial
techniques like bead based optical detection and electrochemiluminescent (ECL) assays hold a
great prospect in performing multiplex immunoassay. 13,14 But low cost, automation, better
detection limits with wider dynamic ranges are some challenges still need to be addressed.
Goal of this research is to develop such new age diagnostic assay platforms that can detect
multiple proteins in serum samples with extreme ease and automation. The thesis address several
strategies employed to develop such automated platforms that performs immunoassays with
fraction of costs compared to current commercial platforms while getting good sensitivities and
broader dynamic ranges. So that the methods can be applied several biomarkers at a time for
several diseased states. We developed ECL based automated biosensors for detection of several
biomarkers like Prostate specific antigen (PSA), Prostate specific membrane antigen (PSMA),
Platelet factor-4 (PF-4), Interlukin-6 (IL-6) etc., relevant to early diagnosis of prostate cancer. In
this thesis we demonstrated that we developed several biosensors that are high throughput and
easy to use diagnostic platforms. Our platforms were designed with vision of thier performance in
doctor’s office or clinic as simple point of care diagnostic tools that can help in better therapeutic
outcomes and relieve patients for mental and physical stress. The first 5 chapters of this thesis deal
with such prostate cancer biomarker detection platforms with significant improvement from our
previous efforts. Our efforts here using ECL based platforms utilizes nanostructured detection
platforms with light emitting ruthenium bipyridine substrate (RuBPY/Ru(bpy)32+) in a silica
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nanoparticle as detection label. When applied voltage/potential in presence of a co-reactant light
emitted and captured by a simple CCD camera. Chapter 1 gives overall view of the principles and
background relevant to the work.
Chapter 2 demonstrates development of automated multiplexed ECL immunoarrays for
prostate cancer biomarkers from human serum samples. This platform here described is a simple,
low cost, microprocessor controlled microfluidic immunoarray for detection of 4 proteins
simultaneously. The device mainly includes a 30-microwell detection chip coupled with
sample/reagent loading cassette connected by micropumps. The reagent/sample loading cassette
has all the reagents required to complete the immunoassay and micropumps controlled by Arduino
microprocessor delivers all the reagents on to single walled carbon nanotube forest with capture
antibodies for selective proteins capture. RuBPY silica detection antibody conjugate completes the
sandwich immunoassay that emits ECL when applied with potential in presence of a co-reactant
tripropylamine which is measured by a CCD camera. Our assays were thoroughly validated with
real cancer patient samples by comparison with gold standard ELISA and found good correlation.
In chapter 3 we demonstrated the use of 3-D printing for the first time in developing
immunoassay based diagnostic platform. 3-D printing being an attractive alternative to traditional
methods of microfluidic device fabrication. We used low cost desktop fused deposition modeling
based 3-D printer to fabricate a low tech immunoarray. Here we demonstared pumpless gravity
assisted microfluidic immunoarray to detect 3 prostate cancer biomarkers simultaneously from
serm samples using ECL based sandwich immunoassay. Here we used detection antibody coated
RuBPY silica nanoparticles as detection labels which emits ECL from the sandwich immunoassay
in presence of co-reactant tripropylamine which is measured by a CCD camera. Here for the first
time we also showed use of portable, miniaturized power source like supercapacitors to apply
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potential for ECL generation for futuristic diagnostic platforms. The supercapacitors were rapidly
photo charged via a solar panel to power ECL reaction, and we demonstrated high sensitivity
detection of 3 biomarkers and validated with comparison by single protein ELISAs.
In chapter 4, we demonstrated use of stereolithographic 3-D printers to make clear plastic
compact microfluidic devices for sensitive detection of 2 prostate cancer biomarkers from human
serum samples. We showed here use of low volumes of serum samples compared to our previous
platforms with shortened assay times resulting similar sensitive detection limits and dynamic
ranges. Here we utilized advantages of microfluidics for automated liquid handling resulting in
completion of immunoassays with minimal manual interference. In this project we also wanted to
demonstrate diagnostic significance of PSMA as prostate cancer biomarker hence we analyzed
relatively higher number of patient samples (38) than our previous array to see their concentrations
in serum and further validated with gold standard single protein ELISA.
Chapter 5 briefly discusses about automated detection of big panel of prostate cancer
biomarkers, 8 proteins at a time on a single array. We utilized all our experience from previous
projects to develop this low cost, point of care ECL based immunosensor. One thing we haven’t
addressed in previous arrays was user friendly modules to have coherent work flow and show the
steps of immunoassay while happening, so that the operator has better user experience while
performing the assays. We showed the reproducibility of our 8 protein assay platform with spiked
samples in human serum and analysis of real human serum samples.
Chapter 6 with introduction of genotoxicity & 7 we used 3-D printing to develop automated
DNA based genotoxicity sensor that can perform multi-analyte analysis from environmental
samples. The electrochemiluminescent (ECL) detection platform incorporates layer-by-layer (LbL)
assembled films of microsomal enzymes, DNA and an ECL-emitting ruthenium metallopolymer in ~10 nm
deep microwells. Liquid samples are introduced into the array, metabolized by the human enzymes,
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products react with DNA if possible, and DNA damage is detected by ECL with a camera. Here we assessed
genotoxic potential of E-cigarettes and polluted water samples. This array is addressed towards onsite
monitoring application with rapid assessment.

Chapter 8, briefly discusses LC-MS/MS based genotoxic evaluation methods that can
detect site specific DNA damage of carcinogens. Our goal was to develop analytical method that
pin points the possible site of adduction that might result in mutation, which further can be
correlated with an organ specific cancer.

1-2. Electrochemiluminescence and sandwich immunoassay

Electrochemiluminescence (ECL) is also called electro generated chemiluminescence
where chemical species at a electrode surface undergo high energy electron transfer reactions to
reach excited state that can emit light when they relax. 15,16,17 ECL has become a powerful tool in
analytical field with its applications in many field like immunoassays. Environmental analysis,
bio-imaging, toxicology studies etc.17 The major advantage of ECL over chemiluminescence (CL)
in analytical platforms is that ECL allows control over time and position of reaction happening.
Controlling position of ECL reaction specific to detector improves sensitivity by decreasing the
signal to noise to ratio. This also allowed multiple reactions monitoring in a same sample. 18 In our
case multiple reactions can be monitored in a same array with different microwells. Compared to
fluorescence ECL is much more sensitive as there is no background signal from a light source to
generate signal. 19 Use of ECL as detection platform has been increased in the recent past for
detection of serum proteins as biomarkers to diagnose a diseased state.
Protein detection based on ECL mainly depends of presence of ECL label such as
Ru(bpy)32+ as detection tag. Usually ECL tags are preferentially labelled to antibodies and these
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antibodies as part of sandwich immunoassay give ECL signal. In a simple sandwich immunoassay
the specific capture antibodies are attached to detection platform usually a solid support/solid
electrode. The proteins of interest are captured from samples and followed ECL tagged
detection/secondary antibodies are attached to form sandwich immunoassay. The concentration of
analytes/proteins is proportional to ECL species tagged secondary antibody. ECL signals produced
in presence of ECL co-reactant are usually measured by charge-coupled device (CCD) camera 20
or a much more sensitive photo-multiplier tube. 21 Thus ECL can be used as ultrasensitive detection
technique for biomolecule identification and quantification. Besides the advantages of ECL being
sensitive, ECL can be used in high throughput biosensor technologies that is capable of
multiplexed detection with good selectivity and low detection limits.

1-3. ECL generation using Ru(bpy)32+ and Tripropylamine (TPrA)
After the sandwich immunoassay was done ECL was generated from reduction of
[Ru(bpy)3]2+ via direct oxidation of TPrA. TPrA was oxidized at electrode surface with 0.95 -1.0
V vs Ag/AgCl forming a TPrA cation radical (TPrA*+) as shown in scheme 1.1, step1. TPrA*+
was then deprotonated to form TPrA* when reacted with [Ru(bpy)3]2+ scheme 1.1, step2. TPrA* is
necessary reduce [Ru(bpy)3]2+ to [Ru(bpy)3]+ scheme 1.1, step3. The TPrA*+ in the system then
oxidizes [Ru(bpy)3]+ to photo excited [Ru(bpy)3]2+* the emits light at 610 nm scheme 1.1, step4&5.
This RuBPY/TPrA system has been widely utilized for ECL generation as this provides extremely
sensitive subpicomolar protein concentration detection. 22,23 RuBPY/TPrA has been successfully
implemented in commercial protein detection platforms from Meso-Scale Discovery (MSD).14
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STEP 1: TPrA → TPrA•+ + eSTEP 2: TPrA•+ → TPrA• + H+
STEP 3:
TPrA• + [Ru-(bpy)3]2+] → [Ru-(bpy)3]+] + Products
STEP 4:
[Ru-(bpy)3]+] + TPrA•+ → [Ru-(bpy)3]2+]* + Products
STEP 5:
[Ru-(bpy)3]2+]* → [Ru-(bpy)3]2+] + hʋ (610 nm)

Scheme 1.1 Proposed mechanism for ECL generation at electrode surface from Ru(bpy)32+ via
TrPA.

1-4. Dye ([Ru(bpy)3]2+) Doped Silica nanoparticles for Amplified ECL detection
Nanoparticles have been excellent choice in the recent past for many researchers due to
their versatile characteristics like variable compositions, surface modifications, encapsulations and
executional simplicities. The use of nanoparticles have been extended to many fields like
therapeutic monitoring biomedical imaging, 24,25 sensing, 26,27 sensor amplification, 28 drug load and
delivery. 29 From the time since Stöber et al.,30 showed that availability of colloid silica nanoparticles
with defined structure and porosity, silica nanoparticles have been used in many fields of Biomedical
research where the mesoporous nature, hybrid construction capabilities and load carrying capacity have
been exploited.31 Dye doped silica nanoparticles with combination of various surface modifications
could provide great edge in selective recognition for bio-sensing and imaging.32 Dye doped silica
nanoparticles as they can enclose large number of dye molecules in confined silica matrix can enhance
their signal enormously compared to that of organic fluorophores.33 These advantages make our dye
doped mesoporous silica nanoparticles suitable for using them as both amplification and detection probe
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in our immunoassays without need for introducing another signal amplification strategies. In this work
we synthesized dye doped ([Ru(bpy)3]2+) silica nanoparticles where positively charged [Ru(bpy)3]2+
were electrostatically enclosed and bound to negatively charged silica particles. Nanoparticles
have been prepared using in water in oil emulsion methods where controlled hydrolysis of
tetraethyl orthosilicate (TEOS) resulted in monodisperse [Ru(bpy)3]2+ doped silica nanoparticles. 34
As the [Ru(bpy)3]2+ is doped inside the silica network core of the nanoparticle the outer surface
has been use to conjugate the bio-recognition molecules such as antibodies via a stable amide
bond, to use them as detection probes in the immunoassays. 35 These [Ru(bpy)3]2+ silica
nanoparticles can provide amplified detection ECL signal and minimized dye photo degradation
as they are present inside the nanoparticles. In this study we demonstrated the use of [Ru(bpy)3]2+
silica particles for detection of multiple proteins on a single platform by decorating them with
detection antibodies as required.

1-5. Single Wall Carbon Nanotube (SWCNT) forests
Carbon nanotubes have been previously reported in 1991 by Iijima using simple carbon
arc synthesis as finite graphite structures that are needle like tubes called carbon nanotubes. 36
Carbon nanotubes have been recognized to have wide range of interesting properties like high
thermal stability, chemical stability, flexibility, great conductivity and excellent mechanical
strength. 37 Previously carbon nanotubes have been exploited for their advantages and been sued
in many applications like electrochemical sensing and ECL platforms. 38,39 High surface areas
estimated as high as 1600 m2g-1 40and excellent conductivity along with presence of functionalized
surface groups relates to achieving high biomolecule densities such as antibodies and proteins for
sensing applications. 41 This in turn facilitated device miniaturization while not sacrificing the
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sensitivity. Previously a team from UCONN led by Dr. Fotios Papadimitrakopoulos demonstrated
self-assembly of 20-30 nm single walled carbon nanotubes (SWCNT) in solid supports into dense
carboxylate functionalized SWCNT forest. 42 These forests developed as SWCNTs as standing
upright bundles on a nafion - iron oxide decorated conductive surfaces with coverage >98%.
Efficient electrical communication was also established between electrode surface via carbon
nanotubes to the biomolecules like HRP attached to the ends. 43 Our group has previously shown
using carbon nanotubes as amplification strategy for highly sensitive detection of cancer
biomarkers. 44 These single walled carbon nanotube forests have been successfully used to detect
single and multiple proteins from complex serum matrix of prostate and oral cancer patients. 45-47
These amplification strategies with capture antibodies enabled high capture protein efficiency
resulting in sensitive ultralow detection limits.
Briefly single walled carbon nanotube forest is prepared by firstly shortening the long
SWCNTs to short 20-30 nm size SWCNTs. The carboxylated ends of the SWCNTs was formed
by oxidation via acid treatment with HNO2 and H2SO4 as shown in scheme 1 described in detail
in reference.42 These SWCNTs stand in upright bundles on thin nafion iron oxide films prepared
on a pyrolytic graphite chip. The carboxylated ends exposed will enable conjugation of capture
antibodies efficiently via a amide bond by EDC-NHSS amidization. Firstly thin layer of negatively
charged polyelectrolyte nafion and Fe(OH)x was prepared on the surface of the pyrolytic graphite
chip. Then DMF dispersions of shortened SWCNTs was allowed to self-assembled on previously
prepared metal functionalized substrate Scheme 1. The elevated pH of DMF wash and DMF in
SWCNTs solution causes surface immobilized Fe3+ layer to transform into its basic hydroxide form
that provides initial driving force for acid base neutralization of carboxylated SWCNTs and
Fe(OH)x layer resulting in self-assembly to occur. This allowed the upright position of SWCNTs
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bundles as carboxyl groups were only present at the ends. In my research these SWCNTs forest
that provides high capture antibody density along with signal amplification from RuBPY doped
silica nanoparticles provided sensitive detection of multiple cancer biomarker proteins from serum
samples at ultralow detection limits.

Scheme 1-2. Schematic representation of preparation of single walled carbon nanotube forest.42
(Reprinted from reference 42, Copyright 2001, with permission from American Chemical Society).

1-6. Microfluidics and automation
Microfluidics refers to phenomenon with set of technologies involved in efficient
manipulation of fluids in small volumes within an artificially fabricated system. 48 Microfluidics
offer portability of conventional immunoassay platforms with better fluidic handing. Microfluidics
enable to reduce risk of operator errors, increase reaction efficiencies and lower assay times. 49
Microfluidics enables to miniaturize, integrate complex procedures and automate diagnostic assay
platforms. Microfluidics allows small sample volume as it has enhanced surface area to volume
ratio in a confined space such as micro channels. In case on sandwich immunoassay this allows
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high analyte capture efficiency in a given small volume of sample provided availability of capture
agents on the surface. Fluidic arrays provide short diffusion distance inside the channels, providing
reduced use of sample volumes for similar or enhanced chemical or biological reactions compared
to conventional methods. 50 In addition to the development of platforms, overall time, sample
volume, and automation are other important factors to be addressed for POC applications. In
accordance with the CLIA regulations, integration of microfluidics with the analytical system is
crucial for reducing the overall immunoassay times and sample volumes, and for introducing
pump-less reagent delivery. 51 Microfluidic designing is a well-researched area, 52 but lithographybased prototyping is a costly and time consuming process due to the requirement of mask designing
and master-mold development. Therefore, new tools for enabling such rapid microfluidic
prototyping are highly sought that are also easy to use even for new entrants. Using microfluidics
as path our group’s goal to develop diagnostic platforms that can be easily translated to physician’s
clinics for onsite pint of care diagnostics. We have developed many microfluidic assay platforms
for detection of cancer biomarkers in serum samples efficiently with ultralow detection limits. 53- 57
Besides conventional methods of fabricating the microfluidic arrays we have been pioneers since
past two years in utilizing 3-D printing for rapid fabrication of our bio-analytical microfluidic
arrays.

1-7. 3-D printing
3D printing involves the production of an object from a computer-aided design (CAD) file
by depositing a material or multiple materials in successive layers using precisely controlled
positioning and delivery systems. In general, 3D printing requires few steps: preparation of a
design file using CAD software, generation of instructions for the printing process using a slicer
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program, printing the designed object by delivering or hardening a material onto a platform
according to the instructions defined by the slicer program, removal of the object from the printer
platform, and post-processing to remove printed supports or other extraneous material. 58 This
simple approach enables relatively rapid production of a wide variety of prototypes and offers an
advantage over other fabrication methods, which usually require multiple production steps and
greater capital investment in infrastructure. 3D printing, also called additive manufacturing, can
be accomplished by several strategies that vary in basic operating principles, complexity, and cost.
Such techniques include deposition of thin threads of heated thermoplastic (fused deposition
modeling (FDM)) or viscoelastic materials (syringe deposition or direct ink writing), sintering of
powders, or by exposure of photocurable resins (stereolithography (SLA)) or inks (MultiJet,
PolyJet) using a laser, digital light processing (DLP) projector, or other light source. 59,60 In my
research we mainly used FDM based printers and SLA based printers for device fabrication.
In FDM, a thermoplastic filament, typically 1.75 or 3.00 mm in diameter, is forced through
a heated nozzle about 0.2–0.5 mm in diameter onto a moving platform. Common thermoplastic
filament materials include poly(lactic acid), poly(carbonate), and acrylonitrile butadiene styrene
(ABS). SLA was the first form of 3D printing that was invented and commercialized. This method
employs a light source, such as a laser, to fabricate objects in a layer-by-layer fashion from
photocurable resin. Bioanalytical measurements often require systems capable of handling small
volumes (μl or less). We used 3-D printing to fabricate the diagnostic assay platforms to detect the
biomarker proteins for serum. The new age printers have good printing resolutions enabled us to
produce the microfluidic structures as low as 500 µM resulting in use of low sample volume which
are often scarce in biological samples. The use of 3D printing as a quick and easy alternative to
traditional methods for preparing fluidic devices in case of diagnostics will enable their faster
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translation into public healthcare. We used 3-D printing in both cancer diagnostics and genotoxic
evaluation of environmental pollutants at relatively to low cost and low sample volumes. Our
initiate in using 3-D printing has opened up huge bio-analytical space where our methods can be
adapted to many more applications. In the coming chapters of this thesis we will discuss
elaborately all the strategies mentioned in this chapter to develop and enhance our immunoassay
platforms for sensitive detection cancer biomarker proteins for serum.
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CHAPTER 2

Automated Multiplexed ECL Immunoarrays for Cancer
Biomarker Proteins

2-1 ABSTRACT
Point-of-care diagnostics based on multiplexed protein measurements face challenges of
simple, automated, low cost, high throughput operation with high sensitivity. Herein we describe
an automated, microprocessor-controlled microfluidic immunoarray for simultaneous multiplexed
detection of small protein panels in complex samples. A microfluidic sample/reagent delivery
cassette was coupled to a 30 microwell detection array to achieve sensitive detection of 4 prostate
cancer biomarker proteins in serum. The proteins are prostate specific antigen (PSA), prostate
specific membrane antigen (PSMA), platelet factor-4 (PF-4) and interlukin-6 (IL-6). The six
channel system is driven by integrated micropumps controlled by an inexpensive programmable
microprocessor. The reagent delivery cassette and detection array feature channels made by
precision-cut 0.8 mm silicone gaskets. Single-wall carbon nanotube forests were grown in printed
microwells on a pyrolytic graphite detection chip and decorated with capture antibodies. The
detection chip is housed in a machined microfluidic chamber with a steel metal shim counter
electrode and Ag/AgCl reference electrode for electrochemiluminescent (ECL) measurements.
The preloaded sample/reagent cassette automatically delivers antigen proteins, wash buffers and
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ECL RuBPY-silica-antibody detection nanoparticles sequentially. An on-board microcontroller
controls micropumps and reagent flow to the detection chamber according to a preset program.
Detection employs tripropylamine, a sacrificial reductant, while applying 0.95 V vs Ag/AgCl.
Resulting ECL light was measured by a CCD camera. Ultralow detection limits of 10-100 fg mL1

were achieved in simultaneous detection of the four protein in 36 min. assays. Results for the 4

proteins in prostate cancer patient serum gave excellent correlation with single protein ELISA.
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2-2.

Introduction
Biomarker protein panels hold great promise for future personalized cancer diagnostics. 1- 5

Widespread use of diagnostic protein measurements at clinical point-of-care will require simple,
cheap, fast, sensitive, automated assay devices.4-6 Microfluidic devices integrated with sensitive
nanomaterials-based measurement technologies have potential for future devices that fit these
requirements. 7- 11 Microfluidic immunoarrays have evolved to feature glass substrates with silicon
patterns, 12 fabricated microchannels 13 and valves 14 made with soft lithography. A major practical
challenge involves integrating components into low cost, fully automated devices for clinical
use. 15
Many current methods of specific biomarker protein detection are based on enzyme linked
immunosorbent assays (ELISA), including commercial magnetic bead-based devices.10,16 Critical
issues in these systems are cost, method complexity, and the need for technically trained operators
and frequent maintenance. Immunoassays in general suffer from multiple operations to load
samples and add reagents to block non-specific binding, remove interferences, and detect target
proteins. Significantly improved automation is needed to translate immunoassays to point-of-care
use.6,15 While semi-automated microfluidic reagent addition was reported previously for single and
2-antigen immunoassays, those systems do not achieve ultrasensitive detection and employ passive
fluid delivery by a downstream syringe that requires operator attention. 17
We previously developed modular microfluidic immunoarrays for multiplexed protein
detection on 8-unit gold nanoparticle AuNP film sensor arrays using magnetic beads heavily
loaded with enzyme labels and antibodies for detection. 18- 20 In the latest version of this device,
target proteins are captured on-line on the magnetic beads and delivered to an amperometric
detection chamber. We have determined up to 4 biomarker proteins in serum at levels as low as 5
24

fg

mL-1

with

this

system.

We

also

developed

microfluidic

immunoarrays

for

electrochemiluminescence (ECL) detection 21 using a slightly different approach. Here, a thin
pyrolytic graphite (PG) wafer was equipped with printed microwells, single-wall carbon nanotube
(SWCNT) forests were grown in the microwells and decorated with antibodies, and Ru(bpy)32+
(RuBPY) labels embedded in 100 nm silica nanoparticles coated with antibodies were used for
protein detection at 10-100 fg mL-1 levels. 22 ECL detection obviates the need for individually
addressable sensors, and the microwells need only be separated in space on the chip for light
detection with a camera. While these systems afford some degree of automation, a skilled operator

is needed to add samples and reagents and co-ordinate assay timing.

Scheme 2-1. Schematic representation of automated PCB integrated electrochemiluminescent
microfluidic array. Detection array is connected to the sample loading cassette and micro pumps.
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Preprogrammed Arduino microcontroller controls the micropump on-off cycles according to an
optimized program. Insert depicts sandwich immunoassay and ECL detection.

Figure 2-1. Automated microfluidic system featuring 30-microwell detection array connected to
sample/reagent cassette and PCB-controlled micropumps. An onboard programmed Arduino
microcontroller runs a micropump program to achieve the assay.
In this paper, we describe an inexpensive automated multiplexed protein immunoarray
featuring an onboard microprocessor to control micropumps, 23 and a microfluidic sample/reagent
cassette upstream of a microwell ECL immunoarray (Figure 2-1, and Scheme 2-1). The
microfluidic channels are precision cut from silicone gaskets. The system automatically delivers
all necessary samples and reagents, and controls timing of sample-sensor and detection particle
incubations. The detection module features six 60 µL microfluidic channels on a single PG chip
with 30 computer printed microwells containing dense, upright SWCNT forests decorated with
capture antibodies. We demonstrate the properties of the device by simultaneous detection of four
proteins employing 120 nm RuBPY-silica (RuBPY-Si) nanoparticles coated with secondary
antibodies (Ab2), with detection by CCD camera. We targeted a general panel of prostate cancer
26

biomarkers including prostate specific antigen (PSA), 24,25 interleukin-6 (IL-6), platelet factor-4
(PF-4), and prostate specific membrane antigen (PSMA). 26 Simultaneous detection of the four
proteins in undiluted calf serum was achieved with high specificity and selectivity in 36 min
assays, with detection limits of 10-100 fg mL-1. Assays on human serum samples from prostate
cancer patients confirmed very good correlations with single protein ELISAs.

2-3.

Experimental Section

2-3.1 Chemicals. Pooled human serum was from Capital Biosciences and individual patient serum
samples were provided by George Washington University Hospital. RuBPY-Si nanoparticles with
average diameter 121±9 nm (Figure 2-2) were prepared and coated with layers of
polydiallyldimethylammonium chloride (PDDA) and polyacrylic acid (PAA), then covalently
linked to secondary antibodies (Ab2) as described previously. 27 Two RuBPY-Si detection
nanoparticles were made, one with antibodies for PSA (PSA-Ab2) and IL-6 (IL-6-Ab2), and a
second featuring PSMA-Ab2 and PF-4-Ab2. We measured averages of 4.6 x 105 RuBPY and 44
Ab2 per Si nanoparticle (Figure 2-2). Immunoreagents were dissolved in pH 7.2 phosphate buffer
saline (PBS). Co-reactant solution to develop ECL was 200 mM tripropylamine (TPrA) with
0.05% Tween-20 (T20) and 0.05% Triton-X in 0.2 M Phosphate buffer. Calf serum as a surrogate
for human serum was used to dissolve standard proteins. 28

2-3.2 Synthesis of [Ru(bpy)3]2+ -doped silica (RuBPY-Silica) nanoparticles
[Ru(bpy)3]2+ -doped silica (RuBPY-Silica) nanoparticles were synthesized by water in oil (W/O)
microemulsion. 29 0.04 M [Ru(bpy)3]2+ stock solution was prepared by dissolving [Ru(bpy)3]2+ in
pure water. 340 µL of stock was mixed with 1.8 g of Triton X 100, 1.8 mL of n-hexanol and 7.5
27

mL of cyclohexane and stirred for 30 minutes. 60 µL of fresh ammonium hydroxide (28-30 %
weight) and 100 µL of tetraethylorthosilicate (TEOS) were added to the above mixture and stirred
for 24 hours in dark. This mixture was precipitated using acetone. The precipitate was separated
using a centrifuge followed by washing with ethanol and water for three times each. This
precipitate was vacuum dried at room temperature overnight. The final product was weighed and
stored in dark at 4ºC. These particles were further characterized using transmission electron
microscopy (TEM).

2-3.3 Characterization of RuBPY silica nanoparticles by TEM
2.0 mg of RuBPY particles were dispersed in 1 mL of pure water and further diluted five times to
prepare the sample for TEM. A drop of this dispersion was added on to carbon coated copper TEM
grid and dried under vacuum. The average diameter of these particles was 121 ± 9 nm. These
RuBPY particles were modified to prepare ECL label. (Figure 2-2A & B)

A

B

Figure 2-2. (A) TEM image of RuBPY-silica nano particles on a 200 nm scale bar. (B) Size
distribution of RuBPY silica nanoparticles with an average diameter of 121 ± 9 nm.
28

2-3.4 RuBPY-Silica nanoparticles bioconjugate preparation
2 mg mL-1 RuBPY silica particles are used in making the bioconjugate. The solid particles
are firstly sonicated for a minute to remove any loosely bound or leaked [Ru-(bpy)3]2+ from the
particles and separated using centrifugation at 10,000 rpm for 10 min. Layer of
polydiallyldimethylammonium chloride (PDDA) was formed by adding 0.33mg mL-1 of aqueous
PDDA solution. The mixture was allowed to stand for 15min to form a thin layer. This was further
centrifuged at 9,000 rpm to remove excess and subsequently washed 3X with water. Later these
particles were suspended in 0.33mg mL-1 of polyacrylic acid (PAA) for 15 min to form a carboxylic
acid groups on the surface of the nanoparticle. Excess PAA was removed by centrifugation and
washing 3X with water. Carboxylic acid groups present on the surface was used to bind the desired
protein using (400mM-100mM) EDC-NHSS amidization. After leaving the nanoparticles with
EDC-NHSS mixture for 10 min the excess was removed and washed with water as explained
earlier at 9,000 rpm. Multiplexed label was prepared by adding mixture of PSA Ab2 (8µg mL-1 )
and IL-6 Ab2 (3µg mL-1) on one set of prepared particles and PSMA Ab2 (4.5µg mL-1) and PF-4
Ab2 (4.5µg mL-1) on other set of particles. The prepared mixture with proteins and modified
RuBYP silica nanoparticles are incubated overnight on a rotor. The resultant mixture with excess
proteins were removed by centrifugation at 8,000rpm in a refrigerated centrifuge and washed 3X
with PBS buffer at 7.4 pH. The resultant bioconjugate is finally dispersed in 1 mL of 2% BSA in
0.05% Tween-20/PBS buffer (7.4 pH) to block any nonspecific binding during the immunoassay
also helping in forming a uniform dispersion. These prepared bioconjugates (one set with PSA,
IL-6 and other with PSMA, PF-4 secondary antibodies) were mixed in equal ratios prior to a
multiplexed detection.
29

2-3.5 Estimating the number of RuBPY in Si particles
Relation between viscosity of a dilute solution of spherical nanoparticles and the volume
fraction of suspended nanoparticles (Φ) as shown in equation1, where h is the viscosity of the
nanoparticle suspension and h0 is the viscosity of the solution without nanoparticles. Viscosity of
the nanoparticle suspension was estimated to be 1.0078 and the viscosity of pure solvent is 1.00.
Substituting the values in equation 1, we get the value of volume fraction (Φ), to be 0.0031.
h/h0 = 1 + 2.5Φ

(1)

The number of nanoparticles (N) per volume was obtained by using equation 2, where r is
the radius of the particles in cm. The diameter of the nanoparticles was estimated using
transmission electron microscopy to be 120 ± 9 nm. Substituting these values in equation 2 we
calculated number of particles to be 3.4 X 1012 per mL of solution.
N = Φ /(4/3πr3)

(2)

2-3.6 Ratio of Ab2/RuBPY Silica particles in ECL bio-conjugate label
Fluorescence emission spectroscopy was used to calculate the number of antibodies
attached to the RuBPY Silica particles. Antibodies contain tryptophan, which excites specifically
at 280nm. Calibration curve was developed for known concentration of Ab2 as shown in figure 23A. The unknown concentration of Ab2 on the bio-conjugate label (PSA-Ab2, IL-6-Ab2, PSMAAb2, PF4-Ab2 in 2 % BSA, PBS Tween-20; at pH7.2) and a control (2 % BSA, PBS Tween-20; at
pH7.2) was estimated from the linear calibration curves. After exciting at 280 nm, the fluorescence
intensity obtained for control was 180 and for the bio-conjugate label was 310. The difference was
calculated to be 130 and the corresponding concentration for Ab2 from calibration curve obtained
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was 39.9 µgmL-1. The number of Ab2 in the ECL bio-conjugate label was calculated to be 1.5 X
1014. Therefore the ratio of Ab2/RuBPY Silica nanoparticles was estimated to be 44:1.

A

B

Figure 2-3. Influence of concentration of secondary antibody and [[Ru-(bpy)3]2+] on fluorescence
intensity (a) at 280nm wavelength with [secondary antibody] range: 3.125 - 75 μg mL-1. (b) at 457
nm wavelength with [[Ru-(bpy)3]2+] range: 0.5 - 2 mg mL-1

[[Ru-(bpy)3]2+] per RuBPY-Si nanoparticle. A calibration curve for different RuBPY was
prepared using fluorescence spectroscopy by exciting at 457 nm. The unknown concentration of
RuBPY in the bio-conjugate label was determined by extrapolating from the linear calibration
curve (Figure 2-3B). The number of moles were obtained using the molecular weight of Tris(2,2’bipyridine)dichlororuthenium(II) hexahydrate, 748.62. The number of Ru-(bpy)3]2+ ions were
estimated using Avogadro’s number. Rel. fluorescence intensity 192 was obtained for ECL- bioconjugate label when excited at 457 nm. The amount of Ru-(bpy)3]2+ ions was estimated to be 1.9
mg/mL and the number of Ru-(bpy)3]2+ ions were calculated to be 1.55 x1018. The number of Ru-
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(bpy)3]2+] ions per particle were estimated by dividing with the total number of RuBPY silica nano
particles in 1 mL of bio-conjugate label dispersion, which is 4.6 X 105.

Figure 2-4. Fabrication of printed circuit board integrated with potentiometer and micro controller
units connected to micro pumps. A) PCB circuit design prepared on autocad for integrating 6 micro
controller units printed on glossy paper. B) PCB design heat transferred on copper plate. C) Etched
copper plate with conductive tracks for assembly of various electronics. D) Micro controller units
mounted on the bottom side of PCB. E) 15 turn Potentiometers mounted on the top side of PCB.

2-3.7 Microfluidic device. Figure 1 shows the automated microfluidic immunoarray featuring (i)
printed-circuit board (PCB)-linked, microprocessor-controlled micropumps, (ii) 6-channel
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sample/reagent delivery cassette, and (iii) 6-channel microfluidic detection array. A PCB circuit
design was constructed to serve 6 micropumps. Micropumps (Mp6, Bartels) featuring piezoactuated membranes were optimized to 155 ± 1.5 µL min-1 by tuning potentiometers for each pump

(Figure 2-4). An Arduino microcontroller was used to switch on and off micropumps according to
a preset program to deliver sample and immunoreagents, and to stop flow for incubations (Figure
2-5).

Figure 2-5. Arduino program for automated stepwise delivery of sample/reagent into the ECL
immunoarray from sample/reagent loading cassette.

Microfluidic channels were made by precision cutting 0.80 mm silicone gaskets (MSC
industrial Supply) with the desired patterns using an inexpensive, programmable Accugraphic
Klic-N-Kut (KNK) groove cutting machine. The cut gaskets (Figure 2-6A) were placed, between
two machined hard PMMA plates (Figure 2-6B&C) to assemble the final sample/reagent delivery
cassette (Figure 2-6D. The final assembled sample/reagent delivery cassette was 11 in x 5.5 inches
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with six channels, each having 7 loading chambers separated individually by smaller air-filled
channels to ensure delivery of reagents without mixing (Figure 2-6D). The top PMMA plate was
machined with 1 mm dia. holes to fill the chambers, and the bottom plate has screw holes to tighten
and seal the assembly. Each chamber holds 80 µL volume. Chambers were prefilled by syringe,
and openings sealed with tape

Figure 2-6. Immunoarray components: On left, sample/reagent delivery cassette consisting of (A)
0.8 mm silicon gasket cut to scale using a KNK cutter, (B) Upper hard PMMA plate machined
with injection ports, (C) lower PMMA plate and (D) Assembled sample/reagent cassette shown
with chambers for solutions, assembled with screws. Right panels show detection array consisting
of (E) PG wafer with computer-printed microwells, (F) silicone gasket cut with 6 precision
channels, (G) top PMMA plate showing attached stainless steel counter electrode on top with clear
windows for ECL detection and Ag/AgCl reference electrode and (H) fully assembled microfluidic
detection array with clear windows in top PMMA plate positioned above microwells in each
channel.
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The detection chamber also features 6 microfluidic channels (60 ± 2 µL) cut from a silicone
gasket that is then placed on a thin 2 x 3 in PG wafer with computer-printed microwells22,30 (Figure
2-6E). This gasket (Figure 2-6F) is placed on the PG slab and sealed by bolting between two flat
machined PMMA plates. The top PMMA plate (Figure 2-6G) houses symmetrically placed
Ag/AgCl reference and stainless steel metal shim (MSC Industrial Supply) counter electrodes that
are aligned into each of six channels completing a symmetric electrochemical cell with the entire
PG chip as working electrode (Figure 2-6H). The top PMMA plate is fitted with optically clear
acrylic22 windows above each microwell channel to pass ECL light to a CCD camera.

Roughness: 10 ± 2 nm

A

Roughness: 17 ± 4 nm

C

Roughness: 17 ± 4 nm

Roughness: 10 ± 4 nm

B

D

Hydrophobic
Toner
100 nm

SWCNT Forest

Figure 2-7. Tapping mode AFM images (A) Nafion/FeO(OH)-FeOCl bilayer on freshly cleaved
mica surface; (B) SWCNT forests on Nafion/FeO(OH)-FeOCl bilayer; (C) SWCNT forests on
Nafion/FeO(OH)-FeOCl bilayer at the edge of microwell formed by hydrophobic toner
boundaries; (D) Covalently linked Ab1 on SWCNT forest in the bottom of a microwell.
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Dense SWCNT forests were grown in each microwell (volume 2 ± 0.5 L).22,31 Tappingmode atomic force microscopy and Raman spectrum confirmed vertical aligned SWCNT forests

in the microwells with surface roughness 17 ± 4 nm surrounded by the hydrophobic printed wall
(Figure 2-7 & 2-8). Terminal carboxylic groups on SWCNTs were activated by freshly prepared
400 mM EDC + 100 mM NHSS to attach cognate primary antibodies (Ab1) by amidization.22,28
Figure 2-8. Raman spectrum of SWCNT forest on a silicon wafers over frequency range using E
laser

= 514 nm showing the radial breathing mode (RBM), the graphite-like in-plane mode G-band,

the disorder-induced D-band and its second-order harmonic G'-band.

2-3.8 Immunoassay Protocol, The Ab1-decorated PG chip microwells containing SWCNT-Ab1
were spotted with 2% BSA in PBS containing 0.05% Tween 20 to minimize non-specific binding
(NSB). The PG chip was assembled into the detection chamber, which was then connected to a
prefilled sample/reagent cassette. The Arduino microcontroller precisely times sample and reagent
delivery by micropumps to the detection chamber according to a pre-optimized program.
The immunoassay protocol was developed by optimizing micropump flow rates (Figure 29), using a 15 turn 10kOhms. Flow rates were optimized at 155 µL-1 by carefully changing the
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amplitude of all the micro pumps while turning the screw of the potentiometer. Incubation times
were also optimized for protein binding steps to ensure high sensitivity and reproducibility with
spot to spot variability <10%. The capture antibody-decorated immunoarray sensor chamber was

incubated with 2% BSA in PBS T20 prior to the assay to block the non-specific binding (NSB) for
50 min, then washed with PBS T20 and PBS. Patient serum samples of 5-10 µL were diluting 30500 fold in calf serum prior to assay.

Figure 2-9. Optimization of flow rates using 15 turn 10kOhm potentiometers mounted on PCB,
Figure showing six potentiometers used for setting the amplitude of all the 6 micropumps. Table
in the figure shows average flow rate of all the micropumps along with their individual flow rates
and standard deviation.
Once the sample/reagent cassette is loaded, micropumps turn on initially for 55 s to deliver
sample to the detector. Second, flow is stopped for 20 min to allow analyte proteins in the sample
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to bind onto Ab1’s in microwells. Next, micropumps activate again for 220 s to deliver wash buffer
to move sample solution and unbound target proteins out of the detection channels. Then, pumps
deliver RuBPY-Si-Ab2 nanoparticles to the detector, and a 900 s stopped-flow incubation follows.
Flow then turns on to wash away unbound RuBPY-silica nanoparticles. Finally, with the detection
STEP 1: TPrA → TPrA•+ + eSTEP 2: TPrA•+ → TPrA• + H+
STEP 3:
TPrA• + [Ru-(bpy)3]2+] → [Ru-(bpy)3]+] + Products
STEP 4:
[Ru-(bpy)3]+] + TPrA•+ → [Ru-(bpy)3]2+]* + Products
STEP 5:
[Ru-(bpy)3]2+]* → [Ru-(bpy)3]2+] + hʋ (610 nm)

chamber in a dark box, micropumps deliver TPrA co-reactant to the detection channels (Scheme
2-2), and a potential of 0.95 V vs. Ag/AgCl is applied for 400 s to generate ECL from RuBPY-Si
particles, while a CCD camera captures the ECL light.

Scheme 2-2. ECL generation mechanism at 0.95 V vs Ag/AgCl when reacted with tripropylamine
that in turn reacts with RuBPY. Direct oxidation of Tripropylamine (TPrA) on the electrode
surface to TPrA cation radical which in return forms TPrA radical and H+. TPrA radical reacts
with [[Ru-(bpy)3]2+] to generate [[Ru-(bpy)3]+]. This [[Ru-(bpy)3]+] reacts with TPrA cation radical
to generative photo excited [[Ru-(bpy)3]2+]* that readily generates ECL light at 610nm

2-4.

Results

2-4.1 Reproducibility Relative ECL intensities for the immunoarray with controls (undiluted calf
serum) showed spot to spot variability of <9 % for n=5 per channel (Figure 2-10). First and the
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last channels were used for controls and the inner 4 channels were used for detection of the four
target proteins. Array to array reproducibility of background signals was measured by injecting

undiluted calf serum into all six channels (Figure 2-10) giving array to array variability ~11 %.
Calibrations were then done for each of the four individual proteins in calf serum giving relative
standard deviations <10% (see Figure 2-11 and 2-12).
Figure 2-10. Reproducibility of immunoarray (n=3) to undiluted calf serum (control 0 pg mL-1
test protein)
Figure 2-11. Recolorized ECL CCD images (A-D) for different concentrations showing
reproducibility of individual biomarkers. A) IL-6 from 0.1 pgmL-1 to 125 pgmL-1 B) PF-4 from
0.1 pgmL-1 to 250 pgmL-1 C) PSA from 0.1 pgmL-1 to 100 pgmL-1 D) PSMA from 0.1 pgmL-1 to
A

B

C

D

100 pgmL-1. ECL images were accumulated over 400 seconds in dark box at 0.95 V versus
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Ag/AgCl in the presence of 0.05 % Tween-20+0.05 % Triton-X 100 and 200 mM TPrA in 0.2 M
phosphate buffer, pH 7.4

A

B

C

D

Figure 2-12. Calibration curves for single biomarker detection A) IL-6 from 0.1 pgmL-1 to 125
pgmL-1 B) PF-4 from 0.1 pgmL-1 to 250 pgmL-1 C) PSA from 0.1 pgmL-1 to 100 pgmL-1 D) PSMA
from 0.1 pgmL-1 to 100 pgmL-1. Error bars show standard deviation, n=5.

2-4.2 Multiplexed detection. . Calibration studies were done by dissolving the four target protein
standards in calf serum, which serves as a human serum surrogate without human proteins.31 Thus,
the four proteins were detected selectively and simultaneously from samples containing thousands
of proteins. Channels 1 and 6 in the detection array were used as controls, and only undiluted calf
serum was introduced into these channels. Channels 2 to 5 were assigned for detection of IL-6,
PF4, PSMA and PSA, respectively. Simultaneous detection was achieved by using a mixture of
the 2 RuBPY-Si-Ab2 detection nanoparticles that were each decorated with antibodies for 2 of the
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4 proteins. RuBPY-Si-Ab2 were prepared with 4.5 x 105 [[Ru-(bpy)3]2+] ions and 44 Ab2 per
particle.

Figure 2-13. Recolourized CCD images of 3 microfluidic immunoarray experiments showing
reproducibility in simultaneous detection of IL-6, PF-4, PSMA and PSA in calf with respective
controls at protein concentrations: (A) 10 pg mL-1 (B) 1000 pg mL-1 (C) 5000 pg mL-1.

Figure 2-14. Calibration curves in undiluted calf serum, with ECL responses integrated over 400
s, for A) IL-6 B) PF-4 concentration on ECL signal, C) influence of PSA concentration on ECL
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signal, D) influence of PSMA concentration on ECL signal. Error bars show standard deviation,
n=5.
CCD camera images of the ECL response for multiple protien detection (Figure 2-13)
illustrate increased ECL light with increased concentrations of proteins in the mixture. Using the
average ECL signal divided by the average blank on each chip, we achieved dynamic ranges for
of 100 fg mL-1 to 1 ng mL-1 for PSA ,100 fg mL-1 to 10 ng mL-1 for PSMA, and 100 fg mL-1 to 5
ng mL-1 for IL-6 and PF-4 (Figure 2-14). There is a small amount of nonlinearity in these curves
so powerfit was used as curve fitting with corelation coefficient (R) value ≥ 0.99, but they are
perfectly suitable for use in protein determinations. Limits of detection (LD) were measured 3
standard deviations of the zero protien control signal at 50 fg mL-1 for PSA , 100 fg mL-1 for PSMA
and IL-6, and 10 fg mL-1 for PF4.
2-4.3 Assay validation. Nine serum samples from prostate cancer patients and two samples from
cancer free patients were analyzed and compared with single protein ELISA. ELISA was
performed on the samples using commercially available kits, PSA (RAB0331- Human PSA total
ELISA kit), IL-6 (RAB0306- Human IL-6 total ELISA kit), and PF-4 (RAB0402- Human PF-4
total ELISA kit) were obtained from Sigma Aldrich. PSMA (EL008782HU-96 – Human
PSMA/FOLH1 ELISA Kit) was obtained from Lifeome Biolabs/Cusabio. Samples were diluted
30-500 fold in calf serum prior to assay to bring ECL responses in acceptable range of the
calibration curves. Concentrations of PF-4, PSMA and PSA fall within the detection limits of
ELISA but IL-6 concentrations in the serum samples were well below the detection limit of ELISA.
For purposes of the validation study, we spiked the samples with known concentrations of IL-6
from 100 pg mL-1 to 500 pg mL-1 and then analyzed them by both methods. The immunoarray
values gave good correspondence with ELISA values (Figure 2-15). Variability of the assay in
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terms of standard deviations might have resulted in small variation in the spiked human serum
sample of IL-6 results for ECL and ELISA. Unspiked samples gave IL-6 values from <1 to ~17

A

B

C

D

pg mL-1 (Figure 2-16)

Figure 2-15.

Assays of human serum samples comparing immunoarray single protein ELISA

Results. Samples 1 - 9 from prostate cancer patients and 10-11 from cancer-free patients. A) IL-6
was spiked into samples as follows: 1 (500 pg mL-1), 2 (450 pg mL-1), 3 (400 pg mL-1), 4 (350pg
mL-1), 5 (300 pg mL-1), 6 (250 pg mL-1), 7 (200pg mL-1), 8 (150 pg mL-1), 9 (100 pg mL-1), 10
(30 pg mL-1), 11 (20 pg mL-1). (B) PF-4 (C) PSA, and (D) PSMA. Error bars are standard
deviations for ECL (n=5) and ELISA (n=3).
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Figure 2-16. IL-6 results from unspiked human serum samples from ECL array.

Linear correlation plots of the ELISA vs. immunoarray data (Figure 2-17, Table 2-1) gave
slopes that were all close to 1.0, i.e. 1.14 ± 0.1 for IL-6, 0.97 ± 0.046 for PF-4, 1.11 ± 0.035 for
PSA and 0.96 ± 0.029 for PSMA. Intercepts of these plots were within one standard deviation of
zero, i.e. 0.022 ± 0.029 for IL-6, 0.011 ± 0.029 for PF-4, -0.0367 ± 0.158 for PSA and -0.013 ±
0.021 for PSMA. Excellent correlation of the automated immunoassay results with ELISA on
patient serum samples confirms the high selectivity and specificity of the assay for each of the four
proteins in the presence of thousands of other proteins, many at higher concentrations, in the
human serum 32.

Figure 2-17. Correlation plots of ELISA vs. ECL immunoarray for human serum samples for (A)
IL-6, (B) PF-4, (C) PSA, and (D) PSMA.
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Table 2-1 Results from correlation plots of ECL array assays vs. ELISA for patient samples
Protein
PSMA

2-5.

Slope

Intercept

Correlation Coefficient

0.96 ± 0.029 -0.013 ± 0.021

0.9959

PF-4

0.97 ± 0.046

0.011 ± 0.029

0.9898

PSA

1.11 ± 0.035 -0.367 ± 0.158

0.9955

IL-6

1.14 ± 0.100 -0.022 ± 0.029

0.9675

DISCUSSION
Results above demonstrate an automated immunoarray requiring minimal operator

attention for sensitive, simultaneous quantitative measurements of up to 4 proteins. Once the
sample/reagent cassette is filled, automated operation and detection takes less than 40 min.
Including two control lanes in the detector enables dividing the average protein signals by the
average blank signal for each individual assay to minimize chip-to-chip variability (Figure 2-12).
Ultrasensitive detection in serum was achieved down to concentrations of 10 fg mL-1 over dynamic
ranges of 5 orders of magnitude in concentration (Figure 2-14). We observed relative standard
deviations ranging from 1-15%, these standard deviations do not effect the value of the assay since
we were able to achieve comparable or better standard deviations than ELISA (Figure 2-15).
Immunoarray assays showed very good correlations with standard ELISA for serum from prostate
cancer patients using only 5-10 µL of sample (Figures 2-15 and 2-17). Selectivity and specificity
of the assay was established by determining the four proteins of interest from a pool of thousands
of proteins present in human serum samples.32 In addition, the immunoarray successfully
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determined levels of IL-6 below 3 pg mL-1 (Figure 2-16) that were below the detection limit of
ELISA.
Automation of the methodology is under control of the Arduino microcontroller that turns
micropumps on and off according to a preset program and controls the flow of reagents from the
preloaded sample/reagent cassette to the detection chamber then to waste (Figure 2-1). This open
source electronic platform is very cheap and utilizes free software. The program is easily changed
to accommodate changes in the assay protocol, so that the system can be adapted to any reasonable
set of assay conditions.
The microfluidic channels (Figure 2-6) in the sample/reagent cassette and the detection
chamber were precision cut using an inexpensive, programmable KNK cutter from a 0.8 mm
silicon gasket of the kind used in automobile engines. The cut gaskets are then press fitted between
appropriately machined hard plastic plates to seal the channels and provide inlets and outlets. This
approach is cheap and versatile, allows rapid design changes, and avoids lithography, molding and
polymerization steps. The resulting system performs as well or better than a non-automated ECL
microfluidic immunoarray we constructed using molded, polymerized polydimethylsiloxane
(PDMS) channels.22 Sample/reagent cassette and detection device made by this approach costs
just 15$, whereas micropumps and other electronics cost 450$. All these components are reusable,
making the cost per assay very economical.
We have adapted several features from our earlier non-automated immunoarrays to the
automated system. Utilization of the SWCNT forests in detector chip microwells provides a higharea nanostructured surface to enhance antibody concentration in each microwell, contributing
significantly to high sensitivity.27,28 The multilabel RuBPY-Si-Ab2 nanoparticle provides nearly ½
million RuBPY labels per bound target protein to provide the second important component for
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ultrasensitive detection. The use of TPrA in Triton X-100 detergent solution as co-reactant allows
a detection potential of 0.95 V vs. Ag/AgCl where only TPrA is oxidized electrochemically to
enhance production and deprotonation of TPrA*+ to drive the complex redox process that provides
electronically excited [RuBPY]2+* for ECL.22,27,33

2-6.

SUMMARY
In summary, a cheap, automated, microprocessor controlled microfluidic immunoarray has

been developed for simultaneous detection of four prostate cancer biomarkers at high sensitivity.
Inexpensive components and simple fabrication procedures facilitate a low cost device costing
about $550 in materials. The device is versatile and in principle can be reprogrammed for the
detection of virtually any small protein panel.
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CHAPTER 3

3D-Printed Supercapacitor-Powered Electrochemiluminescent
Protein Immunoarray

3-1. Abstract
Herein we report a low cost, sensitive, supercapacitor-powered electrochemiluminescent
(ECL) protein immunoarray fabricated by an inexpensive 3-dimensional (3D) printer. The
immunosensor detects three cancer biomarker proteins in serum in 35 min. The 3D-printed device
employs hand screen printed carbon sensors with gravity flow for sample and reagent delivery and
washing. Prostate cancer biomarker proteins prostate specific antigen (PSA), prostate specific
membrane antigen (PSMA) and platelet factor-4 (PF-4 ) in serum were captured on the antibodycoated carbon sensors followed by delivery of detection-antibody-coated Ru(bpy)32+ (RuBPY)doped silica nanoparticles in a sandwich immunoassay. ECL light was initiated from RuBPY in
the silica nanoparticles by electrochemical oxidation with tripropylamine (TPrA) co-reactant using
supercapacitor power and ECL was captured with a CCD camera. The supercapacitor was rapidly
photo-recharged between assays using an inexpensive solar cell. Detection limits were 300-500 fg
mL-1 for the 3 proteins in undiluted calf serum. Assays of 6 prostate cancer patient serum samples
gave good correlation with conventional single protein ELISAs. This technology could provide
sensitive onsite cancer diagnostic tests in resource-limited settings with the need for only
moderate-level training.
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3-2. Introduction
The recent emergence of inexpensive 3D printers offers revolutionary low cost options for
designing and constructing biosensor systems. 1 Fabrication of microfluidic devices by 3D-printing
has been explored for rapid prototyping. Early applications include master for faster production of
microfluidic channels from PDMS 2 and reaction ware for chemical synthesis and spectroscopic
analysis. 3,4 Flow injection systems for monitoring metal ions 5 and add-on accessories for turning
smartphones into sensors for food allergens and albumin have been printed. 6,7,8,9,10 Milli- and
microfluidic devices have been printed for nanoparticle synthesis.11, 12 Other applications include
calorimetry, 13 cell growth monitoring 14, blood evaluation 15 and pathogenic bacteria detection. 16
Electrochemical sensing integrated into a 3D-printed fluidic device was used to detect dopamine
and nitric oxide. 17 We recently reported a 3D-printed microfluidic amperometric sensor for
hydrogen peroxide. 18
Microfluidic arrays integrating complex procedures into simple, portable, inexpensive
diagnostic platforms will be valuable for future personalized healthcare.

19,20

Detection of

biomarker panels holds great promise for early cancer detection and monitoring, 21,22,23,24,25 and
promises to lead to improved therapeutic outcomes. 26 Ideally, widespread clinical applications
will require low cost, low tech, multiplexed assay devices.21,22,23,24,25,27 Sensitive, fast, accurate
multiplexed protein detection has been achieved using conventionally fabricated microfluidic
arrays integrated with nanoscale materials.23,24,25,28
Microfluidic array devices are often made using lithography, 29,30,31,32 but prototype
development time and cost can be limiting factors. Injection molding can also be used, but both
approaches require economies of scale to become cost effective. 33,34 We have developed
microfluidic arrays for multiple biomarker detection using molded or precision cut microfluidic
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channels. We coupled amperometric detection on gold nanostructured sensor arrays with magnetic
particles massively loaded with enzyme labels and antibodies, and demonstrated simultaneous
ultrasensitive detection of up to four cancer biomarker proteins. 35,36,37 We also developed
electrochemiluminescent (ECL) 38 arrays with antibody-coated Ru(bpy)32+ (RuBPY)-doped silica
nanoparticles for detection on single wall carbon nanotube forests patterned on pyrolytic graphite
chips. 39,40 Both approaches utilized non-lithographic fabrication to achieve ultrasensitive detection
of multiple proteins in short assays (~35 min). Nonetheless, decreasing time and cost of
prototyping and optimizing such devices may lead to benefits in faster translation to public health
care. 41
Electronically simple, miniature power sources are also important for clinical immunoarray
development. Small supercapacitors, i.e. high performance electrochemical capacitors (EC) that
store electrical energy, 42 have not been widely explored for powering sensors. They have unique
advantages including high power density, multiple cycling capability43and fast charge-discharge
rates. 44 There are few reports of integrating supercapacitors into analytical systems for signal
amplification, 45,46 but no examples of powering biosensors.
Herein we report a 3D-printed, gravity flow microfluidic immunoarray for multiple protein
detection. These arrays are powered by inexpensive light-rechargeable supercapacitor costing €10
that supplies voltage to screen-printed carbon electrodes for electrochemiluminescence (ECL)
light generation that is detected by CCD camera. Simultaneous measurement of prostate cancer
biomarkers, prostate specific antigen (PSA), 47,48 prostate specific membrane antigen (PSMA) and
platelet factor-4 (PF-4) 49 was achieved at clinically relevant detection limits 0.3-0.5 pg mL-1. To
our knowledge, this is the first 3D-printed microfluidic immunosensor, and first application of
supercapacitors to a voltage-driven biosensor. Assays of human serum from cancer patients and
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cancer-free controls gave good correlations to single-protein enzyme-linked immunosorbent
assays (ELISA).

3-3. Experimental Section
3-3.1 Chemicals and Materials
Polylactic acid (PLA) filaments, 1.75 mm diameter for 3D-printing were from MakerBot.
Carbon graphite (C2050106D7) and silver/silver chloride inks (C2051014P10) were from Gwent
Electronics. Poly(diallyldimethylammoniumchloride) (PDDA), poly(acrylic acid) (PAA), bovine
serum albumin (BSA), 1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimidehydrochloride (EDC)
and N-hydroxysulfosuccinimide (NHSS) were from Sigma. Pooled human serum samples were
from Capital Biosciences and individual patient serum samples were provided by George
Washington University Hospital. Calf serum as a surrogate for human serum 50 was used for all
calibrations with standard proteins.

3-3.2 Array Device Fabrication
A commercial desktop 3D Fused Deposition Modeling (FDM) printer, MakerBot
Replicator 2X, was used. The microfluidic immunoarray was printed from polylactic acid (PLA). 51
Initially, a computer-aided design (CAD) was created with 123D Design (Autodesk), and
converted to 3D printer format using splicing software. Optimized printer settings are crucial for
good resolution and reproducibility. The heated platform was set to 60 ºC and extruder temperature
was 230 ºC, with layer height 200 µm. Extruder speed while travelling was optimized at 80 mm s1

, whereas speed while extruding was 40 mm s-1. Figure 3-1A shows the main array printed with

40 mm length x 30 mm width of the base. It has three reagent chambers connected to a common
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downstream microfluidic channel, Figure 3-2. The volume of the reagent chambers is 170 ± 5 µL
and the volume required for the microfluidic channel to fill completely is 160 µL. Reservoir
volumes were chosen to completely fill the detection channel in a horizontal position under
hydrostatic pressure. The reservoirs are prefilled with sample or reagents through port holes
located in custom fit 3D-printed inserts (Figure 3-1A) with rods that seal the outlets of the
reservoirs. Flow of sample and reagents is controlled by placing the insert to seal the reservoir, or
removing it to drain the reservoir into the detection channel in a horizontal position. All reagents
are prefilled on the array, and the operator needs only to release reagents sequentially by removing
the inserts.

Figure 3-1. 3D-printed main array and wash reservoir module. (A) Basic array showing three
reagent reservoirs equipped with inserts along with flow path for reagents to reach microfluidic
channel. (B) Wash reservoir module (1B Left) 3D model showing freely moving lever to change
between wash and load position along with wash reservoirs aligned with main array, (1B Right)
assembled immunoarray setup with both main array and wash module.
Figure 3-1B shows the add-on wash reservoir designed to work with a lever-assisted
moving platform device that accommodates the sensor array, wash reservoirs and a waste collector
at the bottom. The wash reservoir was designed to align with reagent reservoirs of the main array
and is 68 mm length x 44 mm width x 26 mm height with capacity of ~1.6 mL buffer. Wash buffer
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in these reservoirs is used to wash off excess sample/reagent from the main array microfluidic
channels after the immunoassay. Wash reservoirs employ custom fit inserts to turn flow on and off
similar to the reagent chambers. Normal load position has the detection channel with the sensors
horizontal. Changing the lever on the wash reservoir to wash position provides a 25º tilt angle to
the sensor array (Figure 3-1B), which enables washing of the immunoreagents to a waste chamber
at the bottom of the detection channel.

Figure. 3-2. Bottom view of main array showing reservoir’s outlet leading to microfluidic channel.
(A) Blue color food dye solution released from reservoir 1 reaching a common microfluidic
channel (B) Blue color food dye solution released from reservoir 2 reaching a common
microfluidic channel (C) Blue color food dye solution released from reservoir 3 reaching a
common microfluidic channel.
The sensor electrodes were fabricated by hand screen printing carbon graphitic ink using a
patterned adhesive-backed vinyl mask template. 52 First, a mask template was designed using
AutoCAD and converted to compatible format for cutting, then a vinyl mask was cut using a
portable precision desktop cutter (Cameo®, Silhouette America, Inc.). A vinyl sheet was patterned
with a common working electrode and a counter electrode. Then, this vinyl mask was transferred
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onto heat resistant transparency film (Highland

TM

707 clear film) and screen printing was done

by spreading a thin layer of carbon graphitic ink evenly over the patterned surface, followed by
heating at 90 ºC for 15 min. Subsequently, the adhesive vinyl mask was removed revealing the
patterned screen printed electrodes (Figure. 3-3A). A patterned 100 µm thick lamination film with
holes revealing the electrodes was also made by precision cutting. These lamination films were
sealed onto the pattern of electrodes in a heat press at 110 ºC, creating hydrophobic microwells
around the sensors that hold up to 5 µL of aqueous solution (Figure 3-3B). Lastly, a template was
patterned from transparency film to print Ag/AgCl paste reference electrode (Figure 3-3B). The
laminated, screen-printed sensor assembly was then attached to the 3D-printed immunoarray using
silicone glue (Proseal clear RTV silicone adhesive sealant), which was dried for at least 2 hr (Figure
3-3C).
Supercapacitors (Cellergy, 2.1 V, 80 mF) used to power ECL arrays were low equivalent
series resistance (ESR) aqueous state electrolyte, high output electrochemical double layer
capacitors (EDLC’s). A solar panel (Sparkfun, 0.45 W, 94 mA) was used to charge the
supercapacitor to 1.5 V under ambient room, sun, or iPhone light. Voltage was checked with a
digital multimeter prior to every experiment to ensure accuracy.

ECL was generated by

electrochemical oxidation of both tripropylamine (TPrA) and RuBPY on the sensors when 1.5 V
was applied. This initiates a complex redox pathway involving RuBPY in the silica nanoparticle
and results in electronically excited [RuBPY]2+* that emits light at 610 nm.38,53 Generated ECL
was captured from the sensor array using a CCD camera.39
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Figure 3-3. Schematic representation of steps for screen printing carbon electrodes and assembling
the immunosensor chip. (A) Technique to screen print carbon graphitic ink over the vinyl electrode
template using an ink spreader followed by heating to form solid screen printed electrodes. (B)
Laminating the exposed electrodes to leave 4 microwells followed by screen printing Ag/AgCl
reference electrode. (C) Printed electrodes glued to complete immunoarray device.

RuBPY-silica nanoparticles (RuBPY-SiNP) with average diameter of 117 ± 10 nm were
synthesized and characterized as described previously and coated with successive layers of PDDA
and PAA, followed by covalently linking secondary antibodies to –COOH groups of PAA.39 Three
different RuBPY-SiNP-Ab2 were prepared featuring anti-PSA, anti-PSMA and anti-PF-4 as Ab2.
Optimized Ab2 concentrations for attachment onto RuBPY-SiNPs were 8 µg mL-1 for PSA, and
7.5 µg mL-1 for PSMA and PF-4, Figure 3-4. For simultaneous detection of all 3 proteins, the three
RuBPY-SiNPs were mixed in equal proportions. The Ab2/RuBPY-SiNP ratio was measured at
38:1. Estimated yield and cost for preparation of silica nanoparticle-Ab2 bio-conjugate per assay
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is approximately 47 % and €0.20 respectively. Covalent linking of antibodies to RuBPY silica
nanoparticles have been successfully used previously39,40 and are stable up to 30 days when stored
at 4ºC. TprA at 350 mM in 0.2 M phosphate buffer + 0.05% Tween-20 (T20) and 0.05% Triton-X
at pH 7.5 was used as ECL co-reactant.

Figure 3-4. Optimization of detection antibody (Ab2) concentrations used to derivatize RuBPY
silica nanoparticles. Concentrations in the circle were found to give largest difference between
control and protein signal: (A) PSA, optimized Ab2 8 µg mL-1 (B) PSMA, optimized Ab2 is 7.5 µg
mL-1 (C) PF-4, Optimized Ab2 7.5 µg mL-1

3-3.3 Assay Procedure
Carbon sensors were modified by covalently attaching capture antibody (Ab1) using EDCNHSS. Complete details in supplementary information. Ab1-coated sensors were incubated with 1
% casein in PBS for 1 hr to minimize non-specific binding (NSB). These capture antibody coated
carbon sensors are stable up to 7 days when stored at 4ºC. Reagent chambers on the array were
prefilled with serum samples, detection antibody (Ab2)-coated RuBPY-SiNP dispersions, and
TprA solution. Serum samples (2-5 µL) were first diluted 500-fold in calf serum prior to loading.
Delivery of sample/reagents from prefilled reservoirs of the main array is accomplished by
removing the insert top. The reagents flow downstream to fill the detection channel. Prefilled wash
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buffers from wash reservoirs flush the detection channel when the wash module lever is adjusted
to 25º tilt angle.

Figure 3-5. Details of the assay procedure: (A) Cartoon showing removal of insert for sample
delivery from reservoir by gravity flow. (B) Load position shown with blue food color solution
filling the horizontal detection channel with lever up. (C) Cartoon showing buffer delivery from
wash reservoir to detection channel for washing away unbound proteins (inset shows sandwich
immunoassay on sensors). (D) Wash position showing blue food color solution delivered from
wash reservoir to main array when lever is down for 25º tilt of detection channel.

Individual assay steps are: (1) Release sample from its reservoir to fill the detection channel
and incubate for 20 min (Figure 3-5A) in horizontal load position (Figure 3-5B). This allows
analyte proteins to be captured on Ab1-coated sensors. (2) Move platform to wash position (25o
tilt) by pushing the lever down, then release wash buffer from its reservoir (Figure 3-5C). Buffer
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from the larger wash reservoir passes through the sample reservoir into the detection channel and
flushes unbound protein to waste (Figure 3-5D). (3) The platform lever is then returned to the load
position, followed by release of Ab2-RuBPY-SiNPs into the horizontal detection chamber, and
incubation for 15 min is allowed to bind to previously captured proteins. (4) Wash unbound silica
nanoparticles to waste by placing the lever in wash position. (5) TPrA solution is released from its
reservoir into the horizontal detection channel, the array is placed under the CCD camera in a dark
box and potential of 1.5 V vs. Ag/AgCl is applied with the supercapacitor to generate ECL for 60
s. Acquired ECL images are then processed by software to estimate light intensities from each
microwell on the array.39

Figure 3-6. Scanning electron microscopy (A-B) PDDA/PAA modified SCE at (A) 5 µM scale
revealed rough surface (B) 1 µM scale image for SCE.
3-4. Results
3-4.1 Array Characterization & Optimization
Surface areas of the screen printed electrode, Figure 3-6 were measured from cyclic voltammetry
(CV) of 0.06 mM methanol (FcMeOH) in 1 M NaCl from 10 - 750 mV s-1 showing a diffusioncontrolled, one electron reversible oxidation-reduction peak pair with separations 60-67 mV,
Figure 3-7. From the slope of peak current (ip) versus square root of scan rate (ν1/2) using the
Randles-Sevcik equation, 54 and diffusion coefficient 2.5 x 10-7 cm2 s-1, Figure 3-8 55 estimated
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surface area of the printed electrodes at 0.293 ± 0.015 cm2, RSD ± 5% (n=12). Electrochemically
measured area is higher compared to geometric area of 0.071 cm2 due to the rough, porous nature
of the screen printed electrodes as confirmed by scanning electron microscopy, Figure 3-6.
Supercapacitor was characterized by cyclic voltammetry (CV), Figure 3-7B and by observing
galvanostatic charge-discharge cycles (CC), Figure 3-7C. Results show rectangular CVs at scan
rates up to 2 V s-1, as well as triangular CC curves at current density 30 mA cm-2 suggesting nearly
ideal capacitive behavior under fast charge-discharge conditions.

Figure 3-7. Electroanalytical characterization of sensors and supercapacitor: (A) Cyclic
voltammograms of screen printed carbon electrodes with 0.06 mM FcMeOH in 1 M NaCl,
showing oxidation-reduction reversible peak pair separated by ~60 mV at low scan rates. (B) CV’s
for supercapacitors up to 2 V s-1 showing nearly ideal electrical double layer capacitance behavior.
(C) Galvanostatic charge-discharge cycles at current density 30 mA cm-2. (D) Recolorized ECL
images demonstrating reproducibility between 9 spots across 3 arrays at 0 pg mL-1 PF-4; (E)
Recolorized ECL image demonstrating reproducibility between 9 spots across 3 arrays at 500 pg
mL-1 PF-4. (F) Mounted supercapacitor connected to ECL array inside a dark box.
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Figure 3-8. Cyclic voltammetry characterization of screen printed carbon electrode showing
trumpet plot of peak current vs. square root of scan rate.

Figure 3-9. Calibration curves for single protein detection (A-C) demonstrating good
reproducibility: A) PSA from 0.5 pg mL-1 to 10,000 pg mL-1 B) PSMA from 0.5 pg mL-1 to 10,000
pg mL-1 C) PF-4 from 0.5 pg mL-1 to 10,000 pg mL-1.Error bars show standard deviation, n=3.
3-4.2 Reproducibility & Immunoarray Calibrations
Reproducibility of array sensors was evaluated at 0 and 500 pg mL-1 for the 3 protein analytes.
Variation in relative ECL intensities was ≤ 7 % (n=3) array-to-array and ≤10 % spot-to-spot (n=9)
(Figure 3-7D&E. Out of four sensors on the array, sensors 1, 3 and 4 were used for specific protein
detection. Sensor 2 at the center was used to measure background for each array, and was coated
with 1 % casein only. Calibrations were done for all 3 proteins individually in calf serum, with
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relative standard deviations ≤ 13 % Figure 3-9. Figure 3-7F shows the supercapacitor mounted on
a printed circuit board (PCB), connected to the array inside a dark box to generate ECL.

Figure 3-10. Calibration data in undiluted calf serum showing influence of biomarker protein
concentration on ECL response: (A) Recolorized ECL images of 8 arrays with showing increase
in ECL intensity with increased concentration. ECL signals digitized for (B) PSA, (C) PSMA and
(D) PF-4 in calf serum. Error bars show standard deviation for n = 4.
We tested the immunoarrays by determining several proteins simultaneously using mixtures
of 3 protein standards in undiluted calf serum Figure 3-10A. Calibration curves were obtained by
assigning sensor 1 to detect PSA, Figure 3-10B, 2 to background, 3 to PSMA (Figure 3-10C) and
4 to PF-4, Figure 3-10D. Specific capture antibodies (Ab1) were first immobilized on the carbon
sensors by adding 3 µL of Ab1 and incubating for 2.5 hr at room temperature followed by adding
1 % casein and incubated for 1 hr. Then, protein mixtures were introduced onto these sensors,
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followed by the delivery of multiplexed RuBPY-SiNP ECL labels and development reagents from
the prefilled chambers.
Calibration curves for multiplexed detection were obtained by dividing average ECL signal
for each concentration by control signals on each sensor chip (n=4). Dynamic ranges were from
500 fg mL-1 to 10 ng mL-1 for all protiens and detection limits as 3 times the standard deviations
of zero protien controls were 300 fg mL-1 for PSA, 535 fg mL-1 for PSMA and 420 fg mL-1 for PF4.
3-4.3 Assays of Human Serum Samples
We measured the analyte protiens from 4 prostate cancer patient serum samples and 2 cancer
free human samples using the calibration curves in Figure 3-10. ECL immunoassay results
correlated well with single protein ELISA assays (Figure 3-11. A,B&C). Linear correlation plots
obtained for ELISA vs. ECL immunoarray data (Figure 3-12. A,B&C, Table 3-1) had slopes close
to 1.0 & intercepts of these plots were close to zero consistent with good correlation.

Figure 3-11. Comparisons of ECL vs. ELISA assays on human serum samples. Samples 1-4 are
from prostate cancer patients and 5-6 are from cancer free individuals: (A) PSA (B) PSMA (C)
PF-4 as bar graphs. Error bars are standard deviations with n=4 for ECL arrays and n=3 for ELISA.
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Figure 3-11. Linear correlation plots of ECL vs. ELISA validation studies for (A) PSA, (B) PSMA
and (C) PF-4.
Table 3-1. Results from correlation plots of ECL array assays vs. ELISA for patient samples
Protein
PSA

Slope

Intercept

Correlation Coefficient

1.46 ± 0.16 -1.3627 ± 0.681

0.9767

PSMA

0.77 ± 0.05

0.0081 ± 0.035

0.9900

PF-4

0.99 ± 0.08

0.0015 ± 0.041

0.9883

3-5. Discussion
Results above demonstrate successful development of inexpensive, portable, 3D-printed
ECL immunoarray capable of measuring three proteins simultaneously. These arrays use lightactivated supercapacitors to generate ECL. The cost per assay is ~€0.50 when the arrays are reused with the replaceable sensor chip. The platform utilizes simple steps to complete the
immunoassay in 35 min without external equipment except a CCD camera. Assay time was
considered from the time serum proteins were exposed to capture antibodies till detection.
Good repeatability was found between different arrays for finite concentration with RSD
≤ 7 % for single protein detection. RSD for various concentrations of multiplexed detection
between different arrays range from 1-13%, which is a little larger than desirable for bioanalytical
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devices. However, variability has been compromised somewhat in return for simplicity and very
low cost.
Detection limits of 300 fg mL-1 for PSA 535 fg mL-1 for PSMA and 420 fgmL-1 for PF-4
were achieved with dynamic ranges from 500 fg mL-1 to 10 ng mL-1, Figure 3-10 that readily
correspond to clinical ranges of these proteins in serum after appropriate dilutions.
Accuracy of the ECL immunoassays was confirmed by correlations to standard ELISA
(Figure 3-11, 3-12) for prostate cancer patient samples. Sample volumes as low as 5 µL were 500fold diluted in calf serum to mimic the possibility of determining very low concentrations of
proteins in a full serum matrix. These experiments revealed reasonably accurate detection of 3
analyte proteins in the presence of thousands of other proteins 56 in mixed serum media,
demonstrating high selectivity. Good correlation between ELISA and the ECL arrays along with
relatively small array-to-array standard deviations indicates potential for future clinical
applications (Figure 3-11, 3-12 & Table 3-1).
These 3D-printed ECL microfluidic arrays could serve as a simple, low cost diagnostic
platform for applications in both low and moderate resource environments. Printed components of
the array cost ~€0.90 in materials. The screen-printed 4-sensor chip is a disposable and costs
~€0.20 in materials, whereas the reusable wash module costs ~€0.70. Considering all costs for
immunoreagents, a single immunoassay costs ~€1.20, considering the entire platform (€0.90) to
be disposable, or ~€0.50 if the wash module is reused. Our 3D printed main arrays can also be
reused by detaching and replacing the screen printed carbon sensors. A detailed comparison of
cost, time and detection limits between our ECL arrays and ELISA were provided in Table 3-2.
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Table 3-2. Comparison between single protein ELISA vs. 3D printed ECL array from this
study.
Method

ELISA

3D Printed ECL Array

Number of Proteins

Single Protein

& Instrumentation

Requires Plate reader and Plate Requires CCD camera in a Dark

Cost

Three Proteins

washer

box.

409$ for PSA,PF-4 each &

~€1.20 Per Array +

567$ for PSMA Per Plate

10$ Supercapacitor + 12$ Solar
panel

Assay Time

4 hours 45 minutes

35 minutes

Dynamic range

10 pg mL-1 to 2500pg mL-1 PSA

500fg mL-1 to 10ng mL-1 for PSA,

20pg mL-1 to 15,000 pg mL-1 PF- PF-4 & PSMA.
4
39pg

mL-1 to 2500pg mL-1

PSMA
Detection limits

~8 pg mL-1 for PSA,

300 fg mL-1 for PSA,

~19 pg mL-1 for PF-4 &

420 fg mL-1 for PF-4 &

~12 pg mL-1 for PSMA

535 fg mL-1 for PSMA.

Screen printing of the sensors employs an inexpensive precision desktop craft cutter for
patterning templates. Using adhesive-backed patterned vinyl sheets for hand screen printing the
electrodes provided acceptably reproducible sensor surface areas (±5%). Lamination after printing
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provides an effective hydrophobic boundary when attaching capture antibodies from aqueous
solutions.
Solar panels allowed rapid light-driven charging to 1.5 V of the supercapacitor power
source to drive the ECL generation step. Integration of this small power source on the immunoarray
helps make it portable, avoids potentiostatic equipment, and makes the assay simpler for the
operator. Future coupling of our immunosensors with a cell phone digital camera could provide a
complete onsite cancer detection array for resource limited settings.

3-6. Summary
In summary, results demonstrate a novel, very low cost, gravity-flow, 3D-printed, portable
immunoarray for sensitive detection of proteins. The system results in ECL-based assays for 3
proteins that cost ~€0.50 each and can be completed in 35 min. without high level technical
expertise. Using an inexpensive, robust, portable supercapacitor (€10) for power with a solar panel
(€12) for recharging, the entire immunoarray costs ~€25, not including the CCD camera. A
drawback of this system, however, is that a significant number of sequential tasks must be
completed by the operator to complete an immunoassay. Nevertheless, this device is suitable for
low and moderate resource clinical environments. This method can be adapted to detect other
disease related proteins, nucleic acids or carbohydrates (Hu et al., 2010). We have previously
measured other proteins IL-6 with similar strategies.38,39 This work also suggests that 3D-printing
can be used to develop more sophisticated immunoarray devices with a higher level of automation.
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CHAPTER 4

Automated Small Volume Serum Sample Immunoassays using
Rapid 3-D Printed Microfluidic ECL Arrays
for Prostate Cancer Biomarkers

4-1. Abstract
Multiplexed detection of serum proteins relevant to a diseased state holds promise in
accurate diagnosis in early stages. Miniaturized assay platforms are of great demand that require
small sample volumes of precious biological sample. There is a need for miniaturized microfluidic
arrays that can detect multiple protein markers from serum that is simple, highly sensitive, rapid
and high throughput with significant cut down in cost. Automation in microfluidics could provide
faster translation of such immunoarrays into personalized public health care as it requires minimal
user interference. Herein we report a compact 3-D printed ECL immunoarray that detects 2
prostate cancer biomarkers simultaneously from complex serum matrix with high sensitivity and
selectivity. Our proposed method is fast, requires only 18 minutes assay time, accurate and
extremely low cost with only 0.75$ per assay, if reused the cost per assay is 0.35$. Our
immunoarray just requires sub microliter sample volumes to complete immunoassay with desirable
dilutions while total assay volume is just 20 µL. The 3-D printed array here is a clear fluidic device
fabricated on an inexpensive desktop SLA 3-D printer. Design includes strategically arranged
reagent/sample chambers to facilitate rapid delivery of immunoreagents to detection channels with
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minimized dead volumes.

We used simple programmable syringe pump to program the

immunoassay timing intervals, allowing pump and pause of the reagents as required for completion
of sandwich immunoassay. Sandwich immunoassay built on a nanostructured single wall carbon
nanotube forest with RuBPY silica nanoparticles as detection labels enabled sensitive detection of
both prostate specific antigen (PSA) and prostate specific memberane antigen (PSMA)
simultaneously on a same array. Detection limits of 150 fg mL-1 for PSA and 230 fg mL-1 for
PSMA was obtained with dynamic ranges extending up to 5 ng mL-1. Validation assay with human
serum samples showed good correlation with single protein ELISA. ROC curve analysis for the
human serum samples suggest PSMA can be used as potential marker for prostate cancer in
conjunction with PSA. While further studies are warranted with larger patient sample size to
establish PSMA as an additional tool to differentiate cancer vs non cancer samples and staging the
prostate cancer. Our immunoarray has potential to expand to several markers detection at a time
for better personalized public healthcare.

77

4-2. Introduction
Prostate cancer is the second most frequent cause of cancer death for men in the United
States, behind only lung cancer. Roughly 1 man in 39 will die of prostate cancer, and about 1 in
7 will be diagnosed with prostate cancer during his lifetime. 1 Therefore a more sensitive and more
accurate test for prostate cancer presence than currently used is a necessity for increasing the
survival rate through early detection and monitoring. Currently Prostate specific antigen (PSA) is
being widely used as clinical serum biomarker for prostate cancer as early screening tool. PSA
levels above 4 ng mL-1 suggests possibility of early stage of cancer and often referred to further
evaluation by biopsy. 2 PSA test alone has low specificity for cancer, about 75% of men who have
a prostate biopsy ordered due to elevated PSA levels 4.0 to 10.0 ng ml-1 do not have the cancer 3
reason being the several benign prostate diseases can also elevate PSA leading to false positives. 4
Measuring multiple biomarkers simultaneously can provide improved predictive power in
diagnosing the diseased state leading to better personalized therapeutic monitoring.5,6,7,8 Thus there
is great need for the ability to measure multiple proteins in a single device using only a small
sample of blood. Prostate specific membrane antigen (PSMA) can be a potential serum marker
that can be used in conjunction with PSA to evaluate the prostate cancer in early stages. PSMA is
considered to be upregulated by many fold in prostate cancer, metastatic disease and hormone
refractory prostate cancers. 9 It’s shown that increased levels of PSMA have promoted the
progression of prostate cancer. 10 In prostate cancer the average serum PSMA levels for malignant
stage (> 620 ng mL-1) vs benign state (>120 ng mL-1) were significantly different. 11 PSA values
generally fall to low values post treatment of prostate cancer with surgery, radiation, chemotheraoy
etc., whereas it is noticed that elevated levels of PSMA can be used to understand the stage of
clinical progression or clinical resistance. 12
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Currently for specific protein marker detection single protein enzyme linked
immunosorbent assay (ELISA) function as a gold standard. 13 Quantifying multiple analytes from
biological samples using singleplex platforms like ELISA and western blot is time consuming and
increased risk of errors between assays. Running parallel assays for multiple proteins besides being
expensive and complex, also requires increased sample/analyte volume. Thus sample volume
requirements increase with increase in number of proteins to be analyzed which could be major
hurdle in establishing protein panels detection for error free diagnosis of a disease. Acquiring
biological samples like blood, serum or tissues for multiple protein analysis could provide a greater
challenge as they are limited. 14 Hence there is need for miniaturization of assay platforms which
can perform multiple analyte analysis simultaneously. 15,16 This ensures use of less sample volume
for precious biological samples and more cohesive workflow that minimizes the errors between
running different assays for different proteins. Use of miniaturized microfluidics not only helps in
reducing use of high sample volume but also helps in minimizing the assay reagent costs, assay
times and detection processing times. 17 There is additional need for a clinical device that is
inexpensive, fast, reliable, accurate, and user friendly. Possibility of automated liquid handing in
microfluidics is an attractive candidate in developing multiplexed immunoarrays as compact
diagnostic platforms for resource poor settings. 18
Microfluidics assists control of fluid reagents within a closed environment with small
sample size that carryout reactions and detection with ease, high sensitivity, low operations cost,
short analysis time and portability. 19 Microfluidics has been explored in many fields like chemical
synthesis, 20 high throughput biological assays, 21 PCR-based DNA analysis, 22 DNA toxicity
studies, 23,24 Proteomics 25 and diagnostic assays. 26,27,8 Even with such unique benefits and its multidisciplinary applications traditional microfluidic manufacturing methods like soft lithography and
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sometimes injection molding requires longer prototyping times, specialized skills and specialized
equipment which are often not readily available. 28,29,30 We have previously developed such
microfluidic devices using simple machining and molded or precision cut microfluidic channels
for detection of cancer biomarkers from serum samples. We demonstrated detection of multiple
biomarkers

simultaneous

in

such

devices

using

both

amperometry31,32

and

electrochemiluminescent (ECL) 33 arrays. 34 Both the approaches successfully demonstrated use of
nanostructured electrode surface as detection platform and nanoparticles as detection probes for
ultrasensitive detection of multiples proteins with shorter assays times of ~30-40 minutes.31,32,35
Reducing prototyping costs and array development times along with increasing production scale
might lead to faster translation of such diagnostic tools to public health care market. 36
Three-dimensional (3D) printing of bioanalytical devices can significantly reduce cost and
time of prototyping. 37 Current availability of inexpensive bench-top 3-D printers and materials
provides great resource for ease of fabrication at much faster pace without need for sophisticated
manufacturing facilities. 38 The accessibility of easier consumer technology with 3-D printers and
its effortless use in creating custom objects by non experts is creating a shift in paradigm of
additive manufacturing in various fields. 39 Some of the applications in bio-analytical field for
manufacturing fluidic devices include producing masters for making channels from
poly(dimethylsiloxane)(PDMS), 40 reaction ware for chemical synthesis, 41 milli- and microfluidic
arrays for nanoparticles synthesis 42,43,44 and metal ion monitoring using flow injection devices.45
Several sensors and sensor accessories have been printed for detection of food allergens, 46 albumin
testing in urine, 47 blood component evaluation, 48 single DNA molecule sizing, 49 and pathogenic
bacteria. 50 Since past 2 years we reported use of desktop 3-D printed microfluidic devices based
on fused deposition modeling (FDM) and stereolithographic (SLA) 3-D printers for several
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sensing purposes and cancer diagnostics. We showcased use of FDM printer based fluidic devices
in nanoparticle synthesis and sensitive amperometric sensing of hydrogen peroxide,44 gravity flow
assisted microfluidic immunosensor for detection of prostate cancer biomarkers. 51 SLA printed
optically transparent microfluidic sensors were explored for Chemiluminescence (CL) based
cancer biomarker detection 52 and Electrochemiluminescence (ECL) based DNA sensors. 53
Automation along with microfluidics could provide an excellent opportunity to reduce
operator errors with simplified assay protocols.35,54 Currently immunoassays suffer from lack of
automation thus require multiple operations by the user to either load or pipette sample or reagent
to complete the assay. Significant efforts are essential to achieve streamlining of several steps of
immunoassays like adding blocking reagents, sample, wash reagents and detections labels
automatically. Such automation efforts could lead to faster translation of immunoassays for better
health care and point of care use. 55,56 In order to be most effective point of care devices must be
rapid, reproducible with very low device failure rates and able to be operated by technicians with
minimal training and operator attention. 57,58 We previously demonstrated ECL based fully
automated, microprocessor controlled, microfluidic arrays with reagent/sample loading cassette to
complete detection of multiple prostate cancer biomarkers in serum samples. These arrays utilize
detection antibody-coated Ru(bpy)32+ (RuBPY)-doped silica nanoparticles for detection of 4
biomarkers simultaneously on a single wall carbon nanotube forest patterned pyrolytic graphite
chip.35 While we were successful in getting absolute automation until detection step with
ultrasensitive detection limits of 10-100 fg mL-1 the size of whole immunoarray, sample/reagent
volume and assay times were relatively high and thus need to be addressed for achieving futuristic
personalized point of care applications.
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Here we present a compact packaged (3cm x 4cm x 0.3cm) simple 3-D printed microfluidic array
that promises simultaneous and automated detection of two prostate cancer biomarker proteins
within 18 min assay time for under $1. Our developed method does not require exclusive training
to be operated and require ultralow sample volumes less than 1 µL for diluted sample analysis.
Total volume of reagent and sample chambers are 20 ± 2 µL. We were able to run multiple
immunoarrays at a time using programmable multi syringe pump. This results in total assay time
of 18 minutes for 4 different samples, Figure 4-1. To our knowledge this is the first report of ECL
based compact 3-D printed array with ultralow sample volume for detection of multiple cancer
biomarkers in serum samples. We demonstrated sensitive detection of two proteins on a
nanostructures surface using RuBPY silica nanoparticle coated with detection antibodies as label
with detection limits of 150 - 230 fg mL-1. Validation assays on human serum samples from
prostate cancer patients showed good correlation with standard single protein ELISA. ROC curves
for the patient sample analysis showed PSMA can be used to increase the predictive power of
distinguishing the cancer vs cancer free human serum samples.

Figure 4-1. Concept image with programmable pump performing four parallel immunoassays on
3-D printed microfluidic immunoarray and 3-D model of the simple and compact immunoarray
attached to the pyrolytic graphite sheet (PGS) detection array via double sided adhesive.
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Figure 4-2. (A) TEM image of RuBPY-silica nanoparticles on a 500 nm scale bar. (B) Size
distribution of RuBPY silica nanoparticles with an average diameter of 115 ± 13 nm.

4-3. Experimental
4-3.1 Materials. Thin pyrolytic highly oriented graphite sheets (PGS) were obtained from
Panasonic Industrial Devices and Solutions. Clear resin (GCPL02) from Formlabs (Somervlle,
MA). PSA capture antibodies (M0-T40081A), detection antibodies (M0-T40081B), PSMA
capture antibodies (MO-T40086A) and detection antibodies (MO-T40086B) from Anogen.
Standard PSA protein (P3235) from Sigma-Aldrich and PSMA standard protein from Novus
Biologicals. Single protein ELISA kits for PSA (RAB0331) from Sigma-Aldrich and for PSMA
(EL008782HU-96) from Lifeome Biolabs/Cusabio. Human serum samples were obtained from
George Washington University Hospital. RuBPY silica nanoparticles used as detection labels were
synthesized in our lab as described previously34 with average diameter of 115 ± 13 nm (Figure 42) further coated with layers of polydiallyldimethylammonium chloride (PDDA) and poly(acrylic
acid) (PAA) and were then covalently linked to secondary antibodies (Ab2) using 1-(3(Dimethyla-

mino)propyl)-3-ethylcarbodiimidehydrochloride
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(EDC)

and

N-

hydroxysulfosuccinimide

(NHSS)

as

described

previously.34

RuBPY-Silica

detection

nanoparticles were decorated with two different types of antibodies, PSA (PSA-Ab2) and PSMA
(PSMA-Ab2). Optimized Ab2 concentrations of 8 µg mL-1 for both PSA and PSMA was used to
make the RuBPY-SiNP- Ab2 conjugate. The Ab2 / RuBPY –SiNP ratio was measure at 38:1 as
shown previously.51 All immunoreagents were dissolved in pH 7.2 phosphate buffered saline
(PBS). Co-reactant solution to develop ECL was 500 mM tripropylamine (TrPA) with 0.05%
Tween-20 (T20) and 0.05% Triton-X in 0.2 M phosphate buffer.
The immunoarray was 3D printed on a Form 1+ SLA printer from Formlabs (Somerville, MA).
Initially a computer aided design (CAD) with required features were generated using 123D design
software (Autodesk), Figure 1 and later converted to 3-D printed splicing software preform to
make a print file. Later the preform file with 3-D design was subjected to selected optimized
orientation and generated supports to produce final print file. The print orientation was adjusted
onto the build platform so that the reagent chambers in the array are longitudinal while printing,
this allowed the channels to flush the resin automatically through the reagent loading port holes.
This also allowed us to get reproducible prints with no defects and also made easier for post
treatment process. The layer height was selected to be 50 µM that gave us faster prints without
sacrificing the print quality and resolution. The printed arrays were then removed from the build
platform, supports were removed, submerged into isopropanol and subjected to sonication for 15
min to remove any uncured resin present on the outside or inside of the array. The dried arrays
were then spray coated with clear acrylic spray (Krylon™) and allowed to air dry for an hour to
adjust the transparency to clear for ECL detection.
Microfluidic immunoarray features a unibody design with microfluidic channels that act as
chambers to hold reagents and sample for immunoassay. The immunoarray is 3 cm x 4 cm x 0.3
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cm in dimensions with 1 inlet port, 1 outlet, 8 chambers inside the array and 1 chamber that is
open, present outside at the bottom of the array for electrode attachment, Figure 4-3 A&B. This
design allowed us to have the detection chamber complete once sealed with a detection array, thus
eliminating need for silicone gasket or PDMS channels. Dimensions of reagent/sample chambers
were (Length x Width x Height) 18 mm x 2.5 mm x 0.5 mm, for the detection chamber (L x W x
H) were 12 mm x 2.8 mm x 0.5 mm. Out of 8 chambers inside the immunoarray starting from the
inlet, chamber 1 and 2 were designated for wash buffer (PBS buffer with 0.05% Tween-20, pH
7.4) followed by air gap chamber 3 to avoid intermixing of reagents. The 4th chamber was
designated for RuBPY Si-NP-Ab2 ECL label, followed by air gap chamber 5. 6th chamber was
designated for wash buffer (PBS buffer, pH 7.4) followed by air gap chamber 7. The last chamber,
was designated for sample which is right next to detection chamber that was placed downstream
at the bottom of the array to facilitate attachment of detection array. Total volume of reagent
chambers was 20 ± 2 μL, having very tiny turn to connect to the detection chamber allowed us to
have tiny or no dead volume making the detection chamber volume to be slightly less than 20 μL.
The reagents/sample were added through a 0.8 mm hole present at the top of the reagent
chamber. We call them injection ports and we also assembled few more ports called vent holes
between each turns to facilitate reproducible filling of the chambers, Figure 4-3A & B. The holes
on the both ends of the chambers in the turns helps to fill the chambers evenly without choosing a
direction. As we are dealing with tiny volume in a confined space, the added reagents will replace
the air in the chamber. These vent holes near the ends of each chamber pushes the air out of the
chambers as the liquids enter the chamber resulting precise addition of reagents. This is rather an
important part of our design and we optimized the position of these vent holes for precision of
reagent/sample loading. This also ensured better control over automated reagent delivery to
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detection chamber. We used calibrated micropipettes to add the reagents/samples into their
respective chambers prior to immunoassay. The detection chamber was equipped with holes and
grooves to hold 0.4 mm platinum counter electrode wire and 0.6 mm Ag/AgCl reference electrode
wire that run parallel within the detection chamber to complete a 3 electrode setup with pyrolytic
graphite sheets as working electrodes.

4-3.2 Detection platforms were prepared from highly conductive, flexible, inexpensive pyrolytic
graphite sheets (PG sheets). The PG sheets were initially cut to desired size and placed on adhesive
plastic support followed by patterning with microwells using print and peel technology59
developed in our lab. Microwells formed by hydrophobic toner boundaries allowed us to build
single wall carbon nanotube tube (SWCNT) forest 60,61 within them using tiny volumes of reagents.
Our detection platforms features 4 microwells with diameter of 1 mm, designated 2 each for PSA
and PSMA detection. The template for the 4 microwells were designed using Inkscape software
and the pattern was inkjet printed onto glossy paper (Avery ™ 5263) followed by transferring them
onto PG sheets via heat press for 60 s at 275 °C. Patterned microwell PG sheet array with SWCNT
forest and detection antibody (Ab1) were then attached onto the 3D printed array using a double
sided adhesive. The presence of dense SWCNT forests were confirmed by tapping mode atomic
force microscopy previously showing vertically aligned SWCNT forest with increased surface
roughness.34,35 The carboxyl terminal SWCNT’s were further activated with 400mM EDC +
100mM NHSS to conjugate primary/capture antibody (Ab1) by amidization. 62,34
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Figure 4-3. Schematic representation of 3-D printed array and Sandwich immunoassay. (A) 3-D
printed microfluidic array with reagent chambers designated for sample/analyte, wash buffers,
detection label and co-reactant for ECL generation connected to detection platform with pyrolytic
graphite detection chip. Programmable pump connected to the microfluidic array via inlet port to
sequentially deliver chamber contents to complete the sandwich immunoassay. (B) Image of 3-D
printed microfluidic array and fluidic chambers filled with colored food dyes for representation.
(C) Disposable pyrolytic graphite sheet with microwells formed by hydrophobic toner print. Insert
showing sandwich immunoassay on a single wall carbon nanotube forest (SWCNT).

4-3.3 Immunoassay protocol. SWCNT and Ab1 modified detection platform were attached to 3D printed array via a precut double sided adhesive. The 3-D printed array was prefilled with
reagents and sample through the injection ports to each of the chambers as mentioned earlier. The
injection ports and vent holes are then sealed with one-sided transparent scotch tape to make an
airtight continuous channel too deliver the reagent sequentially to detection chamber. A flexible
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tubing was then inserted into the inlet port of the 3-D printed array and connected to BD Plastic
4.78 mm, 1mL syringe via a luer adaptor. Prior to inserting the tubing into the inlet, 100 µL of
500 mM tripropylamine (TrPA) in 0.2 M phosphate buffer + 0.05% Tween-20 and 0.05% tritonX at pH 7.5 was drawn into the tubing. Excess TrPA was used for additional washing and as coreactant for ECL generation. Syringe was then placed into a Chemyx Fusion Touch programmable
syringe pump that has a three step program loaded. Sample incubation, Label incubation followed
by washing and delivery of TrPA. Initial pump cycle at 90 μL/min, delivers 27 μL volume
(includes initial pressure buildup delay, slight dead volume and 20 μL sample) to the detection
chamber. Program delayed for 8 minutes to allow the sample to incubate on the array. Second
pump cycle, delivers 130 μL of volume to wash the array to flush the unreacted sample and leave
the detection antibody decorated RuBPY silica nanoparticles on the surface of the detection
platform for 7 minutes. Finally 600 μL pump cycle to wash the unreacted detection label and fill
the detection chamber with TrPA ECL generation. The immunoarray was then placed under the
CCD camera and a potential of 1.0 V was applied vs Ag/AgCl with a handheld potentiostat to
generate ECL for 180 s. TrPA in detergent solution as co-reactant allows use of 1.0 V vs Ag/AgCl
to oxidize TrPA. This electrochemical oxidation only TrPA enhances production and
deprotonation of TrPA*+ to drive complex redox process that generates electronically excited
[RuBPY]2+* for ECL. 63,61 Acquired ECL images were then processed to get ECL intensities. 34

4-4. Results
4-4.1 Reproducibility. Relative ECL responses captured by CCD camera from the 3-D printed
immunoarray with three trails of controls (undiluted calf serum) and 1 pg mL-1 PSMA showed an
average relative standard deviation (RSD) of 8 % for spot to spot (n=4) and 6 % for array to array
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(n=3). For single protein analysis all the four sensors on the detection PG chip were coated with
either PSA or PSMA capture antibodies and the detection label has either PSA or PSMA detection
antibodies. Initially the 3-D printed arrays were calibrated by developing single protein calibration
curves where increase in ECL responses were observed with increase in concentration of the
respective analyte. Obtained ECL signal intensities from CCD camera for different analyte
concentrations were further processed by dividing with ECL intensity obtained from control to get
relative ECL intensity. Relative ECL intensities were plotted against concentration as show in
Figure 4-4.

Figure 4-4. Calibration curves in undiluted calf serum with ECL responses captured over 180 s,
A) PSA and B) PSMA vs concentration with applied ECL generation potential of 1V vs. Ag/AgCl.
Error bars show standard deviation, n=4.

4-4.2 Multiplexed detection. PSMA and PSA were simultaneously detected by using a mixture
of standard concentrations of PSA and PSMA in undiluted calf serum. Out of four
sensors/microwells on the detection chip, first two sensors were coated with PSMA capture
antibodies and the last two sensors were coated with PSA capture antibodies as shown in Figure
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4-3 A. The detection label has both PSA and PSMA detection antibodies coated on the RuBPY
SiNP. Specific capture antibodies were coated on the single wall carbon nanotube decorated
detection sensor wells for 2.5 hours at room temperature followed by adding 2% BSA as a blocking
agent to avoid nonspecific binding. The mixture of standard protein samples were then allowed to
flow from analyte/sample chamber and incubated for 8 minutes followed by washing with 10 mM
PBS buffer, 7.4 pH. Multiplexed detection label, RuBPY SiNP was then flowed on to the detection
sensors from reagent chamber and allowed to incubate for 7 minutes, followed by washing with
10 mM PBS and PBS T20 buffer, pH 7.4 from the prefilled chambers. The ECL responses were
then captured by CCD camera when 1.0 V vs. Ag/AgCl was applied from a handheld potentiostat
and signal was accumulated for 180 s. Obtained ECL responses were further processed as
explained earlier to get relative ECL intensities, that were plotted against concentrations to get
multiplexed calibration curves as shown in Figure 4-5.

Figure 4-5. Calibration data for multiplexed detection of PSMA and PSA simultaneously in
undiluted calf serum with ECL responses integrated over 180 s at 1.0 V vs Ag/AgCl. (A)
Recolorized CCD images of 5 arrays showing increase in ECL response with increase in
concentration for both PSMA and PSA on a single array. Influence of ECL responses with increase
in concentrations for (B) PSMA and (C) PSA, error bars show standard deviation, n=4.

90

Recolorized CCD images from Figure 4-5A shows ECL responses with increase in
concentrations of mixture of proteins (PSMA and PSA). ECL response obtained for specific
concentrations were divided with controls and obtained relative ECL intensities were plotted
against concentration to get multiplexed calibration curves as show in Figure 4-5B & C. Dynamic
range from 250 fg mL-1 to 5 ng mL-1 was obtained for both the proteins with detection limit of 150
fg mL-1 for PSA and 230 fg mL-1 for PSMA. Detection limit was measures at 3 times standard
deviation of signal from 0 pg mL-1 protein control.

Figure 4-6. Elisa vs ECL immunoarray comparison results for 9 patient human serum samples.
Bar graph showing ECL vs ELISA results for (A) PSA and (B) PSMA. Linear correlation plots
for (C) PSA and (D) PSMA. Error bars are standard deviations with n=4 for ECL and n=3 for
ELISA.
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4-4.3 Patient Sample Analysis. 32 cancer patient samples and 6 cancer free individual samples
were analyzed using our 3-D printed array. 9 patient samples were compared with gold standard
single protein ELISA for both PSA and PSMA to establish the correlation between the two
methods. Considering the dynamic range of the calibration curves, patient and cancer free
individual samples were diluted from 100-500 fold in undiluted calf serum prior to analysis to
bring the ECL responses to acceptable range. Obtained ECL immunoarray responses were
corresponded well with ELISA results as shown in Figure 4-6. Linear correlation plots, Figure 46 C&D with slopes close to 1.0, PSA 1.22 ± 0.14 and for PSMA 1.04 ± 0.12 whereas intercepts
were close to zero, -0.36 ± 0.70 and -0.12 ± 0.10 suggest a good correlation between our automated
ECL immunoarray and ELISA.

Figure 4-7. Receiver operating characteristic curves (ROC) for 18 human serum samples. (A) Red
line for PSMA and Blue line for PSA shows AUC to be 0.92 for PSA, 100 % specificity and 83.3
% sensitivity and for PSMA, AUC was calculated to be 0.94, 100 % specificity and 91.7 %
sensitivity. (B) Normalized PSA and PSMA results suggest 0.92 AUC, 100 % specificity and 91.7
% sensitivity.
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Figure 4-8. Receiver operating characteristic curves (ROC) for 38 human serum samples. (A) Red
line for PSMA and Blue line for PSA shows AUC to be 0.89 for PSA, 100 % specificity and 78.1
% sensitivity and for PSMA, AUC was calculated to be 0.92, 100 % specificity and 78.1 %
sensitivity. (B) Normalized PSA and PSMA results suggest 0.95 AUC, 100 % specificity and 81.3
% sensitivity.
Receiver operating characteristic (ROC) plots were utilized to predict the diagnostic
accuracy for 12 patient samples and 6 cancer free individual samples for which Gleason score were
available, Figure 4-7. For the rest of the 20 patient samples ROC analysis was performed assuming
them to be cancer patient samples as Gleason score data was not available, Figure 4-8. In ROC
analysis the true positive rate (sensitivity) was plotted against false positive rate (specificity). In
an ideal scenario the test with perfect discrimination between cancerous and cancer free samples
has an ROC curve that passes through the upper left corner with 100 % sensitivity and 100 %
specificity. 64 The area under the curve from ROC analysis helps to quantify the ability of the test
to distinguish between healthy individuals and individuals with diseased state. If the observed data
has zero false positives and zero false negatives the area under the curve will be 1.0. ROC analysis
for PSA show AUC to be 0.92 with specificity to be 100 % and sensitivity to be 83.3 % whereas
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for PSMA AUC was 0.94 with 100 % specificity and 91.7 % sensitivity. Normalized mean ROC
values for combined PSA and PSMA for 18 human serum samples were 0.92 for AUC with 100
% specificity and 91.7 % sensitivity. Normalized values showed slightly improved sensitivity.
Associated criteria for cancer vs non cancer based on the obtained sensitivity and specificity values
for PSA > 2.7 ng mL-1 and for PSMA > 86 ng mL-1. Normalized mean ROC values for combined
PSA and PSMA for 38 human serum samples were 0.95 for AUC with 100 % specificity and 81.3
% sensitivity. Normalized values showed slightly improved AUC and similar specificity.

4-5. Discussion
Results achieved using our low cost, automated, 3-D printed array show simultaneous
detection of both PSA and PSMA in complex serum matrix that contains thousands of other
proteins. 65 Our goal was to detect ultralow levels of prostate cancer biomarkers within 20 min
assay time and low sample volume on a compact 3-D printed fluidic array. Utilizing 3-D printing
we established rapid prototyping of transparent miniaturized immunoarrays with microfluidic
structures of dimensions 500 microns resulting in the use of low sample/reagent volumes. We
arranged the reagent reservoirs on the same microfluidic array, Figure 4-3A that allows their
sequential pumping to the detection sensor to complete the sandwich assay. Non-complex layout
of our sample/reagent chambers in a confined space allowed greater control of all immunoreagents
to reach downstream detection sensor efficiently. Programmable pump allowed precise control on
timing the pumping events either ON/OFF to deliver or wash off immunoreagnets to facilitate
incubation and washing excess reagents with minimal user interference. Use of small portable
programmable pump that has non-complex operations with total assay cost of 0.75 $ with detection
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limits in low fg mL-1 for reliable detection of two markers in complex serum matrix makes it an
ideal candidate for its application in resource poor settings.
Detection limits of 150 fg mL-1 for PSA and 230 fg mL-1 for PSMA was achieved with
dynamic ranges extending from 250 fg mL-1 to 5 ng mL-1 for both the proteins, Figure 4-5. These
dynamic ranges are acceptable and matches to the clinical ranges of selected proteins in assay
within 500X dilution eliminating the need for excessive serial dilutions. The relative standard
deviations ranged from 2 to 11 % for both the proteins between all the assayed concentrations.
Good repeatability was obtained in reproducibility assays performed with controls and 1 pg mL-1
concentration of PSMA. We found acceptable standard deviations of 8% (n=4) in spot to spot
variability and 6% between assays (n=3) for the defined concentration.
ECL immunoarrays were validated by accurately measuring both PSA and PSMA in 38
human serum samples further compared to standard single protein ELISA. Comparison studies
between our immunoarray results and ELISA for human serum samples showed very good
correlation, Figure 4-6. Quantifying both PSA and PSMA in full serum matrix accurately
demonstrated high selectivity and specificity of our immunoarray. ROC curves from the human
serum sample data suggest that both PSA and PSMA as serum protein markers have diagnostic
potential in differentiating the cancer vs Non-cancerous individual with 100 % specificity and 83
% - 92 % sensitivity.
3-D printing allowed us to achieve compact design with both reagent chambers and
detection channels on the same array. This allowed us to eliminate any external tubing for
connectivity and leaking issues. Adding detection channel very close to sample chamber allowed
us to eliminate dead volumes that usually comes with the connectors. Efficient transfer of
sample/reagents sequentially as intended with optimized times results in reproducible ECL
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responses. Using this parallel alignment of fluidic chambers with optimized minimal distances
resulted in rapid completion of assays. Pyrolytic graphite sheets were used as an alternative for
traditionally used bulky expensive pyrolytic graphite chip or screen printed carbon electrodes.
These pyrolytic graphite sheets are inexpensive, disposable, robust, highly conductive and can
withstand harsh organic solvent conditions. This enabled us to grow our nano-structured surface
single walled carbon nanotubes forest on the surface for much efficient coating of capture antibody
that in turn facilitated high capture efficiency of selective proteins from the serum. The PG sheets
costs 6 $ for a 7 inch X 5 inch sheet with thickness of 0.0028 inch. These extremely flexible and
tough PG sheets can make up to 75 detection sensor chips with 4 detection spots on each of them
costing only 8 cents per array. 3-D printing costs 0.40 $ in materials to print our 3-D printed
immunoarray. Including all the immunoreagents the total cost per assay is just 0.75 $. Our compact
design plan made them disposable arrays that leave a low ecological foot print. Our arrays are
reusable, assuming the 3-D printed devices are not disposed and used for multiple assays the cost
per assay comes down to as low as 35 cents.

4-6. Summary
In summary we demonstrated use of inexpensive desktop stereolithographic 3-D printer that can
fabricate compact microfluidic array that is optically transparent for ECL detection. Our
immunoarray is low cost and portable with sensitive and selective detection of two prostate cancer
biomarkers from human serum samples. Using commercially available programmable pump we
automated the complex immunoassay process to be easily operated with minimal manual
interference. The assay is cost effective and rapid with good detection limits and dynamic ranges
that are acceptable for clinical analysis. Our fabrication methods enabled our assays as print and
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go method. We minimized the complex operations of microfluidic immunoassay where there is
need for mixing units, connectors, valves etc. Our print and go method just requires a 3-D printed
fluidic device with prefilled immunoreagents, followed by simply attaching capture antibody
coated PG sheet via a double sided adhesive and connected to a preprogrammed syringe pump. In
principle this device can be extended to many other disease related markers and multiple markers
at a time with few changes in the array fabrication.
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CHAPTER 5

Automated 3-D Printed ECL Immunoarrays for 8-Protien Prostate Cancer
Panel
5-1.Abstract
Automated low cost microfluidic diagnostic platforms have great potential to transform
current conventional and reliable methodologies to personalized point of care diagnosis. Prostate
cancer is one of leading cause of death in men, and current diagnostic strategy to detect PSA alone
should be replaced by multiple biomarker detection for reliable conclusions and provide better
therapeutic options for the patients. Here we developed a low cost 3-D printed sensitive
microfluidic platform that could simultaneously detect 8 proteins selectively from human serum
samples. We engineered a touch screen user interface master controller with simple user
commands to operate the diagnostic platform without need for technical expertise. The
miniaturized 3-D printed platform have all the reagent/sample reservoirs required to complete the
immunoassay without need for intermediate manual operations. Patterned pyrolytic graphite
sensor features 16 micro well nanostructured sensors that are selectively coated with capture
antibodies relevant to prostate cancer to efficiently capture the proteins of high diagnostic
significance from the serum sample. The multiplexed platform, we integrated all the digital and
analog commands to simple user friendly options like start/stop and detect with prompts that assure
the stages of the immunoassay. We successfully demonstrated detection of 8 proteins on a single
platform using sample volumes less 1 µL in diluted samples where the detection chamber volumes
were less than 50 µL. We used ECL based immunoassays on a single walled carbon nanotube
forest sensor achieving low detection limits of <500 fg mL-1 from complex serum matrix. We
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validated our analytical precision using spiked human serum samples and found the excellent
analytical performance by recovering the spiked proteins ranging from 88 % to 110%.

5-2 Experimental

We developed our low cost 3-D printed ECL immunoarrays using stereolithographic
desktop 3-D printer Form 2 (Formlabs). These printers are inexpensive and can produce high
resolution objects (~25 μm) with low surface roughness. Briefly a CAD design with desired
structures was prepared using 123 D design software (Autodesk) and transformed later to
stereolithography printing compatible format using printer software called preform. These files
were uploaded to the printer to fabricate the desired object. A clear photo curable resin (GPCL02
formlabs clear resin) was used to produce these 3-D objects. The obtained 3-D objects are compact
plastic devices with internal structures that hold the reagents and sample. These 3-D objects are
optically clear and well suited for Electrochemiluminescence detection. The printed objects were
removed from build platform and subjected slight post treatment procedures to obtain
immunoassay ready platforms. The freshly printed objects were cleaned by flushing, bathing and
sonicating them in isopropanol bath for 10-15 minutes to remove any uncured resins followed by
air drying to reveal all the detailed structures as desired. Later the arrays were spray coated with
acrylic spray (Krylon™) to adjust the optical clarity from slightly opaque to completely clear.
These prepared arrays were then inserted with counter and reference electrode wires in the grooves
and holes that were are already present on the array. The reference Ag/AgCl and counter platinum
wires were used to complete the ECL electrochemical cell when a nanostructured sensor patterned
pyrolytic graphite chip is used as a working electrode.
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The 3-D printed array is a miniaturized platform with dimensions (L) length 40 mm x (W)
width 35 mm x (H) height 3.5 mm. Internal structures the reagent/sample chambers have
dimensions of (L x W x H) 25 mm x 2 mm x 1mm resulting in volumes of 48 ± 2 µL. The
detection chamber is a open bottom channel converted into an closed microfluidic detection
chamber when attached a pyrolytic graphite detection platform. The detection chamber is of 30
mm x 2 mm x 0.6 mm (L x W x H) in dimensions to accommodate the sample and reagents coming
from upstream. The detection chamber volumes were designed and optimized to efficiently fill the
contents of reagent/sample chambers with low dead volumes. So the volume of the detection
chamber is slightly less than 50 µL. The detection channels is designed to accommodate 16
microweel detection sensor spots with 2 spots for each prostate cancer biomarker detection. The
sample and reagents were preloaded into the 3-D printed array prior to the immunoassay and stored
at 4 °C until use. The reagents and sample were loaded onto to the array using a graduated 50 µL
micropipette. To demonstrate the applicability of our array design to commercial purposes we used
the array with preloaded samples and reagents prior and stored them until use at 4 °C. To ensure
the non-specific adsorption of assay constituents to the 3-D printed immunorray, we incubated all
the 3-D arrays with bovine serum albumin at 2 mg mL-1 concentration prior to use. The assay
reagents and samples were added into the inter structures of the 3-D array called reagent and
sample chambers via loading ports present on the top of the array. By placing the pipette’s tip into
the loading ports the assay reagents were simply loaded with good reproducibility. To appeal to
non-expert users we took extreme care in designing the array, we placed vent holes at the end of
each chambers to fill reagents efficiently with absolutely no training. The reagents can be easily
loaded by simply pipetting the desired solutions and placing the pipette upright into the loading
port to deliver the reagents. These vent holes strategically placed to efficiently load the reagents
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and samples every time. All the vent holes and loading ports were closed with a single sided
transparent tape to complete the airtight continuous channel to sequentially deliver the reagents to
downstream detection chamber.
The detection channel that is open at the bottom of the array to deliver the contents placed
in the 3-D array, it is completed by attaching out nanostructured detection platform pyrolytic
graphite chips. The pyrolytic graphite chips were prepared by cutting the pyrolytic graphite sheets
(Panasonic Industrial Devices and Solutions) to desired sizes and attached on to plastic support.
The pyrolytic graphite chip is then patterned with Ink-jet printed toner template to get desired
microwells. We used our lab’s print and peel technology 1 to heat transfer a printed toner design
from a glossy paper to the pyrolytic graphite chip. The patterned array has 16 microwells that can
accommodate tiny volumes of reagents for building single walled carbon nanotube (SWCNT)
forest 2 and coated them with capture antibodies for capturing the selective proteins from serum
samples. The SWCNT forest provided enhanced density of capture antibodies immobilization on
the surface due to increased surface area from SWCNT forest. 3 This allowed ultralow detection
limits of specific cancer biomarker proteins from complex serum matrix. The capture antibody
coated pyrolytic graphite chips were then attached to 3-D printed array via a patterned double sided
adhesive (DSA). Out of 16 sensor spots on the detection platform, 2 sensors spots each were coated
with 8 different capture antibodies. The 8 proteins under study as prostate cancer panel are Insulin
like Growth Factor -1 (IGF-1), 4 Prostate specific antigen (PSA), 5 Platelet Factor-4 (PF-4), 6 cluster
of differentiation protein 14 (CD-14), 7,8 Vascular Endothelial Growth Factor - D (VEGF-D), 9,10
Golgi membrane protein 1(GOLM-1), 11,12 Prostate specific membrane antigen (PSMA) 13 and
Insulin like Growth Factor Binding Protein-3 (IGFBP-3). 14 The capture antibodies for IGF-1, PSA,
PF-4, CD-14, VEGF-D, GOLM-1, PSMA and IGFBP-3 were coated on the array via EDC-NHSS
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amidization and stored at 4°C until use. Before storing the antibody coated arrays were allowed to
incubate with non-specific blocking agent 2% BSA for 1 hr at room temperature to avoid nonspecific binding.

Figure 5-1. Schematic representation of 3-D printed array and Sandwich immunoassay. (A) 3-D
printed microfluidic array with reagent chambers designated for sample/analyte, wash buffers,
detection label and co-reactant for ECL generation connected to detection platform with pyrolytic
graphite detection chip. (B) Disposable pyrolytic graphite sheet with microwells formed by
hydrophobic toner print. Insert showing sandwich immunoassay on a single wall carbon nanotube
forest (SWCNT).

The 3-D printed array features 9 reagent/sample chambers, one inlet port and one out let
port leading to interconnected detection chamber. The each reagent chamber is followed by a
empty air gap chamber to avoid mixing of reagents. The 1st reagent chamber next to pump inlet
port is filled with Tripropylamine (TrPA) our ECL co-reactant followed by 2nd and 3rd chambers
filled with wash reagent (10 mM PBS Buffer + 0.05% Tween 20, pH 7.4). These 2 chambers are
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not separated by air gap chamber as intermixing of wash buffers not adversely effect the assay and
save the real estate space on the array. The 4th chamber is air gap chamber followed by 5th chamber
to be our ECL detection label, detection antibody coated RuBPY doped silica nanoparticles. 6th
chamber is again a air gap chamber followed by a wash buffer chamber. The 8th chamber is again
air gap chamber followed by final 9th chamber sample/serum. The 9th chamber directly leads to
outlet via the detection chamber, Figure 1. The inlet port is connect to micro pump operated digital
analog user interface where all the automated commands are integrated for completion of sandwich
immunoassay by sequential delivery of prefilled reagents.
Automation and User Interface a master controller system that enables simple user
commands. Briefly the construction of the micropump user interface was established by using
voltage controlled oscillator (VCO) latch to control on and off cycles of micropumps and times
assay events. A digital to analog convertor (DAC) latch controls the voltage, amplitude and
frequency for the micropump flow rates. In all, 3 DAC’s are connected to 3 sub-microcontrollers
for three micropumps. An extra DAC with a potentiometer applies 1.0 V precisely to drive the
ECL detection reaction. All components are integrated onto one Arduino microcontroller and a
touch LED screen is used to give digital commands. A small 4.5 V rechargeable lithium ion battery
4.5 V is used to power the control system and drive ECL. Three sequential displays appear on an
LED screen after the user adds sample. Screen 1 presents a settings display with digital commands
to control flow rates and timing. If all settings are optimized, users simply confirm settings. Screen
2 is the start command screen, and the assay is initiated by touching the start button. A digital timer
in terms of step number is displayed for each step of the assay so the user can monitor assay
progress. Screen 3 showing “Done” and Measure OFF, when the immunoassay is complete, and
prompts the user to touch the detect button to drive the ECL reaction and camera data collection,
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Figure 2. When the ECL potential is being applied Measure ON is displayed for given time to
promt the user about ECL detection in progress. In developing assays for the immunoarrays using
this control system, we optimized conditions to attain the best analytical performance
characteristics including high sensitivity, good dynamic range and ultralow detection limits and
optimize assay protocols and device-to-device reproducibility.

Figure 5-2. Immuoassay setup of 3-D printed array with automation platform and touch screen
user interface. 3-D printed microfluidic array with reagent chambers designated for
sample/analyte, wash buffers, detection label and co-reactant for ECL generation connected to
detection platform with pyrolytic graphite detection chip connected to micropumps. Inset figures
showing multiple steps that are automatically completed to perm the immunoassay as designed.
Starting from Start the reaction to completing the assay by measuring ECL under a CCD camera
in a darkbox.
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Assay Procedure The 3-D microfluidic arrays were filled with immunoreagents and
sample and connected to the automated pump user interface module. The pumps and pumping
cycles were initiated by pressing start. The steps to pumps sample and incubation followed by
pushing wash reagents to wash off the excess sample out of the detection channel. Followed by
step 2 to deliver ECL RuBPY label to form ECL sandwich immunoassay. When 1.0 vs Ag/AgCl
was applied from the onboard potentiostat when place under a CCD camera in a dark box results
in ECL generation. The captured ECL light is analyzed to determine the light intensities that relate
to concentration of the analyte. 50 µL of sample and other immunoreagents were filled using a
pipette and 3-D array sealed with a single sided tape. The micro pumps were optimized to deliver
the reagents reproducibly at designated timed intervals at 130 ± 5 µL mL-1 flow rates. When more
than one assay is being performed we ensure synchronization of the 3 pumps by carefully adjusting
their frequency and amplitude via the user interface. The immunoassay incubation times for both
sample incubation and RuBPY incubation were optimized to get desired reproducible ECL signals.
The incubation times for sample and label for multiplexed detection were 10 min each, whereas
for the duplex protein detection the incubation times for sample is 14 min and for RuBPY label is
12 min. ECL is captured at 1.0 V vs Ag/AgCl for 3 min accumulation times in presence of 500
mM tripropylamine in 200mM phosphate buffer + 0.05% Tween 20 + 0.05% Triton-X at pH 7.5.
Relative ECL intensities were obtained by analyzing the light intensities of sample concentrations
and dividing by signal for control. Plotting the relative ECL intensities on Y axis and concentration
of X-axis results in calibration curves that are further used to analyze spike human serum samples.
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Figure 5-3. Calibration data for duplex detection platforms simultaneously in undiluted calf serum
with ECL responses integrated over 180 s at 1.0 V vs Ag/AgCl. (A&B) Duplex assay calibration
curves for PSA and PSMA. (C&D) Duplex assay calibration curves for VEGF-D and PF-4. (E&F)
Duplex assay calibration curves for IGF-1 and CD-14. (G&H) Duplex assay calibration curves for
IGFBP-3 and GOLM-1. Standard deviation for ECL responses at n=4.

5-3 Results
Relative ECL responses captured by CCD camera from the 3-D printed immunoarray with
three trails of controls (undiluted calf serum) and 1 pg mL-1 PSA and PSMA duplex array showed
an average relative standard deviation (RSD) of 5 % for spot to spot (n=8) and 8 % for array to
array (n=3). Initially we performed duplex array where we simultaneously detected 2-proteins at
a time. We did the duplex array to ensure antibody concentrations for sandwich immunoassay and
see reproducible signal from the antibody pairs selected. On the 16 sensor microfluidic chip 4
sensors were addressed for each of the duplex proteins. We calibrated our ECL arrays by
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developing calibration curves for all the 8 proteins in duplexes. We found reproducible ECL
signals with RSDs ranging for 7 to 13%. Increased ECL responses were observed with increase in
concentration of the respective analyte, obtained ECL signal intensities from CCD camera for
different analyte concentrations were further processed by dividing with ECL intensity obtained
from control to get relative ECL intensity. Relative ECL intensities were plotted against
concentration as show in Figure 3. The duplex array formats we coupled PSA and PSMA, VEGFD and PF-4, IGF-1 and CD-14, IGFBP-3 and GOLM-1 as pairs and detected simultaneously.
Dynamic ranges from 0.1 pg mL-1 to 1000 pg mL-1 was obtained for PSA, PSMA, VEGF-D, IGF1, CD-14 and IGFBP-3, 0.1 pg mL-1 to 10,000 pg mL-1 was obtained for GOLM-1 and PF-4.
Detection limits of 78 fg mL-1 to 100 fg mL-1 was obtained for all the 8 proteins.

Figure 5-4. Recolorized CCD images of 5 arrays showing increase in ECL response with increase
in concentration for all the 8 proteins on a single array with ECL aqasition times of 180 sec in
presence of 500 mM TrPA with applied voltage of 1.0 V Ag/AgCl. Influence of ECL responses
with increase in concentrations was shown for 0 pg mL-1 to 1000 pg mL-1.
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Figure 5-5. Calibration data for multiplexed detection platforms simultaneously in undiluted calf
serum with ECL responses integrated over 180 s at 1.0 V vs Ag/AgCl. (A to H) multiplex assay
calibration curves for IGF-1, PSA, PF-4, CD-14, VEGF-D, GOLM-1, PSMA and IGFBP-3.
Standard deviation for ECL responses at n=4.

Multiplexed detection. All the 8 proteins were detected simultaneous on our detection
platforms with 2 sensors allocated for each biomarker. The 8 different capture antibodies were
immobilized onto our single walled carbon nanotube forest sensor microwells. The capture
antibodies were placed in the order of IGF-1, PSA, PF-4, CD-14, VEGF-D, GOLM-1, PSMA and
IGFBP-3 as shown in Figure 1B. The detection label with all the 8 detection antibodes was
prepared by mixing duplex assay labels. 4 duplex assay labels where label 1 with PSA and PSMA,
label 2 VEGF-D and PF-4, label 3 CD-14 and IGF-1, label 4 GOLM-1 and IGFBP-3 were mixed
in equal proportions and sent onto detection platform to complete the sandwich immunoassay. The
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mixture of standard protein samples were then allowed to flow from analyte/sample chamber and
incubated for 10 minutes followed by washing with 10 mM PBS buffer, 7.4 pH. Multiplexed
detection label, RuBPY SiNP was then flowed on to the detection sensors from reagent chamber
and allowed to incubate for 10 minutes, followed by washing with 10 mM PBS and PBS T20
buffer, pH 7.4 from the prefilled chambers. ECL responses were accumulated using CCD camera
as explained before. The relative ECL intensities were plotted against specific concentrations
showing ECL increase with increase in concentration Figure 4 and 5. Acceptable dynamic ranges
from 0.5 pg mL-1 to 10 ng mL-1 was obtained for all the proteins with detection limits ranging from
110 fg mL-1 to 500 fg mL-1 was obtained for all the proteins in multiplexed detection.
To validate our array for using with human serum samples we performed spike and
recovery test to demonstrate the accuracy and reproducibility of our developed method. Spike and
recovery tests were performed for concentrations ranging from 5 ng mL-1 to 0.75 pg ng mL-1.
Spike, recovery and patient samples study will be done to evaluate the validity of the developed
platform.
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Chapter 6

Genotoxic Screening Assays Using
Eletrochemiluminiscence and LC-MS/MS

6-1. Goal & Significance
Cancer is the second leading cause of death in the United States and in 2017, 1,688,780 new cancer cases
and 600,920 cancer deaths are projected. American Cancer Society estimates the number of new cancer cases and
deaths every year according to the data collected from the national Program of Cancer Registries and the North
American Association of Central Cancer Registries. 1 Cancer is caused by both exogenous and endogenous factors
whose mechanism and management still has a lot of unresolved factors. 2 Pharmaceutical and academic institutions
are constantly driving their efforts towards cure and management of cancer.
Toxicity screening plays a significant role in drug development. 95 % of drugs that enter into clinical trials
do not make it to market. 20-40 % of these failures are associated with toxicology and pharmacological reasons. 3
Idiosyncratic adverse drug reactions of pharmaceutical drugs and their metabolites is a major reason for market
withdrawals of many pharmaceutical drugs. 4 Toxicity screening assays estimating the adverse reaction of both drugs
and their metabolites is essential before clinical trials to save millions of dollars associated with drug development.
Animal models and in-silico studies are not always designed keeping in mind the predictive result in humans. More
over even if these experiments were designed as a predictive tool for equivalent response in humans is not always
accurate. 5 Transition from animal models to clinical trials is less than 8 %. 6
Current research focuses of development of high throughput toxicity screening assays for both the
drugs/chemicals and their metabolites that can complement the currently available assays for getting more information
of the drug under study at molecular level and also taking into consideration of their metabolic transformations.
Developed methods are simple and inexpensive. Efforts are also directed towards making these assays automated and
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thus making them adaptive to people with minimum expertise. In addition to drug toxicity these assays can also be
used for estimating the genotoxic assessment of environmental samples.
6-2. Genotoxicity &Current Assays
Ability of chemicals, drugs or environmental pollutants to cause damage to genetic material is known as
genotoxicity. These damages often lead to mutations that can eventually lead to cancer in the absence of inherent
repair mechanism of gene damage. There are number of mechanisms involved in damage to genetic material. Some
of them include DNA hydrolysis, deamination, covalent adduct formation, DNA oxidation, abasic site formation,
strand breaks etc., 7,8

Ames test, comet assay, chromosomal aberration, micronucleus assay, mouse lymphoma
test etc., are some of the commercial assays used for genotoxic testing. Ames test uses biological
assays with bacteria to test a potential chemical/drug for its mutagenicity. 9 Comet assay uses DNA
strand breaks in eukaryotic organisms as a measure of genotoxic potential. 10 Micronucleus test
involves the study of chromosomal fragments in erythrocytes as a measure of genotoxic
potential. 11
These tests give valuable information wither stand alone or in combination. Most of these
assays focus on one single mechanism of genetic material damage or does not give the mechanism
of DNA damage involved. More over the effect reactive metabolites in not known. Hence there is
a need of in-vitro method that can complement the current commercial methods that gives
mechanism of DNA damage and also takes into consideration of multiple mechanisms of DNA
damage and accounts for reactive metabolites formed during biotransformation of drugs or
chemicals.

6-3. ECL based toxicity assays
Microfluidic electrochemical arrays have been developed in our lab for over the past decade. Briefly
microfluidic arrays for DNA damage have been developed for DNA oxidation, DNA adduct formation, strand breaks
etc., These microfluidic arrays contain thin films of DNA, ECL-active polymer [Ru(bpy)2(PVP)10(ClO4)2] and
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microsomal enzyme sources. A negative potential of -0.65 V was initiated first to activate/mimic the fast electron
injection from electrode to microsomal CPR required for transfer of electrons to cyt P450 enzymes which in presence

of oxygen activate the catalytic cycle. This generates metabolites from drugs/chemicals/pollutants.
DNA damage detection then involves oxidation of RuPVP in thin films at +1.25 V, which in turn
oxidizes DNA to produce excited RuIIPVP* that emits ECL light. Thus, +1.25 V vs. Ag/AgCl was
applied for 240 s, at which time the catalytic current for the process was saturated, to generate 610
nm light that was captured by a CCD camera in a dark box. 12

6-4. LC-MS/MS based Genotoxicity assays
LC-MS/MS based approaches give a more elaborate information for specific chemicals under study. LCMS/MS is a valuable tool for predicting the structural and mechanisms of DNA damage. Molecular level of
information regarding the structure of the drug/chemicals, possible metabolites formed upon bioactivation and the
mechanism of DNA damage can be studied using LC-MS/MS. When this approach used in combination of other
genotxic assays can give valuable information in drug development and toxicity screening.

6-5. Summary
In this thesis development of automated 3-D printed microfluidic arrays for high throughput ECL based
genotoxic assays for environmental pollutants was studied and also LC-MS/MS based approaches for sequence
specific DNA damage on P53 tumor suppressor gene for predicting organ specific cancer has been studied in detail.
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Chapter 7
Automated 3-D Printed Arrays to Evaluate Genotoxic Chemistry:
E-Cigarettes and Water Samples

7-1. Abstract
A novel, automated, low cost, 3-D printed microfluidic array was developed to detect DNA
damage from metabolites of chemicals in environmental samples. The electrochemiluminescent
(ECL) detection platform incorporates layer-by-layer (LbL) assembled films of microsomal
enzymes, DNA and an ECL-emitting ruthenium metallopolymer in ~10 nm deep microwells.
Liquid samples are introduced into the array, metabolized by the human enzymes, products react
with DNA if possible, and DNA damage is detected by ECL with a camera. Measurements of
relative DNA damage by the array assess the genotoxic potential of the samples. The array analyses
3 samples simultaneously in 5 min. Measurement of cigarette and e-cigarette smoke extracts and
polluted water samples was used to establish proof of concept. Potentially genotoxic reactions
from e-cigarette vapor similar to smoke from conventional cigarettes were demonstrated.
Untreated waste water showed a high genotoxic potential compared to negligible values for treated
waste water from a pollution control treatment plant. Reactivity of chemicals known to produce
high rates of metabolite-related DNA damage were measured and array results for environmental
samples were expressed in terms of equivalent responses from these standards to assess severity
of possible DNA damage. Genotoxic assessment of waste water samples during processing also
highlighted future on-site monitoring applications.
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7-2. Introduction
Genotoxicity refers to the ability of chemicals or their metabolites to interact with genetic
material. Reactions with DNA include covalent adduct formation, oxidation, strand breaks and
non-covalent intercalations. When damage to DNA is not repaired, subsequent mutations occur
that may lead to cancer. 1 For environmental chemicals and drugs, a battery of tests is typically used
to predictively assess potential genotoxicity and other toxicities. Genotoxicity tests such as Comet,
Ames, micronucleus, and mouse lymphoma assays are very useful for toxicity predictions, but are
limited by ease of use and metabolic generality. 2 We previously developed microfluidic toxicity
screening arrays with the ability to uncover multiple chemical pathways of genotoxicity by
measuring DNA damage.2 These high throughput electrochemiluminescent (ECL) and
electrochemical assays include DNA and human metabolic enzymes that convert chemicals to
metabolites, which are most often the DNA-reactive species in genotoxic pathways. 2
Automated, disposable devices that rapidly detect genotoxic chemistry in environmental
samples can serve to evaluate the potential influence of toxic chemicals and on-site risks to human
health.2,3 We recently reported a paper microfluidic device that estimated the genotoxic potential
of water samples. 4 In this paper, 3-D printing is used to develop a more sophisticated and sensitive
general automated array to assess genotoxic potential of environmental samples. 3D printing was
used to afford cheap, fast design and optimization. It has been used to print fluidic devices that
detect pathogenic bacteria, biomedical markers, food allergens, and heavy metals, as well as in
nanoparticle and chemical synthesis. 5,6 3D printed flow cells were designed for microdroplet
generation, electrochemical sensing, and microfluidic devices. 7 We used desktop 3D printers to
develop devices for flow injection amperometry, flow cells to measure ECL, 8 and microfluidic
immunoarrays to detect cancer biomarker proteins. 9
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The current device is designed for rapid assays of liquid samples. We focus here on two
types of samples for reasons outlined below. The first is cigarette and e-cigarette smoke, since
smoking is a major contributor to heart disease and cancer. 10 The second is contaminated water, a
major public health concern.
Smoking causes more deaths than human immunodeficiency virus, illegal drug use,
alcohol, motor vehicle accidents, and fire related deaths combined. 11 Electronic (e-)cigarettes, are
battery powered devices that vaporize nicotine, and were designed as an alternative to tobacco
cigarettes. Additives in recent e-cigarettes make the vapor less harsh and more rapidly deliver
nicotine to the brain, fostering use and increasing chances of addiction. Between 2011 and 2015
e-cigarette use increased from 1.5 to 16 % among US high school students and from 0.6 to 5.3%
among middle school children. 12 In addition, e-cigarette vapor contains toxic metals such as
cadmium, lead and nickel at levels of 0.022-0.057 ng in 15 puffs of the aerosol. 13
Currently one-third of available fresh water is used for agriculture, industrial and domestic
purpose. 14 Chemical pollution of fresh water lakes and rivers is endemic in populated areas. 15
Toxic pollutants found in water bodies include nitrogenous and phosphorous species, organic
chemicals, metals, and biologically generated compounds. 16 Co-existence of these chemicals in a
mixture has been suggested as an origin of elevated genotoxic effects.14,17
In this paper, we report the first disposable, fully automated 3D-printed array designed to
assess genotoxic potential of liquid environmental samples. This device can analyze vapor extract
samples from cigarettes and water samples in 5 min for less than $1.00 (Figure 7-1). The arrays
assess potential genotoxicity based on DNA reactivity of metabolites generated by enzymes on the
array. To our knowledge, this is the first low cost 3-D printed microfluidic array capable of
evaluating the metabolite-dependent genotoxic potential of environmental samples. Results
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suggest that e-cigarettes can have similar or enhanced genotoxic potential compared to tobacco
cigarettes, depending on use patterns. The genotoxic potential of untreated waste water was high,
but was decreased to very low levels by reclamation in a sewage treatment facility. 18

Figure 7-1. Automated genotoxicity screening array: (A) 3D printed devices without (left) and
with (right) microwell chip and counter electrode wires inserted showing sample chambers
containing dye solutions; coin for size comparison is US 10 cent piece; (B) microwell-patterned
pyrolytic graphite detection array showing the first row holding 1 µL water droplets retained by
the hydrophobic microwell boundaries. Each row is fed by a separate sample line. The working
array features films of DNA, metabolic enzymes, and RuPVP in each microwell; (C) Assembled
array system showing box enclosing electronic microprocessors and micropumps driven by a
rechargeable battery and connected to the 3D printed array below with a wash reservoir (top)
containing pH 7.4 buffer.

7-3. Experimental Section
Safety

note:

Benzo[a]pyrene

(B[a]P),

4-[methyl(nitroso)amino]-1-(3-pyridinyl)-1-

butanone (NNK), N’-Nitroso-2-(3-pyridyl)pyrolidine (NNN), 2-Acetylaminofluorene (2-AAF), 2128

Naphthylamine (2-NA), Aflatoxin-B1 (AFB1) and their metabolites are potential carcinogens.
Handling these chemicals involved protective measures including wearing gloves, safety glasses
and working in a hood.

7-3.1 Chemicals and Materials. B[a]P (MW 252.31), NNK (MW 207.23), NNN (MW 177.20),
2-AAF (MW 223.28), 2-NA (MW 143.19), AFB1 (MW 312.28), poly(diallyldimethylammonium
chloride) (PDDA, avg. MW= 100,000-200,000), poly(acrylic acid) (PAA, avg. MW= 1800), calf
thymus DNA (Type I), and other chemicals were from Sigma Aldrich. Pooled male human liver
microsomes were from BD Gentest. [Ru(bpy)2(PVP)10]2+ {RuPVP; (bpy=2,2-bipyridyl;
PVP=poly(4-vinylpyridine)} was synthesized and characterized as described previously. 19
Pyrolytic graphite (PG) sheets are from Panasonic PGS-P13689-ND 70 µm thick.

Figure 7-2. 3-D Printed PG array: (A) CAD design showing top and bottom view of 3-D printed
arrays with pump inlets, sample chambers, detection channels and grooves for counter and
reference electrodes; (B) Inside view of micropump and microcontrollers along with automation
platform connected to 3-D printed array and operated via 5 V rechargeable battery.
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7-3.2 3-D Printed Microfluidic Arrays. Microfluidic arrays were printed from clear acrylate resin
using a Formlabs Form1+ stereolithographic 3D printer. Design files are available on our
website. 20 Briefly, CAD files incorporating the design were converted to printer instruction files
for input to the printer (details in SI). After printing, devices were rinsed internally and externally
successively with isopropanol and water, then spray coating with clear acrylic spray (Krylon™).
Arrays were printed with 3 sample chambers that feed 3 detection channels designed so that
sample solutions flow directly across shallow 1 mm wide, 10 nm deep microwells on the detection
chip to facilitate reactions with enzyme/DNA films in the wells (Figures 7-1A,B and 7-2).
Detection chips were made from conductive pyrolytic graphite (PG) sheets cut to desired sizes.
PG sheets were patterned with microwells using our print and peel technology 21 to accommodate
tiny volumes of reagents during layer-by-layer (LbL) film assembly (Figure 7-1B). 22 A microwell
template featuring 21 spots of diam. 1 mm in 3 rows with 7 spots per flow channel was inkjet
printed onto glossy paper (Avery ™ 5263) and heat pressed for 45 s at 275 °C to transfer onto
these PG sheets (Figure 7-3, SEM). Patterned PG sheets were attached onto the 3D printed array
using double sided adhesive.

Figure 7-3. SEM images for A) bare pyrolytic graphite sheets and B) Microwell that hold 1 µL
volumes of reagent required to complete layer by layer assembly.
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Array were 3D printed in less than 1 hr using 6 mL resin at fabrication cost $0.80. They
have dimensions 50 mm (length (L)) X 22 mm (width (W)) X 5 mm (height (H)). Sample chamber
dimensions are 17 mm (L) X 5 mm (W) X 2.5 mm (H) and maximum sample or reagent volume
170 ± 5 µL. Sample volume was 150 µL, and detection channels are 23 mm (L) X 3 mm (W) X
0.65 mm (H) with volume 45 ± 5 µL, and are provided with holes and grooves to accommodate
stainless steel wire counter (0.4 mm diam.) and Ag/AgCl wire reference (0.6 mm diam.) electrodes
to complete the ECL electrochemical detection cell (Figure 7-1A).

Figure 7-4. A) Arduino program for pumps automation B) Schematic upload of Arduino program
to ATtiny85 chip.

7-3.3 Automation. Automation was achieved by interfacing three Mp6 micropumps (Bartels) with
an “ATtiny85” microprocessor chip via Bartels OEM microcontrollers (Figure 7-4). Micropump
control features printed-circuit board (PCB)-linked microcontrollers independently connected to
the ATtiny85 chip. The inexpensive 8-bit ATtiny microcontroller chip runs Arduino programs for
pump control at low power consumption (Figure 7-4), 23 and provides ON/OFF commands to
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control voltage input to micropumps from a rechargeable lithium ion battery. Micropumps were
adjusted to flow rate 120 ± 3 µL/min.

7-3.4 Layer by layer film assembly. Sequential layers of ECL metallopolymer RuPVP, human
liver microsome (HLM) enzyme source and DNA were grown in microwells on the PG chip by
layer-by-layer (LbL) alternate electrostatic assembly,22 depositing appropriate solutions
sequentially and incubating 20 min for polyion layers and 30 min for enzyme and DNA layers at
4°C with water washing between adsorption steps. 24 Film architecture optimized for best
signal/noise was PDDA/PAA/(RuPVP/DNA)2/RuPVP/Enzyme/DNA.

7-3.5 Detection of genotoxic reactions. The assay protocol involves two steps. First, the natural
cyt P450 catalytic cycle is activated by applying -0.65 V vs Ag/AgCl while flowing oxygenated
solutions of test samples in 10 mM phosphate buffer pH 7.4 + 1 % DMSO for 45 s. This generates
metabolites from the test compounds that can react with DNA. 25 Second, after washing the array
with buffer, 1.25 V vs Ag/AgCl is applied for 180 s to generate ECL proportional to damage of
co-reactant DNA. This oxidizes RuIIPVP to RuIIIPVP, and RuIIIPVP reacts with guanine in a
complex pathway to form excited state *RuIIPVP that emits ECL light at 610 nm which is captured
with a CCD camera in a dark box. 2 Briefly the complex reaction between RuIIIPVP and guanine
involves oxidation of guanine by RuIIIPVP in an electrochemical catalytic pathway resulting in a
guanine radical. Guanine radical further reacts with RuIIIPVP to form *RuIIPVP that emits ECL
light.19 Covalent metabolite-nucleobase adducts disrupt the DNA double helix and can also form
abasic sites or strand breaks, which all result in more accessible guanines to generate more ECL
light. Electrodes are disposable and are discarded after each use.
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Prior to assays, sample chambers in the microarray (Figure 7-1A) were pre-filled with 150
µL of test solution through the sample injection ports, which are then closed. The micropumps are
connected to inlets with common feed at the back from a wash buffer reservoir (Figure 7-1C).
Application of voltage to the array was controlled by a 3-electrode handheld potentiostat. The
entire device resides inside a dark box. Initially pumps are off, then the program initiates a 135 s
pumping cycle for three steps, 10 s filling the detection channel, 45 s electrolysis and 80 s washing.
Samples were pumped into the 3 separate detection channels and 45 s electrolysis was done at 0.65 V vs Ag/AgCl once channels were full (while continuing flow) to activate the natural catalytic
cycle of cyt P450s.,25 After a subsequent 80 s wash cycle, pumps turn off and visible ECL light is
generated by applying 1.25 V vs Ag/AgCl for 180 s and capturing light with a CCD camera.
Timing was optimized for the best ECL signal/noise.

Figure 7-5. Artificial inhalation setup to extract smoke/vapor from cigarettes on to a cotton plug.

7-3.6 Sample analyses. Smoke (vapor) extracts from e-cigarettes and filtered and non-filtered
tobacco cigarettes were collected using an artificial inhalation device (Figure 7-5). Tubing
connecting a syringe and the cigarette or e-cigarette was attached via a pipette tip plugged with
cotton so that smoke passes through it and chemicals are trapped. This cotton was subsequently
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extracted with 2 mL DMSO. To keep experimental conditions representative and relevant for
vaping usage by smokers we extracted 100 puffs and smoke from 5 tobacco cigarettes for
comparison. Vaping anywhere from 75-175 puffs from e-cigarettes is equivalent on average to 56 tobacco cigarettes per day. 26 Approximately 15-30 puffs from an e-cigarette is considered
equivalent to smoke from one tobacco cigarette.13,28
Polyaromatic hydrocarbons and tobacco specific nitrosamines 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN) are major carcinogens present in
cigarette smoke. 27 Most chemicals in tobacco cigarettes and e-cigarettes are similar with slightly
lower concentrations reported for e-cigarettes.13,28 Usually contents of e-cigarettes are loaded into
a cartridge and used with a battery operated inhalation device that heats and converts a nicotine
solution with additives into an aerosol.13 The contents of the e-cigarette liquid quoted by
manufacturer content lists show tobacco derived nicotine, propylene glycol, vegetable glycerin
and natural and artificial flavoring agents.
Our second test targets featured untreated sewage water, partially treated water and
completely treated reclaimed water as collected from University of Connecticut water pollution
control facility.18 Water samples were passed through a 0.2 µM syringe filters (Thermo Scientific
F2504-6) prior to genotoxic evaluation to remove particulate matter. Genotoxic chemicals present
in waste water 2-acetylaminofluorene (2-AAF), 29 2-naphthylamine (2-NA) 30 and aflatoxin-B1
(AFB1) 31 were used as reference standards.

7-4. Results
Cigarettes and e-cigarettes. Responses to tobacco smoke components B[a]P, NNK and
NNN were measured first. One channel in the microfluidic array was used for each specific
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compound (Figure 7-6). Plots of % ECL increase over the blank (1% DMSO in 10 mM phosphate
buffer, pH 7.4) vs. concentration of standard (Figure 7-6B) serve as standard calibration curves
and their slopes reflect relative rates of DNA damage.2 Dynamic range was from 3 to 150 µM for
all standards. Increase in ECL intensity was observed with increase in test chemical concentration
(Figure 7-6). ECL increases in earlier versions of related genotoxicity arrays were confirmed as
directly related to amounts of specific metabolite-DNA adducts detected by LC-MS/MS.2,4,24 In
the present array, spot-to-spot variability was ±6 % (n=21) and array-to-array variability was ±7%
(n=3) (Figure 7-7). Toluene, with poorly DNA-reactive metabolites, 32 was used as a negative
control with negligible ECL change (Figure 7-6).

Figure 7-6. Array results for tobacco-related standards with DNA-reactive metabolites: (A)
recolorized ECL data using arrays featuring RuPVP/enzyme/DNA microwells treated with
oxygenated solutions of carcinogens B[a]P, NNK and NNN and negative control toluene in 1 %
DMSO + 10 mM phosphate buffer pH 7.4 for 45 s at -0.65 V vs. Ag/AgCl, with ECL captured by
CCD camera after subsequently applying 1.25 V vs Ag/AgCl for 180 s. (B) Calibration plots of %
ECL increase over 1% DMSO control vs. concentration of standards. ECL intensity increases
proportional to DNA damage that disorders ds-DNA and allows co-reactant guanines in the DNA
better access to RuIII sites of RuPVP.2
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Figure 7-7. Recolorized ECL images from PDDA/PAA/(Ru/DNA)2/RuPVP/Enzyme/DNA films
in microwells captured by CCD camera in 10mM phosphate buffer, pH 7.4 upon application of
1.25 V against Ag/AgCl reference electrode for 180 s.

Scheme 1. Cytochrome P450 mediated bioactivation and DNA reactivity of standard
chemicals used for cigarette studies (1) Benzo[a]pyrene (B[a]P), metabolized to benzo[a]pyrene7,8-dihydrodiol-9,10-epoxide that intercalates and covalently binds predominantly with guanine
base in DNA,33 Adapted from information in ref.33 (2) 4-(methylnitrosoamino)-1-(3-pyridyl)-1-
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butanone (NNK) and (3) N-nitrosonicotine (NNN) form hydroxyl forms before binding to
nucleobases within DNA.34 Adapted from information in ref.34.
Previous studies of B[a]P, NNK and NNN confirmed that reactive metabolites of these procarcinogens react with DNA to form covalent DNA adducts (Scheme 7-1). B[a]P is a polyaromatic
hydrocarbon present in coal tar, cigarette smoke, and grilled meat, Metabolic cyt P450s catalyze
B[a]P oxidation to a 7,8 epoxide that is rapidly hydrolyzed to a diol by epoxide hydrolase. The
diol is further oxidized by cyt P450 to an epoxide to form ±-anti-benzo[a]pyrene-7,8-dihydrodiol9.10-epoxide (±-anti-BPDE, eq 1). 33 Major metabolite ±-anti-BPDE is classified as a Group I
carcinogen by the International Agency of Research on Cancer (IARC). It is a strong electrophile
that reacts with DNA nucleobases of to form covalent adducts. The major covalent adduct is
formed by ±-anti-BPDE reaction with the exocyclic amine of nucleobase guanine to form a stable
covalent adduct (Scheme 7-1, eq. 1). Similarly, the tobacco specific nitroso amines NNK and NNN
undergo α-hydroxylation catalyzed by cyt P450s to form reactive metabolites that react with DNA
to form adducts at the N7 position of guanine (Scheme 7-1, eqs 2 and 3).2,34,35
Cigarette smoke and E-cigarette vapor trapped in the inhalation device Figure 7-5 was
extracted into DMSO, and diluted 100-fold in pH 7.4 buffer prior to analysis. Vapor extract from
20 puffs of e-cigarettes was taken as equivalent to smoke from one tobacco cigarette.13,28 We
found large increases in ECL intensity with increases in amount of extracted cigarette smoke and
e-cigarette vapor (Figure 7-8A), suggesting increased amounts of DNA damage2,4 (Figure 78A,B). The most important finding is that %ECL values for equivalent numbers of puffs are
slightly larger for e-cigarettes than for tobacco cigarettes, and much larger than for filtered tobacco
cigarettes and non-nicotine e-cigarettes. These differences are significant at 95% confidence levels
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(t-tests) and suggest that chemicals in the vapor of nicotine e-cigarettes metabolized in the array
are at least as DNA-reactive as those in smoke of unfiltered tobacco cigarettes.

Figure 7-8. ECL array results comparing extracted vapor from e-cigarettes with extracted smoke
from tobacco cigarettes using the conversion that 20 e-cigarette puffs equals smoke from one
tobacco cigarette {Abbrev.: Tobacco Cigarettes (TC), e-Cigarettes (EC), non filtered (nf) and nonnicotine (nn)}:

13,28

(A) Recolorized ECL data from arrays. Each row represents microwells

containing RuPVP/Enzyme/DNA layers treated with smoke extracted from 1, 3 and 5 TC & nfTC (equivalent to 20, 60 and 100 puffs of e-cig.) and 20, 60 and 100 puffs of EC & non-nicotine
(nn)-EC in 1% DMSO containing buffer for 45 s under potential of -0.65 V vs. Ag/AgCl. ECL
captured while applying 1.25 V vs Ag/AgCl for 180 s. (B) % ECL increase over control (1%
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DMSO in buffer) vs. cigarette samples. C) NNK equivalents from %ECL for different cigarette
samples.
The difference in %ECL increase between filtered and non-filtered tobacco cigarettes for
20 puff e-cig. equivalents was not statistically different at the 95 % confidence interval. However,
for 60 and 100 e-cig. puff equivalents, %ECL was statistically larger for unfiltered cigarettes at
the 95% confidence level (Figure 7-8B). DNA reactivity of the non-nicotine e-cigarettes and the
filtered tobacco cigarettes denoted by array signals were comparable, and ~1.8-fold smaller than
from unfiltered tobacco cigarettes.
Table S1. Genotoxic reactivity of cigarette sample assessed in terms of known carcinogen
concentration
Sample

% ECL

1 Gen Cig

NNK

NNN

BaP

[Conc.]

STDEV

[Conc.]

STDEV

[Conc.]

STDEV

23.32

45.74

2.58

26.40

1.49

45.54

2.56

3 Gen Cig

33.58

85.52

8.50

49.74

4.94

77.84

7.74

5 Gen Cig

40.46

117.76

3.36

68.77

1.96

102.37

2.92

1 nf-Gen Cig

24.35

49.25

3.43

28.45

1.98

48.52

3.38

3 nf-Gen Cig

39.58

113.41

10.10

66.20

5.90

99.12

8.83

5 nf-Gen Cig

72.57

320.99

23.45

189.80

13.86

241.63

17.65

15 puff e-cig

32.16

79.39

10.52

46.13

6.11

73.03

9.67

30 puffs e- cig

44.83

140.42

11.38

82.18

6.66

119.02

9.64

60 puffs e-cig

60.66

235.95

13.85

138.99

8.16

185.64

10.90

15 puffs nn e-cig

27.74

61.62

3.70

35.70

2.14

58.79

3.53

30 puffs nn e-cig

34.55

89.80

4.34

52.27

2.53

81.16

3.92

60 buffs nn e-cig

37.44

103.10

12.86

60.11

7.50

91.35

11.40

1 e-cig cartridge

35.74

95.19

7.88

55.44

4.59

85.32

7.07

3 e-cig cartridges

166.15

1330.50

169.94

800.78

102.28

816.67

104.31

5 e-cig cartridges

218.43

2127.83

209.67

1288.16

126.93

1220.95

120.31
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To link these results to known DNA-reactive chemical metabolites, DNA-reactivity of the
samples was expressed in terms of array responses of known tobacco component concentrations
of B[a]P, NNK and NNN using Figure 7-6B. This approach puts the results on a common footing
related to major genotoxic components in tobacco smoke. Figure 7-8C shows the NNK-equivalent
concentration in each of the cigarette types and suggest that nicotine e-cigarettes and unfiltered
cigarettes are equivalent to quite significant levels of the potent tobacco carcinogen NNK.
Equivalence of sample responses in terms of B[a]P and NNN are reported in Table 7-1, and lead
to qualitatively similar conclusions.

Scheme 7-2. Cytochrome P450 mediated bioactivation and DNA reactivity of standard
chemicals used for water samples. (4) Aflatoxin B1 (AFB1), metabolically activated to its
epoxide form that forms covalent adducts with DNA nucleobases.37 Adapted from information in
ref.37 (5) 2-acetylaminofluorene (2-AAF)38 Adapted from information in ref.38 and (6) 2-
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naphthylamine (2-NA) form acetoxy forms upon bioactivation that form covalent adducts with
DNAnucleobases.40 Adapted from information in ref.40.
Water samples. Known water pollutants 2-AAF, 2-NA, AFB1 were first tested as
reference standards to assess genotoxic potential. Aflatoxins are metabolites of fungal organisms
in polluted food and environmental samples and are associated with liver cancer. 36 Aflatoxin B1
is one of the most potent aflatoxins, and requires cyt P450 bioactivation to become carcinogenic.
It is oxidized by cyt P450s to the 8,9-epoxide, which reacts with the N7 position of guanine to
form covalent adducts (Scheme 7-2, eq. 4). 37 Arylamines are commonly associated with bladder
cancer. 38 2-acetylaminofluorene (2-AAF) and 2-naphthylamine are converted by sequential
reactions catalyzed by cyt P450s and acetyl transferase to arylnitrenium ions that react with
nucleobases of DNA to form covalent adducts. A major adduct on the C8 position of guanine is
shown in Scheme 7-2 (eqs 5,6). 35,39,40
Array results for these 3 compounds and toluene negative control are shown in Figure 79A. Plots of % ECL increase over blank (1% DMSO in pH 7.4 buffer) vs. concentration of standard
(Figure 7-9B) serve as calibration curves for water samples. Again, slopes reflect relative rates of
DNA damage.2 Dynamic ranges were from 3 to 100 µM. Limits of detection as %ECL increase 3x
the avg. noise were ~3 µM for these genotoxic compounds.
Samples from the University of Connecticut water treatment facility were assayed on the
array. Figure 7-9C shows a significant increase in ECL for untreated water samples compared to
reclaimed and partially treated water samples. Results from Figure 7-9C are also expressed in
terms of equivalent concentrations of the reference standards (Figure 7-9D) to provide
comparisons of the relative genotoxicity potential of the samples. E.g. the untreated waste water
is equivalent to about 10 µM of the parent chemical 2-AAF.
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Figure 7-9. Array results for standards with known DNA-reactive metabolites: (A) Recolorized
ECL data using arrays featuring RuPVP/enzyme/DNA microwells treated with oxygenated
solutions of carcinogens (2-AAF, 2-NA and Aflatoxin B1 and negative control toluene in 1 %
DMSO + 10 mM phosphate buffer pH 7.4 for 45 s at -0.65 V vs. Ag/AgCl, with ECL captured by
CCD camera after subsequently applying 1.25 V vs Ag/AgCl for 180 s. (B) Calibration plots of %
ECL increase over the blank vs. concentration of standards. ECL intensity increases proportional
to DNA damage. (C) ECL array results comparing ECL intensities obtained from untreated water
(UTW), partially treated water (PTW) and fully treated reclaimed water (RCW) with respect to
1% DMSO controls. Recolorized ECL data from arrays with each row representing microwells
containing RuPVP/Enzyme /DNA layers treated with UTW, PTW, RCW& 1% DMSO in buffer
for 45 s at -0.65 V vs. Ag/AgCL with ECL captured after subsequent application of 1.25 V vs
Ag/AgCl for 180 s. (D) Bar graph showing chemical equivalents from %ECL response for different
water samples.
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Compared to the untreated waste water, the difference from the treated reclaimed water is
significant at the 95% confidence level. Results suggest that more potentially genotoxic chemicals
in the untreated waste water are converted on the array to metabolites that are reactive with DNA
compared to reclaimed or partially treated water samples. The larger % ECL for partially treated
water compared to fully reclaimed water was also statistically significant at 95 % confidence
(Figure 7-9C, D). Genotoxic potential in terms of DNA reactivity of untreated water samples was
~10 fold larger than fully reclaimed water and ~2.4 fold larger than partially treated water.

7-5. Discussion.
Results above illustrate a novel, low cost, 3D-printed microfluidic array capable of
assessing the genotoxic potential of environmental samples. The 3D printed device with disposable
microwell array containing enzyme/DNA/RuPVP films costs less than $1.00 to fabricate.
Advantages of this device include, multi analyte analysis, complete automation, on chip metabolite
generation, and rapid detection of DNA damage (5 min). These disposable arrays are designed to
“plug-in” to a reusable automation platform featuring microcontrollers, micropumps, and battery
that costs $150. The array here was equipped with 21 detection microwells, but is possible to
expand to larger size to accommodate multiple enzymes, multiple analytes, and higher sample
throughput.
DNA-reactivity related to metabolites from smoke or vapor extracts measured by the array
clearly suggests comparable genotoxic potential of tobacco and nicotine e-cigarettes when assayed
by the same protocol (Figure 7-8). Expression of the signals in terms of levels of known tobacco
chemicals with metabolites having high rates of DNA damage, e.g. NNK (Figure 7-8D) provides
a reference point to assess the severity of possible genotoxicity, without having to determine
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individual DNA adducts by expensive LC-MS/MS assays. E-cigarette vapor was reported to have
low concentrations of chemicals with potential to cause DNA damage13 and could be assumed by
some to be a safer alternative to tobacco cigarettes. However, our results suggest similar DNA
damage from e-cigarette vapors and tobacco cigarette smoking.
Results also showed that genotoxic potential for non-nicotine e-cigarettes is about the same
as for filtered tobacco cigarettes, and 1.5-2 fold lower than for e-cigarettes. DNA reactivity for 20
puffs of an e-cigarette was equivalent to about 83 µM NNK (1.6 µg/mL) (Figure 7-8C) compared
to estimated levels of NNK in one tobacco cigarette of 46 µM (0.9 µg/mL). Unfiltered tobacco
cigarettes gave DNA reactivity nearly 2 times greater than filtered tobacco cigarettes (Figure 78B&C). Even non-nicotine e-cigarettes showed significant DNA reactivity, similar to that of
filtered tobacco cigarettes (Figure 7-8C).
The above results are consistent with recent reports using conventional assays that found
significant DNA strand breaks, cytotoxic effects, and cell death caused by e-cigarette vapor with
and without nicotine. 41,42 Ease of use of e-cigarettes may also result in elevated use compared to
tobacco cigarettes, which can result in escalated DNA damage. For example, DNA reactivity as
NNK equivalents in vapor extract from 2 full e-cigarette cartridges was 1.1 mM, roughly
equivalent to 0.9 mM for 20 tobacco cigarettes (Table 7-1).
The arrays also revealed genotoxic potential of water samples (Figure 7-9). ECL responses
from the untreated waste water were about 9 times larger than fully recovered water suggesting
significant presence of genotoxic chemicals. Successful analysis of samples during mid-treatment
suggests that the array can be used to monitor the success of intermediate stages of water treatment.
Expression of these results in terms of water polluting chemicals that cause metabolite-related
DNA damage again provide a rapid assessment of relative severity of the contamination (Figure
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7-9D). Calibration range and LOD of 3 µM for standard water pollutants (Figure 7-9B) suggests
applications in rapid identification of seriously polluted water.

Array results for the untreated

water samples are consistent with reports of genotoxic chemicals in domestic and industrial waste
water. 43 ECL responses from fully reclaimed water did not show significant genotoxic potential
when compared to controls suggesting significant removal of genotoxic chemicals.

7-6. Summary
In summary, we described here a new, portable low cost, automated, toxicity screening tool
to detect metabolite-related genotoxicity chemistry from environmental samples. The 3-D printed
array is fast and accurate in sensing effects of possible genotoxic chemicals. A unique feature is
that test chemicals are converted to their metabolites so that metabolite reactivity towards genetic
material can be measured rapidly and efficiently. This is a major attribute for assessment of
possible genotoxic consequences of pollutant exposure from relevant samples.
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Chapter 8
Sequence Specific Genotoxic Assessment Using LC-MS/MS

8-1. Introduction.
The p53 (or TP53) tumor suppressor gene codes for p53 protein that regulates cell division,
cell death, genomic stability and suppresses cancer. P53 gene mutations occur in over 50% of
human cancers, 1 and are located selectively in exons 5-8, and alter the p53 protein so as to
minimize cancer protection. TP53 (or p53) was confirmed as a tumor suppressor gene in the
1980s, 2 and other tumor suppressor genes such as retinoblastoma (RB), Wilms Tumor 1 (WT1),
Adenomatosis Polyposis Coli (APC), and p16 have also been discovered. Furthermore, mutation
sites within P53 gene are correlated with specific cancers, 3,4 so that prediction of the most reactive
p53 codons toward new chemicals and their metabolites could be a valuable tool to aid in toxicity
and cancer prediction.
Xenobiotic chemicals and their metabolites can damage tumor suppressor genes. More than
50 % of human cancers are known to have mutations in the p53 gene. 5- 9 Human exposure to
various carcinogens and specific mutated codons in the p53 gene leading to the development of
specific cancers.3 Exon 5-8 are most mutated codons in the P53 gene 10,11 Mutational spectra on the
p53 gene are correlated with the incidence of tissue specific cancers. For example, data in the p53
database handbook shows that highly mutated reactive hot spots include codons 157, 158, 248,
249 in lung cancer, codon 273 in brain and prostate cancer, codons 175, 248 and 273 in breast
cancer and codons 175, 282 and 248 in liver cancer. 12 Codon hot spots for reactions of metabolites
on the p53 gene have been linked to human exposure to particular carcinogens. Specifically,
components of tobacco smoke are related to lung cancer, tobacco smoke and alcohol to head and
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neck cancers, aromatic amines to bladder cancer, aflatoxine-B1 and hepatitis B virus to liver cancer
and ultraviolet light to skin cancer. Thus, exposure to specific carcinogens that lead to damage to
the p53 gene can be correlated with organ-specific cancers.
These relationships between the mutational spectra of p53 to organ-specific cancers are clearly
indicated in large databases integrating extensive p53 research. 13 These data include genomic
studies of patient tumors and cell lines, and show that the p53 gene has 7 reactive hot spots between
bases 361 and 920 of the reading frame, one in exon 5, one in exon 6, five in exon 7 and two in
exon 8. Screening of a wide range of carcinogens by assessing reactive hot spots on p53 in vitro
could identify reactive nucleobases within codons that, if correlated with mutational spectra, could
be used to predict tissue specific cancers. This sort of information is not available for large libraries
of potentially reactive compounds or metabolites on p53, and is almost non-existent for other
tumor suppressor genes. 14 New methods for screening reactive metabolites for sequence specific
tumor suppressor gene damage would be valuable tools to assess the potential of new drugs and
environmental chemicals for organ-specific carcinogenicity.
Reactants

such

as

benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide

(BPDE),

7,12-

dimethylbenz(a)anthracene diol epoxide, acrolein, and mitocin C, are more reactive towards
MeCpG sites on the genes.19,20 Limited repair of these reacted sites contributes to their role as
mutational hot spots. Polyaromatic hydrocarbon (PAHs) metabolites preferentially react with
MeCpG sites. 15 E.g., benzo[a]pyrene is metabolized to BPDE by a sequential pathway involving
cytochrome P450s and epoxide hydrolase, 16,17 and reacts with DNA in SN2 reactions to form
nucleobase adducts that lead to mutations. 18 Within the p53 gene, 42 CpG sites are methylcytosines
(MeC), 19,20 and are the most frequently mutated codons or hot spots.21,22 Non-CpG MeC related
to GC>AT transitions are known in lung, head and neck cancer. 23
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Mass spectrometry (MS) is a valuable tool for structural analysis of DNA, and LC-MS/MS
methodologies have been developed over the past decade for sizing and sequencing
oligonucleotides of up to 20 base pairs (bp). 24- 28 Harsch, reacted a 10 base pair oligonucleotide
derived from hypoxanthine-guanine phosphoribosyltransferase gene (HPRT gene) with
benzo[c]phenanthrene and determined positional isomers in the product. 29 Chowdhury and
Guengerich reacted a 15 base pair oligonucleotide incorporating hot spot codon 157 on exon 5 of
p53 gene with mutagenic molecules benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) and
N-hydroxy-4-aminobiphenyl (N-OH-4ABP) and used MS/MS to determine site reactivity. 30 They
also determined C-4 oxidized abasic sites on a 15-mer oligonucleotide.26 Sharma et. al., reacted a
17-mer incorporating codon 135 of p53 with 2-acetylAminofluorene (AAF), and observed
multiple adducts formed from reactions with guanosines. 31 Satterwhite et. al., reacted a 21-mer of
p53 containing codon 273 with BPDE. 32 Xiong et. al., reacted a 14 mer ds DNA containing hot
spot codons 157 and 158 with BPDE. Xiong et. al., reacted a 14 mer ds DNA containing hot spot
codons 157 and 158 with BPDE.24 Sharma et. al., studied a 15 base pair DNA containing codon
135 with 2-AAF 31 and also investigated 14 mer ds DNA with codons 157 and 158

33

in reactions

with BPDE, AAF and N-OH-4ABP.
Previous studies of alkylated CpGs on DNA exon 5 analogs using [15N3,

13

C1]-labeled

guanines and oligonucleotide hydrolysis revealed 2-3 fold increases in yields of BPDE adduction
for MeCs. 34 MeCpG’s also enhanced DNA-acrolein adduction 2-fold. 35,36 A 21-base pair (bp)
oligonucleotide with a CpG site gave MeC-dependent voltammetry suggesting enhanced BPDE
reactivity. 37 A 14 bp oligonucleotide with four MeCpG sites gave 3-4 fold increased adduction
yields compared to unmethylated CpG. 38 In the 1990s, Geacintov measured strong non-covalent
binding between BPDE and ds-poly(dG-dC).(dG-dC) oligonucleotides and proposed enhanced
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subsequent coupling with MeCs related to stronger binding in a preceding step. 39,40 This model
was supported by the studies of alkyl-C exon 5 analogs.34
Previous studies have been restricted to ds-oligonucleotides smaller than 20 bp to enable
direct LC-MS/MS sequencing. The short strands studies thus far contained only a single reaction
site, and thus did not address relative reactivity between different sites or correlations with
mutation frequencies in tumors. Further, short strands may exhibit altered structural specificity in
nucleophilic addition compared to natural tumor suppressor genes that may show tertiary and
quaternary structural influences on codon reactivity. 41- 45
In this paper, we report an LC-MS/MS study of ds fragment of 32 bp of p53 gene exon 7,
from codon 242 to 253. This fragment exhibits up to 5 reactive hot spots13 and our work represents
metabolite reactivity of a p53 strand (>20base pairs) with multiple mutation sites. The 32 bp
fragment was chosen to be long enough to mimic higher order structure-reactivity of DNA.43 This
fragment was reacted with BPDE, the major DNA-reactive metabolite of benzo[a]pyrene, 46- 48 and
then a restriction enzyme was used to cleave the fragment into smaller fragments to enable LCMS/MS sequencing.
Mutational hot spots within this 32 bp fragment include 248, 245, and 249 associated with nonsmall cell lung cancer, 248, 249 and 244 for small cell lung cancer, 248 for head and neck cancer,
248 and 245 for colorectal cancer, 248 and 247 for skin cancer.10,11,14 Using the approaches
described herein, we found that the most frequently BPDE-adducted guanines were within codons
244 and 248, which correlate with frequently mutated p53 sites in several cancers.
For a 32 bp exon 7 p53 duplex fragment, we found adduct yields for reaction with BPDE in
the order of codons 248>243>244. In the present paper, we adapt this method for the first time to
elucidate relationships between codon-specific reaction kinetics with metabolites, and evaluate the
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influence of subtle but important MeC-related p53 gene structure changes on reaction kinetics.
This approach enabling studies of longer nucleotides that have been previously possible are
amenable to uncover the influence of important structural changes relevant to the reactivity of the
entire gene.
We compared a MeC form (19 MeCs) with a non-MeC form (Scheme 8-1) of the 32-bp exon
7 p53 fragment. G in codon 248 CpG had the largest rate constant, which was 3-fold for the MeC
version compared to all-C. Rate constants for reactive G’s in non-CpG codons were 5-8 fold
smaller than codon 248 MeCpG. Conformational and hydrophobicity changes in the MeC-p53
fragment revealed by circular dichroism (CD) and molecular modeling combine to increase the
binding constant of BPDE at the codon 248 site to greatly facilitates the rate of the SN2 coupling
reaction in line with the preceding non-covalent binding pathway.

Scheme 8-1. Exon 7 32 bp fragment of p53 gene with major hot spots 244, 245, 248 and 249
labeled grey, blue, red and green. Restriction enzyme cleavage site CATG in orange a) all-C
version b) MeC version, all Me except C in restriction enzyme cleavage site.
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8-2. Experimental Section

Caution. Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+/-) (anti) (anti BPDE) is a
chemical carcinogen. Protective measures including wearing gloves and protective eyewear and
doing experiments in a closed hood were taken.
8-2.1

Chemicals and Reagents. Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+/-) (anti) (anti

BPDE) was from National Cancer Institute Chemical Carcinogen Reference Standard Repository.
Triethylammonium bicarbonate (TEAB, 1.0 M, pH 8.4-8.6) and 4-nitrobenzyl alcohol were from SigmaAldrich. Custom made single stranded DNA oligomers and the 32-base pair oligonucleotide were from
Sigma-Aldrich. HPLC grade solvents, methanol, tetrahydrofuran and water were from Fischer Scientific.
Restriction enzyme, NIaIII was from New England Biolabs.

8-2.2

Reactions of Oligonucleotides with BPDE. Reactions with BPDE were done with 4 single

stranded (ss) oligonucleotides and the double stranded (ds) 32 bp portion of P53 gene representing codons
242 to 253. 0.1 nmol of each of the 4 ss oligonucleotides were treated with 100 nmol BPDE in a reaction
volume of 150 µL at 37°C for 48 hours in dark, 10 mM Tris buffer, pH 7.4. 2.5 µmol of ds 32 bp fragment
was reacted with 0.1 µmole of BPDE in volume of 150 µL at 37°C for 48 hours in dark, 10 mM Tris buffer,
pH 7.4. A minimum of three replicates of DNA and BPDE reactions were done.
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8-2.3

Removal of excess BPDE. ss DNA fragments were extracted from the BPDE-ss DNA mixture by

extracting with 150 µL of ethylacetate for three times. DNA was recovered from the aqueous phase.
Samples were then dried and reconstituted in 100 µL of pure water to make a final concentration of 1 µM
ss DNA.

Scheme 8.2 Protocol for sample preparation of 32-base pair p53 fragment reacted with BPDE
involving steps: (1) removal of excess BPDE from DNA reaction mixture; (2) restriction enzyme
treatment to cut DNA into smaller fragments; (3) protein removal; (4) desalting and (5) rapid
heating and cooling to give ss DNA.

For the ds-DNA-BPDE mixtures, Millipore 3000 Dalton mass cutoff filter vials were used
to remove unreacted BPDE (Scheme 8-2). Reaction mixture from above was put into a 3000 Da
mass cutoff filter, (catalog # UFC500396) and centrifuged at 13000 rpm for 30 min. ds-DNA was
retained on the filter, while the smaller BPDE molecules pass through. The filter was then
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removed, inverted and placed into a new centrifuge vial, and centrifuged for another 30 min.
Approximately 50 µL of the DNA solution was recovered. Recovered solutions of ds
oligonucleotides were subjected to restriction enzyme treatment (Scheme 8-2).

8-2.4 Restriction enzyme treatment on ds DNA. Approximately 50 µg (2.5 µmol) of DNA was
recovered from above step. 50 units (5 µL) of restriction enzyme, NIaIII was added to 50 µg of
the ds 32 bp oligonucleotides to which 20 µL of 10X NE buffer supplied by New England Biolabs,
was added and the reaction volume made up to 200 µL with pure water. This reaction mixture was
incubated at 37 °C for 8 hours. The resulting solution is mixture of DNA fragments, protein and
salt from the NE reaction buffer given by the manufacturer.

8-2.5 Removal of Proteins from DNA-Protein-Salt mixture. Proteins were removed from the
DNA samples by extraction using 200 µL of water-saturated phenol/chloroform/isoamylalcohol,
25/24/1. Each extraction step involves vortexing on a rotor for 10 min followed by centrifugation
for 10 min prior to aqueous phase collection. DNA in the aqueous phase was collected and the
extraction procedure was repeated twice more. Further extraction of DNA contained in the aqueous
phase was done twice with 200 µL of water-saturated chloroform/isoamylalcohol, 24/1. Finally
the aqueous phases were combined and organic phase was discarded. The resulting sample
containing DNA and salt was approximately 200 µL.

8-2.6 Desalting. Solid phase extraction (SPE) was performed to remove salt from DNA-salt
mixtures to obtain samples suitable for LC-MS/MS analysis. Waters Oasis HLB cartridges were
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used for desalting. The method involves initial equilibration of the cartridge with methanol and
water. Sample was loaded and then washed with 5% methanol in water to remove salts followed
by elution with 100 % methanol. The resultant DNA sample was dried and reconstituted in 100
µL pure water. The ds DNA samples were heated and cooled rapidly to convert ds DNA to ss DNA
and stored at -20 ºC until LC-MS/MS analysis.

8-2.6 LC-MS/MS analysis. A Waters Capillary LC-XE (Milliford, MA) chromatograph with a
Gemini C-18 column (0.3 mm X 150 mm, 5µ for ds DNA fragments & 0.5 mm X 150 mm, 3µ for
ds DNA fragments) and photodiode array detector were used. Separation featured a binary solvent
consisting of A - 25 mM TEAB and B - methanol. Separation was achieved with a gradient of 0
% to 10% B for 10 min followed by increase from 10 to 50 % B for 100 min and 50 to 100 % B
for the final 10 min at flow rate 10 µL/min. m-Nitrobenzylalcohol increases signal intensity and
charge states of oligonucleotide fragments in negative mode, which enhances the fragmentation of
oligonucleotides in tandem mass spectrometry. 49 Thus, 0.1 % m-nitrobenzyl alcohol was infused
at a flow rate of 3 µL/min to mix with the LC flow post-column using a three way connector before
entering the mass spectrometer to produce supercharged oligonucleotide fragments.
ss-DNA fragments were analyzed with an AB Sciex Qtrap 4000 mass spectrometer
interfaced to the capillary LC. Enhanced multiple charge (EMC) mode for sizing (molecular
weight measurement) and enhanced product ion mode (EPI) for sequencing of ss-DNA fragments
in negative mode were employed. Potentials -4500 V (ion spray voltage), 130 V (declustering
potential), -60 eV (collision energy), and 20eV (collision energy spread) were used while GS1,
GS2, and temperature were kept at 35, 20, and 350°C, respectively.
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For analysis of ds-DNA samples, an AB Sciex QSTAR mass spectrometer was interfaced
with the capillary LC. Negative ion mode with a -4500 V ion spray voltage, -130 V declustering
potential and 300°C temperature was used. DNA fragments were subjected to time of flight mass
scan (TOF-MS) mode for sizing of unreacted and adducted DNA fragments and product ion scan
mode was used at -45 eV collision energy for MS/MS sequencing. Only singly adducted fragments
were discussed in this study.

8-2.8 Circular Dichroism. Circular dichroism experiments on the C and MeC ds-32 base pair
exon 7 oligonucleotides were performed on Jasco spectrophotometer (J-710), in 10mM Tris buffer
pH 7.4 and 50 mM sodium chloride. Parameter used within the spectrophotometer include
sensitivity of 100mdeg, wavelength range 195nm to 230nm with a bandwidth of 5.0 nm.

8-2.9 Molecular Modeling. A and B form’s of 32-base pair P53 DNA was modeled using makena software 50 and modified with cytosines methylated using Maestro software and minimized.51
Solvated models of these modified oligonucleotides were created using CHIMERA software. 52,53
Amber solvation model was used for solvation with a box size of 1Å to accommodate water
molecules. Autodock 4.2.6 was used for docking studies. Prepared biomolecule (Solvated MeC
and C 32 base pair exon 7 fragment) were imported into the software. Lamarckian genetic
algorithm (LGA) was used in Autodock 4.2.6 to find binding energy between the gene fragments
and BPDE. Grid or volume for docking studies were kept constant for all the confirmations and
set to be at maximum. Binding energies, binding constants and the distance between the exocyclic
amine of the reactive guanine and epoxide carbon of BPDE were calculated.90 Steps for molecular
modeling are given below.
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STEPS
A and B form’s of 32-base pair P53 DNA was modelled using make-na software and
modified with cytosines methylated using Maestro software and minimized. Solvated models of
these modified olignucloetides were created using CHIMERA software. Amber solvation model
was used for solvation with a box size of 1Å to accommodate water molecules.
Autodock 4.2.6 was used for docking studies. Prepared biomolecule (Solvated MeC and C
32 base pair exon 7 fragment) were imported into the software. Lamarckian genetic algorithm
(LGA) was used in Autodock 4.2.6 to find binding energy between the gene fragments and BPDE.
Grid or volume for docking studies were kept constant for all the confirmations and set to be at
maximum (126X x 126Y x 126Z dimensions). Binding energies, binding constants and the
distance between the exocyclic amine of the reactive guanine and epoxide carbon of BPDE were
calculated. 54
Procedure for Docking
1. Import the biomolecule
2. Add Hydrogens to the biomolecule
3. Compute gasteiger charges
4. Now input the Ligand
5. Save the output format of the ligand to be in PDBQT (autodock suitable format)
6. Preparation for grid
a. Choose Macromolcule (32 bp DNA)
b. Save as PDBQT

164

c. Choose ligand (from set map types)
d. Set grid size (maximum grid size used for our study 126 X 126 X 126).
e. Save out put file as .gpf (grid format for autodock).
f. Run autogrid from run option.
7. Docking
a. Select macromolecule and ligand similar to above from docking menu.
b. Search Paparmeters given as # of GA runs to be 100, population size 150, maximum
evaluations 250000, maximumber of generations 27000 and other factors kept
default. Accept the parameters.
c. Docking parameter kept default.
d. Output saved as default.
e. Run autodock from run menu.

8-3. Results

Initial studies centered on reacting single-strand fragments GGCGGCATG (ss-DNA
Fragment 1), including hot spot codon 244 and 245, AACCGGAGGCCCATCCTCA (ss-DNA
Fragment 2), including hot spot codon 248 and 249, TGAGGATGGGCCTCCGGTTCATG (ssDNA Fragment 3, complementary to fragment 2) and CCGCCCATG (ss-DNA Fragment 4,
complementary to fragment 1) with BPDE to optimize the LC-MS/MS methodology without using
the restriction enzyme.
Our protocol for the 32 base pair exon 7 fragment involves reacting p53 oligonucleotide
sequences with BPDE, then using restriction enzymes to cut the reacted fragment into smaller
fragments suitable for LC-MS/MS (Scheme 8-3). Our 32 bp exon 7 fragment extends from codon
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242 to 253 and includes possible reactive hot spots at codons 244, 245, 247, 248 and 249 related
to the various cancers described above. All codons contain guanine except 247 (ACC), which
contains a possible reactive adenine. Within this sequence, codon 248 is the most frequently
mutated in all cancers. Codons 245, 248 and 249 are adducted for most cancers related to BPDE,
which adds to DNA bases by nucleophilic substitution. Our 32 base pair fragment is a combination
of ss-DNA fragment 1 and ss-DNA fragment 2 with four additional bases CATG added before the
ss-DNA fragment 1. This was done in order to eliminate the possibility of having terminal guanines
with enhanced reactivity.

Scheme 8-3. (A) Sample preparation for LC-MS/MS sizing and sequencing of fragment. (B) 32
bp exon 7 fragment showing cut points for restriction enzyme NIaIII along with resulting
fragments obtained.
In order to sequence products of 32 base pair oligonucleotide reactions with BPDE by LCMS/MS, we used the restriction enzyme NlaIII, which cuts DNA after the sequence CATG
(Scheme 8-3). For our 32 bp fragment, this results in two fragments of 13 and 19 bases that are
double stranded except for 4 bases at their ends (Scheme 8-3B). 13 mer was obtained instead of
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the expected 9 mer since the efficiency of restriction enzymes to cut the dsDNA decreases
drastically when the recognition site in closer to the 5’ end. A minimum of 3-4 extra bases flanking
the recognition site on the 5’ prime end was required for restriction enzyme to act on ds-DNA. 55
These two ds-fragments were rapidly heated and cooled to give in 4 ss-oligonucleotide fragments
(Scheme 8-3A).
We used enhanced multiple charge scanning to size the ss-oligonucleotides, followed by
collision-induced dissociation (CID) MS/MS for sequencing. CID of oligonucleotides shows a
characteristic fragmentation pattern (Scheme 8-4) featuring an-bn and wn ions. 56- 59 Adduction of
BPDE to specific nucleobases within codons was monitored by comparing un-adducted
oligonucleotides to those reacted with BPDE, and detecting the difference in m/z of the an-bn and
wn ions.
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Scheme 8-4. Collision Induced Dissociation (MS/MS or tandem MS) of DNA fragments resulting
in the generation of wn and an-bn ions.
Enhanced multiple charge scans (EMC) were used to determine the m/z of standard and
BPDE-adducted DNA fragments that have an additional mass of 302.323. Expected multiple
charged species possible were calculated using the online database Mongo oligomass calculator. 60
We first present results for the ss-Fragments. With the ionization conditions used, we observed an
m/z of 1388.9 for unreacted ss-Fragment 1 with a charge of -2 and m/z of 1540.5 for the reacted
fragment indicating a singly adducted strand also with charge -2.
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Extracted ion chromatogram of a selected ion as a function of retention time of singly adducted
ss-DNA fragment 1 of m/z 1540.5 shows (Figure 8-1A) that there is a possibility of 2 positional
isomers for the singly adducted ss-Fragment 1 at retention times 38.67 and 43.75 min. CID of
fragment ion 1540.5 for Peak I is as shown in Figure 8-1B and for Peak II in Figure 8-1C.
Differences in m/z of a-b and w ions between the standard ss-DNA fragment 1 and the singly
adducted DNA fragment help locate the exact reacted position on a given oligonucleotide. 61-63
Table 8-1 summarizes fragment ions obtained for standard ss-DNA fragment 1, singly adducted
ss-fragment 1 for peaks I and II. Red numbers indicate those ions increased in mass by 302.32
from adducting with BPDE compared to the unreacted fragment.
MS/MS spectrum for peak I of singly adducted ss-fragment 1 (Figure 8-2B) reveals increase
in mass of all the ions from a3-b3 to a6-b6 and w8 compared with that of unreacted ss DNA standard.
This indicates covalent binding of BPDE on the second G base, GG*CGGCATG. This is
additionally confirmed by the presence of ion a2-b2 with an m/z of 426.2- and all ions from w1 to
w7 with m/z the same as that of the standard.
MS/MS spectrum for peak II of singly adducted ss- fragment 1 reflects increases in m/z for
all the w ions compared to unreacted standard (Table 8-1). This indicates covalent binding of
BPDE to the last G base, GGCGGCATG*, which was supported by all a-b ions having m/z similar
to unreacted standard. Similar experiments were performed all the other fragments and reported as
shown in Table 8-2.
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Figure 8-1. LC-MS of ss-DNA fragment 1 (A) Extracted ion chromatogram for fragment m/z
1540.5 representing z = -2 singly adducted fragment 1. (B) MS/MS spectrum of singly adducted
BPDE ss- DNA fragment 1, m/z 1540.5 for peak I eluting at 38.67 min and (C) MS/MS of peak II
eluting at 43.75 min. (1540.7 or 1540.8 m/z was observed instead of 1540.5 due to isotopic
distribution)
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Table 8-1. Fragment ions for standard ss-DNA Fragment 1 of m/z 1388.9 and singly adducted
BPDE Fragment 1 ion with m/z of 1540.5 from LC-MS/MS.
Fragment Ion

m/z
Peak I
[426.2][1057.5][1347.7][1676.9][346.2][650.3][963.4][1252.5]n/d
n/d
[1099.9]-2
[1416.1]-2

Standard
[426.2][755.5][1044.7][1373.5][346.2]-1
[650.3][963.4][1252.8][1582.0]n/d
[1099.7]-2
[1263.3]-2

a2-b2
a3-b3
a4-b4
a5-b5
w1
w2
w3
w4
w5
w6
w7
w8

Peak II
[426.2][755.4][1044.3][1373.8][648.3][952.5][1265.5]-2
[1555.8][1884.7]n/d
[1251.6]-2
[1415.7]-2

Table 8-2. Standard single stranded DNA fragments with their corresponding base adducted in
comparison with the hot spot database.
Standard
ss-DNA
Fragment 1

Fragment 2

Sequence

LC-MS/MS DATA
Base adducted
Codon

Common Hot Spots
from Database

GG*CGGCATG

244b

244b, 245a,d

GGCGGCATG*

246

244b, 245a,d

AACCGGAGG*C
CCATCCTCA

249a,b

248a,b,c,d,e, 249a,b,

GGCGGCATG
AACCGGAGGC
CCATCCTCA

Complementary Strands
Fragment 3
Fragment 4

GTGAGGATGGGCCTCCGGTTC
ATG
CCGCCCATG

GTGAG*GATGGGCCTCCGGTTC
ATG
CCG*CCCATG
CCGCCCA*TG
CCGCCCATG*

Note: Possible cancers due to BPDE a. Non Small Cell lung cancer, b. Small Cell lung cancer, c.
Head and Neck cancer d. Colorectal cancer, e. Skin Cancer
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Figure 8-2. LC-MS of ds-32 bp exon 7 fragment: (A) Extracted ion chromatogram of singly
adducted fragment 2, m/z 1530.3, z = -4. (B) MS/MS spectrum of 1530.3 showing an-bn and wn
ions. Ions with m/z similar to standard labeled in green and ions with increased m/z in red.

After establishing and optimizing reproducible methodology on the standard single
stranded DNA fragments, the 32 bp ds-p53 exon 7 fragment, which is a combination of fragments
1 and 2 along with the complementary strand, was reacted with BPDE. Four bases, CATG were
added to the front of fragment 1 to avoid terminal guanines. The sequence added is consistent with
the exon 7 sequence. Excess BPDE was removed using mass cutoff filters, then the aqueous extract
was treated with restriction enzyme NIaIII to cut the fragment into smaller fragments suitable for
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LC-MS. Subsequently, heating and rapid cooling gave the four single stranded fragments. In order
to determine sequence specificity on the entire 32 bp fragment, collision induced dissociation (CID
or MS/MS) was performed on all possible single adducted oligonucleotide fragments. Singly
adducted fragment 2 is described here as the fragment containing hot spot 248 and 249 active for
a number of cancers.11,14 Singly adducted fragment 2 upon MS ionization produced a ion of m/z
1530.3 with z = -4. The extracted ion chromatogram (XIC) of m/z 1530.3 (Figure 8-2A) gave only
one major peak indicating that there is one major adduct on the singly adducted fragment 2 of the
reacted 32 bp fragment.
MS/MS spectra for singly adducted fragment 2, m/z 1530.3, shows all an-bn ions up to a5-b5
have m/z similar to that of unreacted standard. An increase in m/z of 302.323 (z = -1) was observed for
a6-b6,

a7-b7,

a8-b8.

This

suggests

that

the

possible

modification

is

on

base

5,

(AACCG*GAGGCCCATCCTCA). This was confirmed by increases in m/z for w15 and w16 ions,
while all w ions below w14 have m/z similar to that of unreacted standard. Similar experiments were
performed on all othet fragments and reported in Table 8-3.
Since the modification is relatively small in the adducted DNA fragments, we assume the
adducted and unadducted fragments have only minor changes in electrospray ionization behavior and
MS response. Relative abundance of specific adducted nucleobases within codons were estimated by
comparing areas of the extracted ion chromatograms of adducted fragments to that of unadducted
fragments, and these ratios were further compared with other adducted fragments ratios. Ratios of
relative amounts of adduction in the 32 bp fragment for codons 248/244 was 1.5 and codons 248/243
was 1.3 with a relative standard deviation less than 6.5% (n=3). According to p53 handbook database,
the mutation frequency ratio of codons 248/243 is 24, 248/244 is 7, 248/249 is 2.7 and 248/245 is 2.1.
Increased reactivity of codon 243 compared to p53 mutation frequency ratio may be related to guanine
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in codon 243 being the first guanine in our 32 bp fragment which may be more available for reaction
due to its position near the end of the strand.

Table 8-3. Fragments of ds-32 bp exon 7 fragment with corresponding base adducted in
comparison with the p53 database.
Fragment
Name
Fragment 1

Fragment 2

Sequence
CATGGGCGGC
ATG
AACCGGAGGC
CCATCCTCA

LC-MS/MS DATA
Base Adducted
Codon
CATG*GGCGGCATG 243

Common Hot Spot
Database
b
244 , 245a,d

CATGG*GCGGCATG

244b

244b,245a,d

AACCG*GAGGCCCA
TCCTCA

248

248a,b,c,d,e, 249a,b

Complementary Strands
Fragment 3

TGAGGATGGGCCTCCGGTTCATG

Fragment 4

CCGCCCATG

TGAGG*ATGGGCCTCCG
GTTCATG
CCG*CCCATG

Note: Possible cancers due to BPDE a. Non Small Cell lung cancer, b. Small Cell lung cancer, c.
Head and Neck cancer d. Colorectal cancer, e. Skin Cancer

Kinetics. Multiple reaction monitoring (MRM) was then used to quantify BPDE adduction
at each reactive codon vs. reaction time. Transitions were selected specific to the ss-fragment
monitored. For example, transition 1085.4→650.0 for singly adducted MeC fragment 1, and
1009.9→650.0 for unadducted fragment 1. Here 1085.4 and 1009.9 are m/z of precursor ions of
single adducted fragment 1 and unadducted fragment 1, respectively, with charge -4. M/z 650.0
represents the product ion of precursor 1085.4 which is also the major transition for the unadducted
precursor ion, m/z 1009.9.
The relative amount of BPDE adduction was measured as ratio of peak area for XIC of
adducted fragment to total peak area of the corresponding adducted+unadducted fragment.
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Relative amounts of BPDE adduction were plotted vs. time for G’s in codons 248, 244 and 243
(Figure 8-3a).

Figure 8-3. Kinetic study of BPDE adduction on MeC and all-C 32 bp p53 exon 7 gene fragments:
a) Relative amount of BPDE adducted to guanine within codons 248, 244 and 243. b) Rate plots
showing natural log of relative amount of undamaged oligo fragments (ln [A]/[A0]) vs time. c) Bar
graph showing comparative rate constants k2 (s-1M-1) calculated from the slope of rate plots for
BPDE adduction. Error bars represent SD for n=3.
Table 8-4. Rate constants k1 and k2 and ratios for different reactive sites.
Rate Constant

MeC Codon
248

k1, s-1
(x106)
k2, s-1M-1
(x102)

26±3

244

C Codon
243

248

244

243

3.0±0.7 4.8±1.0 9.0±1.3 4.0±0.7 6.3±0.9

7.8±1.0 0.9±0.2 1.4±0.3 2.7±0.4 1.2±0.2 1.9±0.3
Rate Constant Ratios

Me-C/C

Ratio

Me-C/Me-C Codon

248

2.9

248/244

244

0.8

248/243 5.4

243

0.8

8.7

C-C Codon
248/244
248/243

2.2
1.4

Note. Rate constants k1, for codon 244 and 243 in the methylated fragments are not significantly
different according to t-test at 95% confidence interval.
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Expressions in eq (1) define k1 as the pseudo-first order rate constant, and k2 as the second
order rate constant, where Co is initial amount of unreacted exon 7 fragment and C the amount
unreacted at time t. Linear plots that fit eq 1 were obtained (Figure 8-3b), as shown for codon 248
for MeC and all C exon 7 fragments. We obtained k1 from the slopes, and k2 from k1 (eq 1).
ln C = ln Co - k1t ; k2 = k1/[BPDE] (1)
Kinetic results show that k2 for BPDE adduction on codon 248 CpG is nearly 3-fold larger
for the MeC fragment vs. C-only (Figure 8c, Table 8-4). Rate constants for non-CpG adduct at
codons 244 and 243, are ~20% smaller for MeC vs C-only, but differences are not statistically
significant. The k2 ratio of the MeC oligonucleotide for codons 248/244 is ~9, close to ratio of
mutational frequencies in the p53 gene.3 For MeC exon 7 (Table 8-4)., codon 248/243 k2 ratio is
5.3 while the mutation ratio is a bit larger at 24. These results demonstrate the influence of MeC
on CpG sites like codon 248 in the p53 gene to greatly increase reaction rates of MeCpG sites.
Results show negligible influence of MeC on reactive non-CpG guanines.
8-4.

DISCUSSION

The 32 bp p53 exon 7 fragment reacted with BPDE had all reactive bases as Gs, and the
most frequently reacted guanine was in codon 248. Guanines within codons 243 and 244 were
adducted to a lesser extent. Codon 248 is the major mutation hot spot for most tissue specific
cancers such as lung, and head and neck. Thus, there is qualitative correlation of the high reactive
frequency of codon 248 in our fragment with its high rate of mutation in many cancers, as well as
the observed reactivity of codons 244 and 243. However, the relative mutation frequencies of
codons 244 and 243 are lower that the relative reactivities we find in the 32 bp p53 fragment.
Differences in reactivity vs. mutation frequency in tumors at codons 244 and 245 is
undoubtedly related to the complexity of living tumors and cell cultures as compared to our in
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vitro reaction system. In addition to complications from organ-based metabolism, which is absent
in our present reactions, differences may be due to DNA being bound to histones and other proteins
in vivo as well as to in vivo DNA repair. Also, sequences in both 244 and 245 codons are GGC.
Codon 243 is close to the end of the fragment, adjacent to an AT sequence, and may be partially
unwound exposing the guanine adjacent to it due to fewer hydrogen bonds. 64 Codon 243 may thus
be more reactive in the fragment than in the full p53 gene. Also, under in vivo conditions, a
considerable fraction of cytosines are methylated which can mediate codon reactivity. 65,66 5Methyl cytosines increase the nucleophilicity of exocyclic amine of adjacent guanine as result of
inductive electronic effects.34 We are currently exploring this issue by additional experiments.
Covalent binding of BPDE preferentially targets guanines in DNA, 67,68 because guanine is
the best nucleophile of all the DNA bases. The N7 position of guanine is the most nucleophilic site
but the exocyclic amine group, also a good nucleophile, is the most favorable target for
polyaromatic hydrocarbon diol epoxides like BPDE. This is because proximity of the N7 group to
the hydrophilic sugar chain of the DNA makes it less susceptible to attack of hydrophobic pyrenyl
moieties. 69- 71
All exocyclic amines of guanines in single stranded DNA are available for covalent
reaction with BPDE. In double stranded DNA the exocyclic amines are involved in hydrogen
bonding with the carbonyl oxygen atom of cytosine hence are not freely available for reactions
with BPDE. Guanines specifically in the minor groove of duplex DNA can form covalent adducts
with BPDE, thereby disrupting the hydrogen bonding between the GC base pair. 72,73
As per p53 handbook, codon 247 is a hot spot for Melonoma and Skin Squamous Cell
Carcinoma, admittedly with a small number of mutations. Although guanine is not in the codon,
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the potential of BPDE to react with adenine exists. Since we did not find any adduction on any
nucleobase within codon 247 in our study, selectivity of BPDE to guanines was further affirmed.
Our results are consistent with the fact that most damaged codons in tumors and cancer cell
cultures involve guanines as the major site of attack by BPDE.67,74 Guanines were also exclusive
targets in the experiments with ss-oligonucleotides. Structural differences of ssDNA and dsDNA
may play a role in sequence specific DNA damage. Short single stranded oligonucleotides used in
our study have a more flexible structure unprotected with a complementary strand and featuring a
free axis of rotation along the phosphodiester backbone. 75,76 Thus, while specificity would be
expected to be much lower for ssDNA compared with that of dsDNA we still find that high
mutation frequency codons 249 and 244 are highly reactive with BDPE in the short ss-fragments.
These results suggest that the relative reactivity of the ds-DNA may be a combination of inherent
chemistry of the codon sites and the ds- and higher structure of the DNA.
Double stranded DNAs are relatively inflexible due to GC and AT base pairing and double
helical structure resulting in their complicated secondary and tertiary structures.43 The double
helical structure also features major and minor groves in duplex DNA. BPDE specifically attacks
the electron donating exocyclic amine in the minor groove containing the nucleophilic GC base
pair of DNA. Therefore reactivity of dsDNA will be different to that of ssDNA.72,73 However in
our experiments, we see that the ss-fragments and ds-32 bp fragment both have selective reactivity
that includes codons with high frequency of mutation in p53. Thus, selectivity is different in the
ss- and ds-fragments, but still exhibited by the single strands.
Very few studies thus far have focused on differential selectivity of specific base
sequences. 77 Jernstroem, et. al suggest that guanines adjacent to or flanked by guanines are more
reactive77- 79 In contradiction, other studies predict that guanines flanked by pyrimidine bases are
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more reactive due to less steric effects as compared to guanines flanked by purine bases.73, 80- 82
The reactive site of codon 248 in our 32 bp fragment is a guanine flanked by guanine, while codons
244 and 243 are guanines flanked by purine on one side and pyrimidine on the other side and show
intermediate reactivity. Codon adduction sites in ss-DNA oligonucleotides are guanines
sandwiched between one purine and one pyrimidine. Hence, our results are in qualitative
agreement with the predictions quoted above. However, relating full guanine sequence specificity
to adjacent bases is undoubtedly an oversimplification, and in addition to base sequence,
specificity most likely involves complex structural and environmental factors in vivo including
bound histones and proteins.
Structural Analysis. Additional studies were aimed at molecular interpretation of the kinetics.
Circular dichroism (CD) spectra of full MeC and C-only versions of the exon 7 fragments (Figure
8-4), suggest different conformations. The MeC exon 7 has an intense negative CD peak at 210
nm and an intense positive peak near 270 nm similar to a pure A-DNA structure, 83 but also a
minimum near 245 nm characteristic of B-DNA. For the non-MeC exon 7, the first minimum is
shifted to longer wavelength and is weaker, and a maximum at 265 nm is broad, with a shoulder
at ~285 nm more characteristic of B DNA83 (Figure 8-4). We interpret both CD spectra in terms
of mixed A-B DNA structures, with MeC’s driving structure toward the A.
Molecular Modeling. A and B forms of Me-C and C versions of exon 7 were constructed and
molecular modeling was done using Autodock software. Structures were solvated with water and
docked with the most reactive isomer (+)anti-BPDE. BPDE conformations at optimal docking sites
were in the minor groove close to codon 248 for conformations with the most negative binding
free energy. Conformations with distances between reactive exocyclic amine of G in codon 248
and the epoxide carbon of BPDE less 4.5 Å were considered, due to probability of subsequently
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forming covalent bonds. Optimal binding of BPDE to guanine in codon 248 (Figure 8-5) gave
binding free energies (∆Gb) for B and A conformations (Table 8-5) which were used to calculate
binding constants (Kb) from Kb = -∆Gb/RT, where R is the ideal gas constant and T in Kelvin.
Larger Kb’s were found for MeC versions in both A and B form of DNA compared to all-C
counterparts. For conformations approximating experimental ones, MeC A-form had 5-fold higher
Kb than all-C A-form. Smaller interatomic distances of reactive atoms were found in A-form of
DNA (Figure 8-5, Table 8-5) indicating better accessibility for BPDE, with the smallest distance
for the MeC A-form. Docking studies were also done with (-) anti BPDE, which gave qualitatively
similar results but less dramatic Kb differences. As a control, we modeled BPDE binding to dspoly(dG-dC).(dG-dC) oligonucleotides with all MeCs and all C, and found 5-fold larger Kb for
MeC version similar to experimental measurements.39 Thus, modeling of MeC exon 7 fragment as
an A DNA structure and all-C version closer to B DNA agreed well with a pathway featuring
preceding non-covalent binding of BPDE in the minor groove near codon 248 that “sets up”
subsequent fast SN2 covalent coupling.

Figure 8-4. a) Circular dichroism showing transition from A to B form of DNA. Reproduced from
J. Kypr et. al., Nucleic Acid Research, 2009, 37, 1713-1725. B) Interpretation of CD spectra of the
P53 exon fragment in terms of A and B-DNA. Results suggest transition from mixed A- and BDNA towards more A-DNA content upon methylation of C’s.
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It’s very likely that stronger binding to the A DNA-like structure of the MeC exon 7 is also
influenced considerably by hydrophobic interactions that increase for A DNA-like MeC
oligonucleotides. An indirect indication of this effect was found in preliminary modeling studies
without water, in which similar trends were found in Kb for systems in Figure 8-5, but Kb
differences between A MeC and B all-C forms were much smaller. We thus attribute a part of the
increases in Kb (Table 8-5) for both the A and B forms of the MeC p53 fragments to the
hydrophobic influence on water structure that tends to increase affinity of BPDE for the codon 248
minor groove.

Figure 8-5. a) Models of BPDE docked close to reactive guanine in codon 248 in A and B forms
of the 32 bp exon 7 p53 fragment in MeC and C versions. Distance is between exocyclic amine of
reactive G and epoxide carbon in Å. (Water is removed for clarity; solvated models with water) b)
Model of Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+) (anti)
Our findings of B-like to A-like structural changes for conversion from the CMeC exon
7 duplexes are consistent with earlier literature. 84,85 Crystalized oligonucleotides are
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predominantly B DNA, but can transition to dehydrated A-forms upon methylation when rich in
CG regions, and intermediate structures between A and B have been crystallized. 86,87 The A form
has a wider minor groove that provides better accessibility for BPDE.83 This enables a shorter
distance for the reactive exocyclic amine of G to the epoxide carbon of BPDE in A-form than in
B form (Table 8-5). Earlier computations showed that epigenetic modifications alter the structure
of the DNA making sites of adduction more accessible.88- 91

Table 8-5. Computed binding free energies, binding constant and distance between exocyclic
amine of reactive G in codon 248 and epoxide carbon of BPDE.
Binding Energy kcal.mol-1, ∆G Binding Constant, Kb, M-1, Distance, Å

DNA
B Form-C

-3.47

3.48 x 102

4.08

B Form-MeC

-4.10

1.00 x 103

4.24

A Form-C

-3.84

6.58 x 102

3.88

A Form-MeC

-4.80

3.32 x 103

3.50

Methods utilized above provide a straightforward approach to directly study kinetics of
gene damage reactions. Results suggest that methylcytosines, which predominate in tumor
suppressor genes,19 and influence the kinetics of SN2 reactions with BPDE mainly at CpG sites of
tumor suppressor genes. In the p53 exon 7 fragment studied, codons 248, 244 and 243 were the
reactive sites for MeC and all-C versions. Codon 248, the featuring CpG, gave the fastest reaction
with the MeC fragment reacting 3-fold faster than the non-MeC version (Table 8-5). CD spectra
and computation modeling uncovered a change in conformation from a mixed A-B to a more A181

like duplex structure that drives free-energy for noncovalent binding of BPDE in the codon 248
region more negative for the MeC version, due to better access to the minor groove site and
increased hydrophobicity. The resulting larger kb most likely lowers activation free energy to
contribute significantly to the faster kinetics of SN2 coupling of BPDE to MeCpG in codon 248.
The structural change does not significantly influence non-CpG codons 244 and 243 that have
similar kinetics for MeC and C versions. The hydrolysis-free methodology used here to measure
direct kinetics of damage by metabolites to oligonucleotides longer than 20 bp is applicable to
correlate gene damage sites for drug and pollutant metabolites with mutation sites. We speculate
that these longer nucleotides are more amenable than shorter fragments to uncover the influence
of important structural changes relevant to the reactivity of the entire gene.

8-5.

Summary

In summary, we have described methodology to screen chemicals, drugs and metabolites
for reactions with oligonucleotides to determine the most frequently adducted nucleobase within
codons. Results show that LC-MS/MS and restriction enzymes can be used to prepare carcinogen
modified oligonucleotides so as to identify the site of adduction on oligonucleotide fragments
longer than 20 base pairs. Our 32 bp fragment reactions represent the first study of a p53 gene
fragment representing more than 20 base pairs with multiple mutation hot spots. The highest
reaction frequency was at codon 248, consistent with the highest mutation frequency of the p53
gene in many cancers. Also, BPDE reactivity found at codons 243 and 244 is consistent with these
codons being mutated in tissue cancers.
Methodology described is directly adaptable to other chemicals and other tumor suppressor
gene fragments to investigate kinetics of their DNA damage reactions. Molecular dynamics
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modeling can be used as an auxiliary tool to gain a more complete assessment of the chemistry of
the associated reaction events. This quantitative methodology can be adapted to multiple chemicals
and multiple exons across multiple tumor suppressor genes to expanding knowledge of
genotoxicity chemistry pathways in relation to organ specificity of carcinogenesis. Next chapter
focuses on development of Magnetic bio-colloid based technology coupled with LC-MS/MS for
screening chemicals/prodrugs which require metabolic activation to cause DNA toxicity and corelation with organ specific cancer.
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